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CHAPTER I 
 
OVERVIEW OF COAGULATION 
 
Hemostasis 
The ability of the body to restore vascular integrity following injury is paramount to 
survival. The rapid formation of a fibrin and platelet rich clot over the site of vascular 
damage, and the subsequent dissolution of the clot at the appropriate time is termed 
“hemostasis”. During the initial phase of hemostasis three processes occur: 
vasoconstriction, platelet plug formation, and fibrin clot formation (Troy et al. 1988). In 
response to vessel injury, vascular smooth muscle cells contract, constricting the damaged 
vessels rapidly to diminish blood loss. Circulating platelets then adhere to exposed 
subendothelial collagen in a reaction involving von Willebrand factor (vWF), and bind to 
each other (aggregation) to form a platelet plug. This process is often referred to as primary 
hemostasis. Simultaneously, plasma proteins called coagulation factors contribute to a 
series of enzymatic reactions to generate the serine protease thrombin. Among its many 
activities, thrombin converts fibrinogen into fibrin strands (previously referred to as 
secondary hemostasis) that act as “molecular glue” to strengthen the platelet plug. One of 
the plasma proteins involved in thrombin generation is the protease factor XIa (FXIa). In 
this dissertation thesis, I will present results of structural and functional studies on FXIa, 
and discuss the biological and therapeutic implications of how this protease contributes to 
thrombin generation. 
Hemostasis is a highly regulated process. Disorders of hemostasis can lead to a risk of 
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bleeding (hemorrhage). Bleeding diatheses can be caused by hypocoagulability due to 
genetic deficiency of certain coagulation factors (for example hemophilia A, factor VIII 
deficiency), to acquired disorders caused by disease states (liver disease, malignancies, 
infections…) or to the use of anticoagulant medications.  
At the other end of the clinical spectrum are thrombotic disorders, which are 
characterized by formation of clot within the lumen of a blood vessel. The thrombus can 
obstruct the circulation at its site of formation, or can break free from its site of origin and 
migrate through the circulation. The latter process is called embolization. 
Thrombo-embolism results in reduced blood flow to tissue leading to ischemia and 
infarction, and ultimately organ malfunction and failure. Collectively, arterial and venous 
thrombosis, and most importantly myocardial infarction, stroke, and deep vein thrombosis 
and its complication pulmonary embolism, constitute major causes of morbidity and 
mortality worldwide. 
Most current antithrombotic therapies fall into two main categories: anticoagulants that 
reduce thrombin generation, and antiplatelet agents that inhibit platelet activation or 
aggregation. Conventional anticoagulants include heparin and the vitamin K-antagonist 
warfarin (Fuster et al., 2012). These anticoagulants have effects on a variety of coagulation 
proteases including thrombin and the protease directly responsible for thrombin 
production, factor Xa (FXa). The consequence of inhibiting these important components of 
hemostasis is that use of these drugs is associated with a significant risk of life-threatening 
bleeding. Drug level monitoring can reduce, but not eliminate the bleeding risk. 
Anticoagulants that specifically inhibit thrombin or FXa have been introduced recently 
into clinical practice (Müller et al., 2011). While these drugs produce a more predictable 
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effect and are, therefore, safer than warfarin, bleeding remains a major problem because 
they inhibit proteins that are critical for hemostasis (to be discussed in the following 
section). A major goal of coagulation research is to develop novel strategies to treat or 
prevent thrombotic disorders with fewer bleeding complications. Therapeutic inhibition of 
FXIa may be such a strategy. 
 
Coagulation Pathways 
Thrombin generation, and subsequent fibrin formation, is mediated by a group of 
plasma proteins (coagulation factors), many of which are zymogens of serine proteases. 
Coagulation factors are components of a proteolytic amplifying process that leads to 
thrombin generation at a wound site (Figure 1-1) (Furie and Furie, 1988). Coagulation 
factors are assigned Roman numerals, with a lowercase “a” appended to the numeral to 
indicate the active form. Initiation of thrombin generation occurs at a site of vessel injury 
when factor VIIa (FVIIa), which accounts for about 1% of factor VII (FVII) in blood, binds 
to the cofactor tissue factor (TF) (Brummel-Ziedins et al., 2012). TF is a trans-membrane 
glycoprotein expressed constitutively on many cells that underlie vascular endothelium. 
TF expression can also be induced on the surface of monocytes and platelets, and it can be 
found on circulating microparticles of monocyte or platelet origin upon vessel injury or in a 
variety of pathological conditions (Mackman et al., 2007). The FVIIa/TF complex 
activates factor X (FX) and factor IX (FIX) in the presence of calcium and phospholipid, 
leading to thrombin and fibrin formation. Activation of FX by FVIIa/TF is quickly 
inhibited by tissue factor pathway inhibitor (TFPI), which provides a negative feedback 
mechanism that is essential for the regulation of hemostasis (Broze et al., 1990). Sustained 
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thrombin generation requires FVIIa/TF activation of FIX. It appears that in most cases FIX 
activation is largely the role of the FVIIa/TF complex. However, in some situations FIX 
activation by the protease factor XIa (FXIa) is also required (Davie et al., 1991). In the 
model shown in Figure 1-1, FXIa contributes to the reinforcement of a clot, after the 
initiation of coagulation.  
FXIa is traditionally thought of as a component of the process of contact activation. 
Contact activation was first identified as a series of reactions that allow blood to clot 
rapidly when it comes into contact with non-biologic charged surfaces such as glass or 
celite, or polyanions such as dextran sulfate. The plasma proteins Factor XII (FXII), 
prekallikrein (PK) and high-molecular-weight-kininogen (HK) are the other components 
necessary for contact activation (Figure 1-2). The process is thought to be initiated by 
autoactivation of FXII on anionic polymers or surfaces. Activated FXII (FXIIa) converts 
PK to α-kallikrein, which in turn activates additional FXII to amplify the process (Kaplan 
et al., 1987). Concurrently, FXIIa activates FXI to FXIa, which then converts FIX to 
FIXaβ in the presence of calcium ions. FIXaβ forms a FX-activating complex with FVIIIa 
Figure 1-1 Model of fibrin 
formation. Fibrin generation is 
initiated by a series of proteolyic 
reactions involving plasma proteases 
(Roman numeral in black). Black and 
white arrows indicate protease- 
mediated reactions, with white arrows 
indicating reactions involved in FXI 
activation and FXIa activity. The red 
arrow indicates feedback inhibition of 
FVIIa/TF by TFPI. Cofactors are 
shown as yellow lettering within black 
ovals. Lower case “a” indicates the 
actived form of the factor.  
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on the surface of activated platelets, thereby contributing to thrombin generation.   
While clinical laboratories widely use assays based on contact activation-initiated 
coagulation to study blood clotting in patients, contact activation is thought to be 
dispensable for hemostasis in vivo. Deficiencies of FXII, PK and HK are not associated 
with hemostatic abnormalities (Gailani et al., 2010). Actually, these proteins appear to play 
more important roles in inflammation and in innate immune responses to infection than to 
coagulation. Currently, the tissue factor-initiated pathways shown in Figure 1-1 are 
thought to be the major initiators of thrombin generation in vivo, while the contact 
activation system plays little, or no, role in hemostasis.  
 
Factor XI in Hemostasis and Thrombosis 
In current models of coagulation, FIX may be activated by either FVIIa/TF or FXIa. 
While severe FIX deficiency is associated with spontaneous hemorrhage into soft tissues 
and joints that can be life threatening (Ragni et al., 2009), FXI deficiency in humans is 
associated with a relatively mild clinical bleeding abnormality (Asakai et al., 1991; 
 
Figure 1-2. Contact Activation. 
Contact activation is initiated by the 
conversion of FXII to FXIIa when 
plasma is exposed to a negatively 
charged surface (gray disk). 
Reciprocal activation of PK to 
α-kallikrein (α-kal) by FXIIa 
(reaction 2), and FXII by α-kal 
(reaction 3) enhances FXII 
activation. FXIIa promotes 
coagulation through activation of 
FXI (reaction 4). α-Kallikrein also 
cleaves high molecular weight 
kininogen (HK) to liberate 
bradykinin (reaction 5).   
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Seligsohn, 2007). FXI-deficient mice do not have a demonstrable bleeding disorder. These 
clinical observations indicate that FXI is unlikely to be required for initiating hemostasis, 
and it is currently thought that the primary function of FXIa is to enhance thrombin 
generation in certain situations to prevent premature clot breakdown by fibrinolysis 
(Gailani and Broze, 1991; von dem Borne et al., 1995). Consistent with this, tissues with 
high intrinsic levels of fibrinolytic activity, including the oropharynx, nasopharynx and the 
urinary tract, are most often sites of excessive bleeding in FXI-deficient patients.  
The relatively modest contribution of FXI to hemostasis intuitively suggests that the 
protein would have a limited impact on pathologic coagulation, particularly thrombosis. 
However, epidemiologic data indicate a clear role for FXI in thrombotic events. In multiple 
studies, elevated FXI levels have been identified as a risk factor for myocardial infarction 
(Doggen et al., 2006), cerebrovascular disease (Yang et al., 2006), and venous thrombosis 
(Meijers et al., 2000); while FXI deficiency reduces risk for these diseases (Salomon et al., 
2008; 2009). Recent work with vascular injury models in mice, rabbits, and primates 
supports the impression that FXI has a disproportionately greater role in thrombosis than in 
hemostasis. FXI-deficient mice are protected from arterial thrombus formation induced by 
FeCl3 to an extent comparable to supratherapeutic doses of heparin (Wang et al., 2005; 
Gailani et al., 2010). FXII deficiency, selectively blocking FXI activation by FXIIa, or 
inhibiting the activation of FIX by FXIa has similar protective effects (Renné et al., 2005; 
Cheng et al., 2010; Tucker et al., 2009). Cumulatively, these data indicate that contact 
activation-driven activation of FXI may contribute to thrombosis, despite being 
unimportant for hemostasis.   
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A Potential Cofactor for Factor XI Activation During Coagulation 
Reactions involving FXI and FXII activation occur very slowly in solution. The 
importance of a negatively charged surface (usually purified clay) for initiation of contact 
activation and for FXI activation in in vitro assays in plasma is well-established, however, 
the identity of endogenous substances that would serve a similar function in vivo has been 
long debated. Some studies have shown that basement membrane-collagen exposed by 
vascular damage can facilitate FXII activation (van der Meijden et al., 2009), while others 
identified extracellular RNA from damaged or necrotic cells as promoters of contact 
activation (Kannemeier et al., 2007). Recently, several groups have provided evidence that 
polymers of inorganic phosphate (polyphosphate [polyP]) secreted during platelet 
activation are activators of the contact system in vivo (Smith et al., 2006).  
PolyP is a linear polymer of orthophosphate groups linked through high-energy 
phosphoanhydride bonds. It is ubiquitous, being found in almost all organisms ranging 
from bacteria to mammals (Kornberg et al., 1999). Each internal phosphate group carries a 
negative charge at physiologic pH, making polyP a highly anionic molecule. PolyP has 
been extensively studied in prokaryotes, where it acts as a calcium chelator in the 
electron-dense acidic organelles called acidocalcisomes (Docampo, 2006). In addition, the 
high energy phosphoanhydride bond serves as an ATP source in times of starvation or 
environmental stress. The dense granules of mammalian platelets are thought to be 
homologous to acidocalcisomes, indicating these organelles were conserved during 
evolution from prokaryotes to eukaryotes (Ruiz et al., 2004). PolyP is present at high 
concentrations in dense granules, and is efficiently secreted upon platelet activation (Smith 
et al., 2006). Upon full platelet activation, human blood is calculated to contain 1 to 3 μM 
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polyP (concentration given in terms of phosphate monomers), and the concentration may 
be much higher in platelet-rich thrombi (Morrissey et al., 2012). After secretion, polyP has 
a half-life of about 1.5 to 2 hours in human blood, and presumably undergoes 
depolymerization by polyphosphatases (Smith et al., 2006). 
A group of recent studies identified polyP as a potent regulator of hemostasis. In 
addition to triggering contact activation, polyP accelerates FV activation, and enhances 
fibrin formation (Morrissey et al., 2012) (Figure 1-3). Recently, polyP was reported to 
serve as a cofactor that accelerates FXI activation by thrombin and FXIa (to be discussed in 
detail in the next chapter) (Choi et al., 2012). The polymer length of polyP varies from only 
a few to several thousand phosphate units, depending on the type of organism or cell type it 
is isolated from. Interestingly, different length polymers exert different effects on 
coagulation (Smith et al., 2010). The very long polymers (hundreds to thousands of 
phosphate units) found in microorganisms are fairly potent triggers of FXII autoactivation 
and the contact pathway. In contrast, the relatively short polymers (~60-100 phosphate 
units) released by activated platelets are less potent activators of contact activation, but 
retain full capacity to promote FV and FXI activation. These findings support the 
hypothesis that platelet polyP functions primarily to enhance clot formation, while the 
longer microbial polyP can trigger contact activation, possibly as part of the host response 
to a pathogen (part of the innate immune response).  
 
The Purpose of Studies Described in this Thesis 
FXI is part of the traditional contact activation pathway, which historically received 
relatively little attention as a significant target to treat thrombosis, based on its minor role 
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in hemostasis. Abundant recent epidemiologic and animal data demonstrating that FXI 
plays a critical role in thrombosis, challenging the previous intuitive assumption that 
thrombosis is merely dysregulated hemostasis. Therapeutically targeting proteases such as 
FXIa or FXIIa could produce an anticoagulant effect with little effect on hemostasis. This 
would allow clinicians to broaden the current clinical indications for antithrombotic 
therapy, and decrease the cost for monitoring bleeding risk for patients under treatment.  
The work discussed in this thesis was designed to provide insight into the mechanisms 
by which FXI is converted to an active protease, and by which FXIa interacts with its 
substrate. The initial set of the experiments focuses on mechanisms involved in FXI 
activation by the proteases FXIIa, thrombin and FXIa, and the effects of polyP and other 
A                          B 
         
Figure 1-3. The role of polyphosphate in blood coagulation (Image adapted from 
Choi et al., 2011). (A) Long-chain polyP (over 500 phosphate units long) acts at 4 points 
in the clotting cascade, indicated in red: 1, initiates the contact pathway of blood clotting; 
2, accelerates FV activation; 3, enhances fibrin polymerization; and 4, accelerates FXI 
activation by thrombin. (B) Platelet-size polyP (60-100 phosphate units) acts primarily at 
points 2 and 4 in clotting cascade, with moderate effect on point 3.  
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polyanions on the activation reaction. The second group of experiments analyzes the novel 
mechanism by which FXIa converts FIX to FIXaβ, and describes a possible FIX binding 
site on FXIa. We expect this work will facilitate development of novel therapeutic agents 
to treat thromboembolic disease, as well as improve our understanding of the role of FXI 
and contact activation in blood coagulation.  
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CHAPTER II 
 
STRUCTURE AND FUNCTION OF FACTOR XI AND FACTOR XIa 
 
Factor XI Structure 
FXI is a 160 kDa dimeric glycoprotein consisting of two identical subunits connected 
by a disulfide bond (Fujikawa et al., 1986; McMullen et al. 1991). It is synthesized in 
hepatocytes, and circulates in blood plasma at a concentration of 25 to 40 nM (4 to 6 
μg/mL) in a noncovalent complex with HK (Bouma and Griffin, 1977; Thompson et al. 
1977). The primary sequence and disulfide bond structure of a FXI polypeptide chain is 
shown in Figure 2-1. Each FXI subunit contains four apple domains designated A1 through 
A4, and a protease domain (Fujikawa et al., 1986). Apple domains are members of the 
PAN (Plasminogen, Apple, Nematode) family of domains. Crystal structures have been 
reported for full-length zymogen FXI (Papagrigoriou et al., 2006), and the isolated active 
protease domain of FXIa in complex with inhibitors (Jin et al., 2005; Navaneetham et al., 
2005).  The catalytic domain of FXIa is a typical chymotrypsin-like serine protease. The 
catalytic domain active site contains a standard catalytic triad consisting of His413, Asp462, 
and Ser557. The four apple domains of each FXI subunit pack into a flat disk-like structure. 
The polypeptide takes a 180° turn between A2 and A3 so that A3 and A4 run anti-parallel 
to A1 and A2 (Figure 2-2). A remarkable feature of the FXI structure is the intimate 
linkage of the apple domains to form a disk-like platform around the base of the catalytic 
domain, resulting in a structure that is compact. This differs significantly from the more 
open linear structures of vitamin K–dependent coagulation proteases. In the FXI dimer the 
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planes of the apple domain disks of the two subunits are inclined at a 70° angle relative to 
each other (Figure 2-2). The FXI subunit shares a high degree of homology in both amino 
acid sequence and domain structures with the monomeric plasma protein PK, which is the 
zymogen of the protease α-kallikrein (Fujikawa et al., 1986; McMullen et al. 1991). 
Comparisons of the amino acid sequences of FXI with PK have greatly facilitated 
identification of residues of functional relevance. 
 
Figure 2-1. The amino acid sequence and disulfide bond locations of human FXI. 
Schematic diagram of the primary structure of FXI as reported by Fujikawa et al. The apple 
domains are designated A1-A4. Cysteine residues that form disulfide bonds within a FXI 
subunit are shown in yellow. Cys321 in A4 forms the disulfide bond between the dimer 
subunits. FXI is cleaved after Arg369 to form FXIa. The residues of the protease domain 
catalytic triad are shown in green. Amino acids that are involved in the hydrophobic core of 
the dimer interface are shown in maroon. The two anion binding sites are in magenta. 
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While the FXI protease domain shares common structural and functional features with 
other trypsin-like coagulation proteases, the apple domains distinguish FXI from other 
proteases required for hemostasis. Apple domains contribute to the majority of binding 
interactions between FXI/FXIa and macromolecular ligands and substrates involved in 
protease function and regulation (Figure 2-3). Studies with FXI/PK chimeras in which 
individual FXI apple domains are replaced by the corresponding domain from PK indicate 
that the A2 domain is required for binding to HK (Renné et al., 2002), with contributions 
from A1 and A4 (Baglia et al., 1990; 1992). Thrombin binds to the A1 domain of FXI, with 
 
 
Figure 2-2 The 
structure of FXI. 
Topology diagram 
showing the structure 
of FXI zymogen. 
A1-A4 domains and 
protease domains are 
shown in gray, blue, 
orange, yellow and 
maroon, respectively.  
Figure 2-3. FXI apple 
domain disk. Shown is the 
disk structure formed by the 
apple domains (A1, A2, A3, 
and A4) of human FXI, which 
are shown in light blue, gray, 
orange, and yellow, 
respectively. Locations of 
amino acids implicated in 
putative ligand binding sites 
are shown as space filling 
images in red for thrombin, 
green for HK, black for 
glycoprotein Ib (Gp Ib), blue 
for heparin and orange for FIX. 
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residues Glu66, Lys83, and Gln84 forming part of the binding site (Baglia et al., 1996; 
Papagrigoriou et al., 2006). The residues involved in binding to FXIIa have not been 
clearly established. While studies using peptide mimicry point to a FXIIa binding site on 
the A4 domain (Ala317-Gly350) (Baglia et al., 1993), a monoclonal antibody binding to A2 
interferes with FXI activation by FXIIa (Cheng et al., 2010). The A3 domain contains a 
binding site for FIX that is only exposed on the activated protease FXIa (Sun et al., 1996; 
Sun et al., 1999). A3 also supports interactions with polyanions and the platelet receptor 
Glycoprotein 1bα (GP 1bα) (Baglia et al., 1995; 2004).  The importance of the A3 domain 
to interactions with FIX will be elaborated on in detail in the next chapter. 
 
The Dimeric Structure of Factor XI 
The most unusual feature of FXI is its homodimeric structure. The dimer interface 
involves residues within the A4 domain on each subunit (Figure 2-4) (Papagrigoriou et al., 
2006).  A loop containing Cys321 projects away from the body of the domain, and Cys321 
forms an interchain disulfide bond with Cys321 from the opposite subunit. The FXI 
homolog PK is a monomer with Cys321 paired with Cys326, a residue not present in FXI 
(McMullen et al., 1991). Human FXI in which Cys321 is replaced with another amino acid 
still forms non-covalently associated dimers (Meijers et al., 1992; Cheng et al., 2003). 
Furthermore, substituting Cys326 in PK with Gly, which prevents intradomain disulfide 
bond formation, does not induce PK dimerization (Cheng et al., 2003). This indicates that 
non-covalent interactions are primarily responsible for maintaining the dimeric structure. 
The FXI crystal structure reveals a mixture of electrostatic and hydrophobic interactions in 
dimer interface (Samuel et al., 2007). Leu284, Ile290, and Tyr329 form the hydrophobic 
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the core of the interface, and salt bridges form between Lys331 from one subunit and 
Glu287 from the other subunit. In Chapter VII, a monomeric FXI species will be generated 
by replacing some of the residues that are critical for dimer formation. 
The dimeric structure of FXI is unique among trypsin-like coagulation proteases, and is 
conserved across mammalian species (Ponczek et al., 2008), indicating functional 
importance. Over the past 35 years a significant amount of effort has been put into 
understanding the physiologic significance of the FXI dimer. Previous speculation on the 
function of the dimeric structure includes proper protein secretion (Meijers et al., 1992) or 
FIX activation (Wolberg et al., 1997). However, subsequent work refuted these 
possibilities (Wu et al., 2008; Smith et al., 2008).  Recent studies by Papagrigoriou et al. 
and Wu et al. suggest FXI may be activated by a trans-activating mechanism, where the 
activating protease binds one FXI subunit while activating the opposite subunit through 
proteolytic cleavage. Work discussed in Chapter VII addresses the importance of the 
 
Figure 2-4. Two perspectives of the FXI A4 domain dimer interface. Left: one A4 
domain as a charge-surface representation, and the other A4 domain as a ribbon diagram 
showing the side chains of residues that interact with the opposite A4 domain. Right: 
ribbon diagram of two A4 domains with the hydrogen bonds and electrostatic interface in 
magenta. (After Papagrigoriou et al., 2006) 
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dimeric structure to zymogen activation in detail. Previous studies of FXI activation were 
performed primarily in systems with purified proteins, and used non-physiologic 
polyanions to enhance the activation rates. We will assess the importance of FXI dimeric 
structure in more physiologically relevant systems, including studies with polyP as a 
cofactor. 
 
Activation of Factor XI 
Conversion of a FXI subunit to FXIa involves cleavage of the Arg369-Ile370 bond, 
resulting in a 45 kDa heavy chain (comprised of the 4 apple domains), and a 35 kDa light 
chain (the catalytic domain). The heavy and light chains remain connected by a disulfide 
bonds between Cys362 in the A4 domain and Cys482 in the catalytic domain (McMullen et 
al., 1991). Cleavage after Arg371 activates PK in a similar manner (Hooley et al., 2007). 
After activation, FXIa Ile370 (the new free N-terminus of the catalytic domain) moves 
approximately 20 Å to insert into the activation pocket of FXIa (Figure 2-5), and 
contributes to the proper conformation of the newly formed active site by forming a salt 
bridge with Asp556 (Navaneetham et al., 2005).  
While crystal structures are not available for full-length dimeric or monomeric FXIa, 
small-angle X-ray scattering and electron microscopy studies indicate that a large 
conformational change occurs with activation, from an elongated (dumbbell-shaped) 
structure to a more compact (box-like) arrangement (Samuel et al., 2007). Consistent with 
this, a comparison of the NMR structure of the isolated FXI A4 domain and the crystal 
structure of A4 in full-length FXI suggests that cleavage of the covalent linkage between 
A4 and the catalytic domain in FXI zymogen causes a major conformational change 
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that brings the two catalytic domains of the dimer into closer proximity (Samuel et al., 
2007). While the structure of full-length FXIa remains speculative, it is clear from 
structures of the isolated FXIa catalytic domain that significant structural changes 
accompany zymogen activation.  
In the original waterfall-cascade model of coagulation, FXI is activated by FXIIa 
(Davie et al., 1991). However, people with FXII deficiency do not have a bleeding disorder 
(Walsh and Gailani 2006), while FXI deficient patients can experience abnormal bleeding 
(Salomon et al., 2006). This suggests that FXIIa is not the only activator of FXI in vivo. In 
1991, two groups reported that thrombin can activate FXI and that FXI can undergo 
autoactivation in the presence of polyanions (Naito and Fujikawa, 1991; Gailani and 
Broze, 1991). There have been different opinions on the importance of thrombin-mediated 
FXI activation. Pedicord et al. did not find evidence for FXIIa-independent activation of 
FXI in plasma, and concluded that previous results demonstrating FXIIa-independent FXI 
 
Figure 2-5. FXI 
catalytic domain. 
Shown is a ribbon 
diagram superimposing 
the protease domain 
structure of FXI 
zymogen (yellow) and 
FXIa (green). Ile370 
(purple) positions into 
the protease core after 
cleavage of the 
Arg369-Ile370 bond. 
(After Papagrigoriou et 
al., 2006) 
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activation may have been compromised by an artifact of plasma preparation (Pedicord et 
al, 2007). Subsequently, Kravtsov et al. showed that FXI can be activated in plasma in the 
absence of FXII under conditions that controlled for FXIa contamination (Kravtsov et al., 
2009). In contrast to the controversy surrounding the role of FXI activation by FXIIa 
during normal hemostasis, multiple recent studies have suggested an important role for this 
reaction in thrombosis. FXI- or FXII-deficient mice have a significant defect in 
experimentally induced arterial thrombus formation (Wang et al., 2005; Renné et al., 
2005), and an antibody blocking FXI activation by FXIIa prevented thrombus formation in 
wild type mice to a similar degree as total FXI deficiency (Cheng et al., 2010).   
It is now thought that thrombin generated as a consequence of FVIIa/TF activity can 
feed back to activate FXI (Figure 1-1), FXIa can then sustain thrombin generation through 
activation of FIX. This seems compatible with proposed role of FXI in maintaining fibrin 
clot integrity during normal hemostasis. FXI can be activated by several products of 
prothrombin activation (von dem Borne et al., 1997; Matafonov et al., 2011). The main 
product, α-thrombin, has two anion binding exosites (ABE I and ABE II) that are required 
for interactions with substrates, receptors, and inhibitors (Krishnaswamy et al., 2005). 
ABE I mediates binding to fibrinogen and fibrin, while ABE II mediates binding to 
polyanions including heparin and polyphosphate. During coagulation, prothrombin is 
converted initially by FXa to the protease meizothrombin, which expresses ABE I 
(Anderson et al., 2003). Meizothrombin is rapidly converted to α-thrombin, which can 
undergo additional cleavage to form β-thrombin and γ-thrombin (Bovill et al., 1995; Jenny 
et al., 2006). The latter two proteases have intact ABE II, but reduced activity for ABE I- 
dependent reactions. There are controversial results concerning the importance of the 
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anion binding sites on thrombin for FXI. Yun et al. suggested that ABE I is required for 
binding and activation of FXI (Yun et al., 2003). However, Matafonov et al. recently 
presented evidence that β-thrombin and γ-thrombin are capable of activating FXI in plasma 
(Matafonov et al., 2011), which argues against the importance of ABE I.  
Although thrombin has received increasing attention as an activator of FXI, the 
physiologic significance of FXI activation by thrombin was questioned because of the 
extremely slow reaction rate in vitro. It had been established that non-physiologic 
polyanions, such as dextran sulfate, heparin, or high levels of sulfatides accelerate FXI 
activation by thrombin (Gailani and Broze, 1991; 1993). In fact, polyanions can support 
FXI activation in the absence of FXIIa or thrombin. This process has been termed 
“autoactivation”, and is likely triggered by traces of FXIa in FXI preparations, although the 
possibility that zymogen FXI has protease activity after binding to polyanions cannot be 
completely ruled out. Recently, polyP from platelet dense granules has been shown to 
promote FXI activation by thrombin or autoactivation (Choi et al., 2011). Synthetic polyP 
of the size secreted by platelets, or boiled platelet releasates (which degrade all associated 
proteins) markedly accelerated the rate of FXI activation by thrombin, suggesting that 
polyP released from platelets is a natural cofactor for FXI activation in vivo. Furthermore, 
FXI binding to polyP appears to be required for cofactor activity. In Chapter IX we will 
examine this interaction using FXI mutants that are defective in binding to polyanions, and 
assess the physiologic consequence of this interaction in vivo.  
As FXI is a homodimer, it must be cleaved at two spatially separated Arg369-Ile370 
bonds for activation of both subunits. Traditionally, this process has been treated as a 
one-step process, in which a protease with both subunits (FXIa) is produced directly from 
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FXI. However, recent work demonstrates that FXI activation by FXIIa or α-thrombin 
proceeds through an intermediate with one activated subunit (1/2-FXIa) (Smith et al., 
2008), which may actually be a major species of activated FXI in plasma. Work examining 
the importance of the dimeric structure of FXI to activation, and the relative activation rate 
of the two FXI subunits is presented in Chapter VI.  
 
Inhibition of Factor XIa 
Activated FXIa is regulated by plasma serine protease inhibitors (serpins), including 
C1-inhibitor (C1-INH) (Forbes et al., 1970), antithrombin (AT) (Damus et al., 1973), 
α1-antitrypsin (Heck and Kaplan, 1974), α2-antiplasmin (Saito et al., 1979), protease nexin 
1 (Knauer et al., 2000) and protein Z-dependent protease inhibitor (Han et al., 2000). The 
specificity of the inhibition is determined to a large extent by basic amino acids in the FXIa 
autolysis loop (Arg504, Lys505, Arg507 and Lys509) (Rezaie et al., 2000). In addition to 
serpins, FXIa is inhibited by protease nexin 2, a Kunitz-type protease inhibitor secreted by 
activated platelets (Smith et al., 1990). The inhibition is reported to be a reversible process 
that requires interactions between the Kunitz protease inhibitor domain of PN2 and the 
catalytic domain of FXIa (Badellino and Walsh, 2000; Navaneetham et al., 2005).  
In plasma, C1-inhibtor (C1-INH) appears to be the predominant regulator of FXIa 
(Wuillemin et al., 1996). While antithrombin (AT) normally inhibits FXIa at lower rates 
than C1-INH, the presence of the glycosaminoglycan heparin, enhances inhibition of FXIa 
by AT up to 500-fold (Zhao et al., 1998; Olson et al., 2004). Two anion binding sites on 
FXIa are involved in the interaction with heparin (Figure 2-6). A binding site on the A3 
domain (Lys252, Lys253 and Lys255) is unique to FXI and FXIa, and facilitates 
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AT-mediated inhibition through a mechanism that involves FXIa and AT binding in 
proximity on the heparin (a template mechanism, Zhao et al., 1998). A second binding site 
on the catalytic domain (Lys529, Arg530, Arg532, Lys536 and Lys540) is similar to heparin 
binding sites found on other coagulation proteases.  Its role in FXIa inhibition is complex 
and may include charge neutralization or an allosteric effect that overcomes repulsive 
interactions between AT and basic residues on the catalytic domain (Yang et al., 2009). 
Like heparin, polyP is a negatively charged polymer that needs to bind to FXI for its effects 
on the protein to become apparent. In Chapter IX we will assess the importance of the 
known anion binding sites on FXI to the FXI interaction with polyP.  
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CHAPTER III 
 
STRUCTURE AND ACTIVATION OF FACTOR IX 
 
Structure of Factor IX 
Factor IX (FIX) is the zymogen of a key enzyme in blood coagulation, factor IXaβ 
(FIXaβ). Deficiency of its activity in plasma results in an X-linked bleeding disorder, 
Hemophilia B, which occurs once in every 25,000-30,000 male births (Ragni et al., 2009). 
The disease is characterized by prolonged or recurrent bleeding after mild trauma, or in 
severe cases, spontaneous joint or deep-muscle bleeding. Zymogen FIX is a single 
polypeptide of 57 kDa (415 amino acids). It is synthesized in hepatocytes and secreted into 
the plasma where it circulates at a concentration of ~80-100 nM (Schmidt and Bajaj, 2003).  
A fraction of secreted FIX forms a non-circulating pool bound to collagen in the 
subendothelial basement membranes of blood vessels (Gui et al., 2009). As discussed in 
Chapter I, both FVIIa/TF and FXIa convert FIX to the active enzyme FIXaβ.  FIXaβ, with 
its cofactor VIIIa, forms the “intrinsic Xase” complex on phospholipid membranes.  
FIX is a member of the family of Vitamin K-dependent (VKD) coagulation proteins. 
Starting from the N-terminus, FIX is composed of an N-terminal Gla domain, a 
hydrophobic stack region, two epidermal growth factor domains (EGF1 and EGF2) 
connected by a short linker, an activation peptide (AP), and a C-terminal trypsin-like 
catalytic serine protease domain (Figure 3-1). There are no published crystal structures for 
full length human FIX or FIXaβ (there are crystal structures for porcine FIXaβ 
[Brandstetter et al., 1995], the EGF2 and protease domain of human FIXaβ [Hopfner et al., 
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1999]; as well as several crystal and NMR structures of individual Gla [Shikamoto et al., 
2003; Huang et al., 2004] and EGF1 domains [Baron et al., 1992]). Figure 3-2 shows a 
space-filling structure for FIX and FIXaβ based on available information (image courtesy 
of Dr S. Paul Bajaj, UCLA). FIX has the typical elongated profile of a VKD coagulation 
protease, with Gla domain and catalytic domains at opposite ends of the molecule. 
Structure-function studies indicate that the Gla, EGF1, EGF2, and catalytic domains of 
FIX are involved in specific interactions with substrates, phospholipid surfaces and 
cofactors. The Gla and EGF1 domains and the AP contain recognition sites for the   
 
Figure 3-1. Amino acid sequence and disulfide bond locations of FIX. Cysteine 
residues are in yellow. γ-carboxylated glutamic acid are shown in green, and the activation 
peptide in blue. Residues Arg145 and Arg180 are the cleavage sites for protease activation. 
The protease domain catalytic triad is shown in red. 
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FVIIa/TF complex, while the protease and EGF2 domains of FIXaβ contain recognition 
sites for FVIIIa (Schmidt and Bajaj, 2003).  
 
The Factor IX Gla Domain 
A structural element common to all VKD proteins is an N-terminal γ-carboxyglutamic 
acid-rich “Gla” domain. The FIX Gla domain contains 12 glutamic acid residues (Figure 
3-1) that undergo post-translational modification by addition of a carboxyl group to the 
γ-carbon (Bandyopadhyay, 2008). This process is mediated by the enzyme γ-glutamyl 
carboxylase, and requires reduced vitamin K as a cofactor. The widely used anticoagulant 
 
A                         B 
 
C                        D 
  
Figure 3-2. Structure of FIX and FIXa. A and B: The schematic diagram of human FIX 
(A) and FIXaβ (B) with the domains labeled. Abbreviations for domains are: Gla - 
γ-carboxyglutamic acid domain, and EGF - epidermal growth factor domain. The 
catalytic domains (CAT) is shown in red and green, and the activation peptide is shown in 
green. C and D: A space filling model of human FIX (C) and FIXaβ (D) based on 
published structure of parts of the molecule. Gla domain is shown in yellow, EGF1 and 2 
are in blue, the activation peptide in white and the catalytic domain in red. Divalent 
cations in the Gla domain are shown as magenta spheres. Model courtesy of Dr. S. Paul 
Bajaj (University of California, Los Angeles).  
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warfarin inhibits γ-carboxylation by interfering with regeneration of reduced vitamin K 
(Holbrook et al., 2005). The malonate-like side chains of γ-carboxylated glutamic acid 
residues in FIX bind 8 divalent metal ions, five of which are internal and three of which are 
on the surface of the Gla domain (Figure 3-3) (Schmidt and Bajaj, 2003). At physiologic 
plasma Ca2+ and Mg2+ concentrations, sites 2, 3, 5 and 6 are occupied by Ca2+, while sites 
1, 4, 7 and 8 are occupied by Mg2+ (Shikamoto et al., 2003; Agah and Bajaj, 2009). 
Binding of these divalent cations induces a structural transition in the Gla domain from an 
unfolded nonfunctional form to one that is tightly folded (Vadivel et al., 2012). This allows 
the entire domain to adopt a “functional” conformation that facilitates binding to 
phospholipids and protein ligands. The Gla domain binds to phospholipid membranes 
through a solvent-exposed hydrophobic patch termed the “ω-loop” (omega loop). In FIX, 
 
Figure 3-3. A ribbon diagram of the Gla domain of FIX. Shown are the N-terminus 
residue to residue 46. Side chains of γ-carboxyglutamic acid residues (γ), and Lys 5, Leu6 
and Phe9 in the omega loop are in green. Divalent cations are shown as cyan spheres 
(numbered). (Adapted from Agah and Bajaj, 2009) 
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the ω-loop is composed of residues 4-11 at the N-terminus of the Gla domain (Huang et al., 
2003). Residues Lys5, Leu6 and Phe9 of the ω-loop interact with the head-group and 
glycerol backbone of phosphotidylserine, while the divalent cations bound to the Gla 
domain form bridges with the negatively charged head-groups (Huang et al., 2003; Grant 
et al., 2004). Residue Lys5 on FIX is also required for binding to type IV collagen, a 
ubiquitous component of endothelial cell basement membrane (Cheung et al., 1992; Gui et 
al., 2002). This interaction is likely to influence distribution of FIX, as described above 
(Gui et al., 2009). 
Although distant from the activation cleavage sites on FIX, the Gla domain plays a 
critical role in FIX activation by FVIIa/TF and FXIa. FVIIa and FIX have similar 
elongated structures. The Gla domains of each protein contribute to assembly of an 
enzyme-substrate complex on a phospholipid membrane. These binding reactions are 
largely responsible for determining the Michaelis constant (Km) for the reaction. In a 
modeled structure of the FVIIa-TF-FIX ternary complex, the FIX Gla and EGF1 domains 
interact with tissue factor near the phospholipid surface (Chen et al., 2002).  
In contrast to FVIIa, FXIa lacks a Gla domain. Probably as a consequence, 
phospholipid does not affect FIX activation by FXIa. However, studies suggest that the 
FIX Gla domain is essential for direct binding to FXIa. A recombinant chimera consisting 
of FIX with the FVII Gla domain (FIX/VII-Gla), as well as recombinant wild type FIX 
(FIX-WT) expressed in the presence of warfarin (to inhibit γ-carboxylation) do not bind to 
FXIa and, therefore, are activated poorly by FXIa (Aktimur et al., 2003). For comparison, 
replacing the FIX Gla domain with the Gla domain of either FVII or protein C does not 
affect its activation by FVIIa/TF (Aktimur et al., 2003; Ndonwi et al., 2007). These 
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findings suggest that the FIX Gla domain contains a specific epitope(s) that interacts with 
FXIa that is distinct from the regions that bind to FVIIa/TF. In Chapter VI, studies 
investigating the residues on the FIX Gla domain that are required for the interaction with 
FXIa will be presented.  
 
Activation of Factor IX 
Activation of human FIX requires proteolytic cleavage of the Arg145-Ala146 and 
Arg180-Val181 peptide bonds, resulting in release of the 35-amino acid activation peptide. 
The activated protease, FIXaβ, contains a light chain (Gla, EGF1 and EGF2 domains) and a 
heavy chain (protease domain) connected by a single disulfide bond (Figure 3-4). Cleavage 
 
 
Figure 3-4. FIX activation. FIX is converted to FIXaβ by sequential cleavage at the 
Arg145-Ala146 and Arg180-Val181 bonds, releasing the activation peptide (green ribbon), 
and converting the inactive catalytic domain (red) to active protease (green). Initial cleavage 
at Arg180-Val181(forming the alternative intermediate factor IXaα) is a minor reaction 
(dashed arrow) during plasma coagulation. 
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of the Arg180-Val181 bond results in formation of a new N-terminus for the heavy chain 
(Val181) that forms a salt bridge with Asp364. This critical event induces the active site of 
the protease domain to assume an active conformation (Thompson, 1991).  
The two proteolytic cleavages that activate FIX appear to be sequential and ordered, as 
only one of the two possible intermediates normally is formed. The FIX activation 
intermediate cleaved after Arg145 (FIXα) is observed during reaction time courses, and a 
recombinant FIX mutant containing Arg145Ala substitution is cleaved poorly by FXIa 
(Smith et al., 2008). These observations indicate that the Arg180-Val181 bond is either not 
readily available or is not preferred for initial cleavage by either FXIa or FVIIa/TF. 
Cleavage after Arg145 may change the conformation of the substrate, facilitating 
subsequent cleavage after Arg180. Interestingly, a protease in the venom from Russell’s 
Viper (RVV) preferentially cleaves FIX at Arg180-Val181, resulting in a FIX intermediate 
with the activation peptide remaining attached to the light chain (FIXaα) (Griffith et al., 
1985). Although the protease domain of FIXaα is in an active conformation, the enzyme 
has only ~20% of the activity of FIXaβ towards activating FX (Griffith et al., 1985), 
suggesting that complete removal of the activation peptide is essential for normal function 
of activated FIX in coagulation.  
After cleavage of the Arg145-Ala146 bond, FIXα is released from FVIIa/TF and must 
rebind for the Arg180-Val181 bond to be cleaved. As the second cleavage is rate-limiting, 
FIXα accumulates during activation. In contrast, FIX activation by FXIa does not require 
phospholipid or a cofactor, and there is little, if any, FIXα accumulation. Therefore, it is 
reasonable to hypothesize that different mechanisms are involved in FIX activation by the 
two proteases. As discussed in Chapter II, FXIa has a homodimeric structure that is very 
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different from that of FVIIa and the other vitamin K-dependent coagulation proteases. A 
possible explanation for the lack of intermediate accumulation during FIX activation by 
FXIa is that the two catalytic domains of FXIa cleave both scissile bonds of FIX 
simultaneously. However, subsequent work demonstrated that each subunit of FXIa 
behaves as an independent enzyme toward FIX (Smith et al., 2008), with little FIXα 
accumulation detected using FXIa species with only one active subunit. A major goal of 
the work discussed in this thesis is to investigate the mechanism by which FXIa activates 
FIX, and to understand the reasons for the absence of FIXα accumulation during the 
reaction.  
Like most trypsin-like serine proteases, the FXIa active site contains a catalytic triad 
consisting of histidine (His413), aspartic acid (Asp462) and serine (Ser557) residues. These 
residues correspond to His57, Asp102 and Ser195 in chymotrypsin. The chymotrypsin 
numbering system is often used to compare trypsin-like serine proteases. Catalysis 
mediated by a trypsin-like protease requires a nucleophilic attack on the carbonyl carbon of 
the properly positioned substrate by Ser195, with His57 and Asp102 involved in positioning 
of Ser195 and in stabilizing the substrate-enzyme intermediate (Stryer, 1995). While the 
catalytic triad is responsible for substrate cleavage, residues flanking the cleavage site on 
the substrate (which are designated P), and their complementary residues on the enzyme 
(designated S) are important for docking interactions between substrate and enzyme 
(Krishnaswamy, 2005). Residues extending from the scissile bond towards the N-terminus 
are designated P1, P2…Pn, and the residues that interact with them on the enzyme are 
designated S1, S2…Sn (Schechter and Berger, 1967). The S1 to S3 sites on FXIa are 
Asp551, Ser576 and Gly578 (Asp189, Ser214 and Gly216 in chymotrypsin numbering). They 
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are located in close proximity to the catalytic triad on the FXIa catalytic domain and 
contribute to the correct conformation of the cleft-shaped active site.  
While specificity of coagulation proteases for small substrates and inhibitors is 
determined largely by sites in proximity to the active site, such as the S1 to S3 sites, 
specificity for macromolecular substrates is often dictated by binding interactions at sites 
remote from the active site (Krishnaswamy et al., 2005). These remote binding sites are 
referred to as exosites. There is compelling evidence that one or more exosites on FXIa are 
required for normal FIX activation (Sun et al., 1999; Ogawa et al., 2005), but there is a lack 
of agreement on their locations. It is established that FIX activation requires the FXIa 
heavy chain (Sinha et al., 1987; Baglia et al., 1989). In 1991 it was reported that a 
FIX-binding exosite resides on A2 domain of FXIa, based on work with inhibitory peptides 
(Baglia et al., 1991). However, studies using FXI proteins in which individual apple 
domains were replaced by the corresponding domains of PK (a poor activator of FIX) 
indicated that FIX interacts with an exosite on the FXIa A3 domain (Sun et al., 1996). 
Subsequent work identified a relatively restricted region within the A3 domain 
(Ile183-Ile197, Phe260-Ser265) that is required for the normal FIX activation by FXIa (Sun 
et al., 1999). More recently, evidence has been presented for a distinct FIX-binding exosite 
on the FXIa catalytic domain (Sinha et al., 2007). The authors reported similar Kms for FIX 
activation by the isolated FXIa catalytic domain (a species lacking the entire heavy chain) 
and full-length FXIa, implying the catalytic domain was largely responsible for 
recognition and specificity of FIX binding. These data are not compatible with those 
showing that FXIa A3 domain substitution results in a marked increase in Km for FIX 
activation (Sun et al., 1999; Ogawa et al., 2005). In Chapter IV, we will present a kinetic 
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analysis of conversion of FIX to the intermediate FIXα and the final product FIXaβ by 
FXIa and FXIa variants that addresses these conflicting results, and will propose a 
mechanism for FIX activation by FXIa. 
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CHAPTER IV 
 
A MECHANISM FOR FACTOR IX ACTIVATION BY FACTOR XIa 
 
Cleavage of Factor IX and Factor IXα by Factor XIa 
During coagulation, FIX is activated by FVIIa/TF and FXIa. Although FIXα forms 
during activation by either FVIIa or FXIa, it does not accumulate during the latter reaction 
(Wolberg et al., 1997; Smith et al., 2008). This indicates that different activation 
mechanisms are involved, and initially raised the possibility that the dimeric FXIa structure 
may be required to catalyze FIX activation without intermediate accumulation.  However, 
subsequent studies clearly demonstrated that an isolated FXIa subunit is able to convert 
FIX to FIXaβ without intermediate accumulation (Smith et al., 2008; Wu et al., 2008). 
This implies sequential cleavages of the two scissile bonds of FIX by a single FXIa subunit, 
and not the two FXIa subunits of one dimer cleaving the two FIX scissile bonds 
simultaneously.  
The combination of sequential cleavage of FIX scissile bonds and the absence of 
intermediate FIXα accumulation could be explained by two distinct mechanisms. FIX 
could be processed to the final product FIXaβ without release of the intermediate FIXα. 
Such a mechanism has been termed “processive” in prior studies (Wolberg et al., 1997). 
However, this mechanism is not consistent with the subsequent observation that active 
site-blocked FXIa is capable of capturing FIXα during FIX activation by FXIa (Smith et al., 
2008). This demonstrates that at least a portion of FIXα is released from the enzyme, and 
indicates a mechanism in which FIXα would be released from FXIa after cleavage of the 
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Arg145-Ala146 bond, with the intermediate being recaptured prior to cleavage of 
Arg180-Val181. Here, cleavage after Arg145 would have to be rate-limiting to account for 
the lack of intermediate accumulation. To address the conflicting hypotheses regarding the 
mechanism of FIX activation by FXIa, we conducted kinetic analysis to measure the 
cleavage rates of each FIX scissile bond.  
Two strategies have been used to follow FIX activation. FIXaβ can be measured by 
cleavage of a chromogenic substrate (Ogawa et al., 2005). However, this method lacks 
sensitivity, making it difficult to measure initial activation rates. Sensitivity can be 
improved by using a coupled assay in which FIXaβ converts FX to FXa in the presence of 
factor VIIIa, and FXa is then detected with a chromogenic substrate (Sun et al., 1996; 
Sinha et al., 2007). Because of its complexity, reproducibility is the major problem with 
this assay. Chromogenic substrate-based techniques share a limitation, in that they are 
uninformative about FIXα generation, because this intermediate lacks enzymatic activity. 
To address this problem, we monitored FIX activation by densitometry of Coomassie 
Blue-stained SDS-PAGE gels imaged at infrared wavelengths. The low signal to noise 
ratio facilitates studying reactions with substrate concentrations down to 25 nM. Full 
progress curves are constructed from data for the disappearance of FIX, and the appearance 
of FIXα and FIXaβ. A disulfide bond connects the polypeptides that comprise FIXα, which 
has essentially the same molecular mass as FIX (Figure 4-1A). Interestingly, despite 
having similar molecular masses, we observed that FIXα migrates slightly faster than FIX 
on non-reducing SDS-PAGE, likely due to conformational changes that accompany 
cleavage. This allowed us to accurately measure the amount of FIX and FIXα at different 
points in reactions by SDS-PAGE. 
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Figure 4-1 FIX and FIXα cleavage by FXIa-WT. (A) Nonreducing 17% 
polyacrylamide SDS gels of 100 nM FIX (top) or FIXα (bottom) in assay buffer (see 
“Methods”) with Ca2+ incubated at room temperature with 3 nM (active sites) FXIa-WT. 
Positions of standards for FIX, FIXα, and FIXaβ are indicated at the right of each panel. 
(B) Progress curves of FIX disappearance (z), and FIXα (О), and FIXaβ (▲) generation 
from panel A (top). Lines represent the least-squares fits to the data. (C) Initial velocities 
of cleavage after Arg145 (conversion of FIX to FIXα) by 1 μM FXIa-WT active sites, as a 
function of FIX concentration. Initial rates were obtained from the slopes of the linear 
portions of progress curves documenting the disappearance of FIX with time. (D) Progress 
curves of FIXα cleavage by FXIa-WT determined from panel A (bottom). (E) Initial 
velocities of cleavage after Arg180 (conversion of FIXα to FIXaβ) by 1 μM FXIa-WT as a 
function of FIXα concentration. 
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We determined steady-state kinetic parameters for FIX cleavage by numerical 
integration and lease-squares fitting of full progress curves of FIX depletion, and FIXα and 
FIXaβ formation at FIX concentrations from 25 to 1000 nM. First, Km, kcat, Kd, Ki, and 
catalytic efficiency (kcat/Km) were determined for both cleavages during FIX activation 
simultaneously (Table 4-1). As a complementary method, a conventional 
Michaelis-Menten approach was also conducted, from which Km and kcat was calculated 
by analyzing the initial cleavage rate after Arg145 as a function of FIX concentration (Table 
4-2). kcat, the turnover number, is the maximum number of substrate molecules converted 
to product per enzyme molecule per minute. The Michaelis constant Km is the substrate 
concentration at which the reaction rate is at half-maximum, and is a measure of the 
substrate affinity for the enzyme. Subsequently, the same method was used with FIXα as 
the initial substrate. As our FIXα preparations had up to 20% FIX contamination, analyses 
of conversion of FIXα to FIXaβ included the cleavage of the contaminating FIX.    
Initially, we assessed FIX conversion to FIXaβ by recombinant FXIa (FXIa-WT) in the 
presence of Ca2+ ions (Figure 4-1 A-C). Ca2+ is essential for proper activation of FIX. As 
expected, little FIXα accumulation was observed. It should be noted that while FIXα is 
usually not detected when FIX is activated by plasma-derived FXIa, traces may be seen 
with recombinant FXIa. The analysis demonstrated that catalytic efficiency for the second 
cleavage after Arg180 is ~7-fold higher than for cleavage after Arg145 (400 ± 100 and 60 ± 
6 μM-1 min-1, respectively), with an estimated ~2.5-fold lower Km and ~3-fold higher kcat 
for cleavage after Arg180. These results support a release-rebind mechanism, in which 
cleavage of the Arg145–Ala146 bond increases the efficiency of cleavage of the Arg180- 
Val181 bond, without FIXα accumulation. 
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In 1997, Wolberg et al. observed that the rate of cleavage of the Arg145–Ala146 bond in 
the intermediate FIXaα (FIX cleaved after Arg180) and the rate of cleavage of the 
Arg180–Val181 bond in FIXα are comparable, and similar to the overall rate for conversion 
of FIX to FIXaβ. Based on this, they suggested that any intermediate formed may not be 
released prior to conversion to FIXaβ, explaining the lack of intermediate accumulation 
during activation by factor XIa. Our results do not agree with this model, and are more 
consistent with the observation that significant FIXα accumulates in competitive reactions 
in which FIX is activated by FXIa in the presence of active site-inhibited FXIa (Smith et al., 
2008).  
We measured the cleavage rate of purified FIXα by FXIa-WT. To our surprise, the 
catalytic efficiency of cleavage after Arg180 in FIXα (130 ± 20 μM-1 min-1) was ~3-fold 
lower than for FIXα formed in situ during FIX activation (Figure 4-1 A, D, and E, and 
Tables 4-1 and 4-2). This may reflect structural perturbations in FIXα acquired during its 
purification. Another possibility that could explain the difference is partial intermediate 
release, with a fraction of FIXα repositioned for cleavage after Arg180 while remaining 
bound to FXIa. This is taken into account in the reaction mechanism of kinetic analysis 
(“Methods”): FIXα* was used to indicate intermediate bound to FXIa in the correct 
orientation for cleavage after Arg180, which is separate from FIXα in the aqueous phase (a 
transition from FIXα • XIa directly to FIXα* • FXIa). We simulated a model, using our 
data, that includes conformational repositioning of FIXα • FXIa to the productive complex 
FIXα* • FXIa without release, in parallel with release rebinding. Because the true ratio of 
FIXα • FXIa to FIXα* • XIa is unknown, we examined a range of values for the ratio 
(0.05–1), and found that the model fits data sets for cleavage after Arg180 for both nascent 
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and purified FIXα by FXIa-WT reasonably well at a ratio of 0.5, a Kd of ~100 nM for 
binding of FIXα to FXIa in a productive complex, and a kcat of ~20 min-1. The results 
suggest a possible upper limit of ~40% (the difference between kcat of 35 min-1 and 20 
min-1) for FIXα proceeding to FIXaβ through repositioning without release-rebinding. If 
the mechanism only involved repositioning of FIXα without release, no transient 
intermediate should be observed in time courses with FXIa-WT, no FIXα would 
competitively bind to active site-blocked FXIa, and kcat for the second cleavage would 
have to be exceedingly large (up to 60 - 150 min-1). Our data indicate this scenario is not 
likely. 
 
Cleavage of Factor IX by Factor XIa Loss-of-function Variants: the Importance of 
Apple Domains 
As discussed in Chapter III, the FXIa heavy chain contains a substrate-binding exosite, 
with one study indicating it is located on the A2 domain (Baglia et al., 1991), and earlier 
work from our laboratory pointing to the A3 domain (Sun et al., 1996). A second 
FIX-binding exosite was postulated to reside on the catalytic domain (Sinha et al., 2007). 
Because of the uncertainty that surrounded this issue, we conducted studies to identify the 
region on the FXIa heavy chain involved in high-affinity binding to FIX and FIXα, and 
investigated the possibility of a second exosite in FIX activation.  
Fortuitously, the gene for FXI is the product of a duplication event involving the PK 
gene. The FXI subunit and PK (a monomeric protein) share identical domain structure, and 
are 58% identical in amino acid sequence in humans. Despite the similarities, the active 
form of PK (α-kallikrein) is a poor FIX activator, indicating that the FIX binding site is  
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unique on FXIa.  FXIa in which the A3 domain is replaced with the PK A3 domain 
(Figure 4-2A) (FXIa/PKA3) was tested for its ability to cleave FIX and FIXα (Figure 4-3, 
Tables 4-1 and 4-2). The cleavage rates of the Arg145–Ala146 and Arg180–Val181 bonds 
were markedly reduced compared with FXIa-WT, with pronounced FIXα accumulation. 
The A3 domain substitution in FXIa/PKA3 results in a Km for FIX cleavage after 
Arg145 that is 25-fold higher compared with FXIa-WT, with a 60-fold reduction in 
catalytic efficiency. The catalytic efficiency of cleavage after Arg180 was impaired to an 
even greater degree. Only kcat/Km could be estimated accurately for the second cleavage 
because saturation could not be achieved for the reaction (Figure 4-3E). The values for Km 
in Tables 1 and 2 should, therefore, be considered lower limits for the actual values. These 
data indicate that the A3 domain is important for binding both FIX and FIXα, and that loss 
of the A3 binding site has a deleterious effect on both cleavages in FIX. With FXIa/PKA3, 
FIXα accumulation is the result of an 11 to 14-fold higher catalytic efficiency for the 
cleavage of FIX Arg145–Ala146 bond compared with the cleavage of Arg180–Val181 bond.  
Figure 4-2. Purified FXI. (A) Nonreducing SDS-polyacrylamide gel stained with 
GelCode blue of recombinant 1. FXI-CD/PK-HC), 2. FXI-WT, 3. FXI/PKA3, and 4. 
FXI/PKA2-Ser140. FXI-CD/PK-HC is an 80-kDa monomer, whereas other FXI species are 
160-kDa dimers. (B) Purified FXIa heavy chain (HC) and catalytic domain (CD) isolated 
from FXI-Ser362/Ser482 are compared with FXIa-WT (XIa) on nonreducing (left) and 
reducing (right) SDS-polyacrylamide gels. Positions of molecular mass standards are 
indicated on the left of each panel in kilodaltons. 
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Figure 4-3. FIX and FIXα cleavage by FXIa/PKA3. (A) Non-reducing 17% 
polyacrylamide-SDS gels of 1000 nM FIX (top) or FIXα (bottom) in Assay Buffer with 
Ca2+ incubated at RT with FXIa/PKA3 (60 nM and 240 nM active sites for FIX and FIXα 
respectively). Positions of standards for FIX, FIXα and FIXaβ are indicated at the right of 
each panel. B) Progress curves of FIX disappearance (c), and FIXα (z) and FIXaβ (▲) 
generation from panel A (top). Lines represent least-squares fits to the data. (C) Initial 
velocities of cleavage after Arg145 (conversion of FIX to FIXα) by 1 nM FXIa/PKA3 
active sites as a function of FIX concentration. The initial rates were obtained from the 
slopes of the linear portions of progress curves documenting disappearance of FIX with 
time. (D) Progress curves of FIXα cleavage by FXIa/PKA3 determined from panel A 
(bottom). (E) Initial velocities of cleavage after Arg180 (conversion of FIXα to FIXaβ) by 
1 nM FXIa/PKA3 active sites as a function of FIXα concentration. 
50 
 
Table 4-1. Kinetic parameters for cleavage of FIX and FIXα by FXIa. 
Fitting of full-progress experimental traces was performed with KinTek software (KinTek 
Explorer version 2.5) using the reaction equation shown under “Methods.” Km and kcat for 
activation were calculated from individual rate constants for each step. Ki values were 
fixed to lower limits obtained by surface plasmon resonance. Values are the mean ± S.D. 
for each experiment. 
 
Cleavage of FIX after Arg145 
Protease  Substrate  
kcat 1 
(min-1)  
Kd 1 (μM) Km 1 (μM) 
Catalytic 
Efficiency 1 
(μM-1 min-1) 
Ki 1 (μM) 
FXIa-WT  FIX  12 ± 1  0.10 ± 0.01 0.20 ± 0.01 60 ± 6  0.14  
FXIa-CD  FIX  3.2 ± 0.1 4.9 ± 0.2  4.9 ± 0.2 0.7 ± 0.1  3  
FXIa/PKA3  FIX  4.9 ± 0.1 4.9 ± 0.2  4.9 ± 0.2 1.0 ± 0.1  3  
FXIa/PKA2-Ser140  FIX  16 ± 1 0.03 ± 0.01 0.10 ± 0.01 160 ± 20  0.15  
FXIa-CD/PK-HC  FIX  1.6 ± 0.1  2.4 ± 0.2  2.4 ± 0.2 0.7 ± 0.1  5  
FXIa-Gly184  FIX  13 ± 3  0.3 ± 0.1  0.7 ± 0.3 19 ± 10  0.4 ± 0.2  
FXIa-Met575  FIX  1.20 ± 0.06 0.20 ± 0.02 0.20 ± 0.02 5.0 ± 0.5  0.70 ± 0.05 
 
Cleavage of FIX after Arg180* 
Protease Substrate 
kcat 2 
(min-1) 
Kd 2 (μM) Km 2 (μM) 
Catalytic 
Efficiency 2 
(μM-1 min-1) 
Ki 2 (μM) 
FXIa-WT  FIX  35 ± 6  0.06 ± 0.01 0.08 ± 0.01 400 ± 100  0.06  
FXIa-WT  FIXα  12 ± 1  0.08 ± 0.01 0.09 ± 0.01 130 ± 20  0.06  
FXIa-CD  FIX  0.5 ± 0.1  11 ± 1  11 ± 1  0.05 ± 0.01  5  
FXIa-CD  FIXα  0.5 ± 0.1  13 ± 2  13 ± 2  0.04 ± 0.01  5  
FXIa/PKA3  FIX  0.6 ± 0.1  7 ± 1  7 ± 1  0.09 ± 0.02  3  
FXIa/PKA3  FIXα  0.6 ± 0.1  7 ± 1  7 ± 1  0.09 ± 0.02  3  
FXIa/PKA2-Ser140  FIX  40 ± 10  0.04 ± 0.01 0.08 ± 0.02 500 ± 200  0.06  
FXIa-CD/PK-HC  FIX  0.4 ± 0.1  10 ± 1  10 ± 1  0.04 ± 0.01  5  
FXIa-CD/PK-HC  FIXα  0.4 ± 0.1  10 ± 1  10 ± 1  0.04 ± 0.01  5  
FXIa-Gly184  FIX  40 ± 10  0.2 ± 0.1  0.2 ± 0.1 200 ± 50  0.5 ± 0.2 
FXIa-Met575  FIX  5.50 ± 0.04 0.50 ± 0.04 0.50 ± 0.04 11.0 ± 0.9  0.040 ± 0.003  
 
* Due to the low affinity between the enzyme and substrate in reactions using FXIa variants, we 
were not able to reach saturation for reactions with FXIa-CD, FXIa/PKA3, or FXIa-CD/PK-HC, or 
FXIa-WT in the absence of Ca2+.  Fits for kcat and Km are linked, with the listed Kms representing 
lower estimates for the reaction. kcat/Km is the appropriate parameter for comparing these 
reactions.     
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Progress curve simulations for cleavage of isolated FIXα by FXIa/PKA3 suggests that 
Arg180–Val181 is cleaved with similar, low catalytic efficiency when FIX or FIXα is the 
starting substrate, indicating that the exosite is important for efficient binding of both FIX 
and FIXα as substrates. 
Previously, Baglia et al. reported that peptides derived from the FXIa A2 domain 
sequence were competitive inhibitors of FIX activation by FXIa, suggesting the presence 
of a FIX binding site on A2 (Baglia et al., 1991). We studied cleavage of FIX by FXIa with 
a PK A2 substitution (Figure 4-2A). Lys140 in PK A2 was replaced with Ser to prevent 
auto-proteolysis (Hooley et al., 2007). The resulting chimera, FXIa/PKA2-Ser140, cleaved  
 
Table 4-2. Kinetic parameters for cleavage of FIX and FIXα by FXIa determined 
from initial velocities.  
The initial velocities (v0) of cleavage after Arg145 in FIX, and cleavage after Arg180 in 
FIXα were plotted against initial substrate concentration, and analyzed using the 
Michaelis-Menten equation. Km and kcat were obtained from direct non-linear least squares 
analysis using Scientist Software. 
 
Protease  Substrate Bond cleaved kcat 1 (min-1) Km 1 (μM)  
Catalytic Efficiency 
1 (μM-1 min-1) 
FXIa-WT  FIX  Arg145  10 ± 1  0.27 ± 0.07  40 ± 10  
FXIa-WT  FIXα  Arg180  7.1 ± 0.3  0.09 ± 0.01  80 ± 10  
FXIa-CD  FIX  Arg145  2.4 ± 0.4  3 ± 1  0.8 ± 0.3  
FXIa-CD  FIXα  Arg180  ND*  > 4  0.018 ± 0.001  
FXIa/PKA3  FIX  Arg145  6 ± 1  3.9 ± 0.9  1.6 ± 0.4  
FXIa/PKA3  FIXα  Arg180  ND*  > 4  0.029 ± 0.003  
FXIa-CD/PK-HC  FIX  Arg145  5 ± 1  3 ± 1  2 ± 1  
FXIa-CD/PK-HC  FIXα  Arg180  ND*  > 4  0.02 ± 0.01  
FXIa-Gly184  FIX  Arg145  11 ± 1  0.8 ± 0.2  12 ± 4  
FXIa-Met575  FIX  Arg145  1.10 ± 0.06  0.05 ± 0.02  20 ± 10  
 
Due to the low affinity between the enzyme and substrate in reactions using FXIa variants, we were 
not able to reach saturation for reactions with FXIa-CD, FXIa/PKA3, and FXIa-CD/PK-HC.  
Thus, values for Km are approximate and values for kcat were not determined (ND) 
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both FIX scissile bonds similarly to FXIa-WT (Table 4-1), indicating that the FXI A2 
domain does not contain a high affinity FIX or FIXα binding site.  
The anti-human FXI monoclonal IgG O1A6 binds to the A3 domain at residues that 
overlap or are in close proximity to the FIX binding site (Sun et al., 1999, Tucker et al., 
2009). In the presence of O1A6, FIX activation by FXIa-WT appears similar to activation 
by FXIa/PKA3, with decreased rates of cleavage for both bonds and FIXα accumulation 
(compare Figure 4-4 A and B, to 4-3B). In contrast, an IgG that binds to the A2 domain 
(14E11) had no effect on FIX activation by FXIa (Figure 4-4C), consistent with the 
interpretation that the A2 domain does not contain a FIX binding site, and that the 
inhibitory effect of O1A6 is not simply due to steric interference. 
 
Figure 4-4. FIX cleavage by 
FXIa-WT in the presence of 
monoclonal antibodies. Shown are 
progress curves of FIX disappearance 
(z), and FIXα (О) and FIXaβ (▲) 
generation. FIX (100 nM) was activated 
by 3 nM FXIa-WT (active sites) in the 
presence of (A) vehicle, (B) 50 nM IgG 
OA16, or (C) 50 nM IgG 14E11.  
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Investigation of a Factor IX Binding Exosite on the Factor XIa Catalytic Domain 
Sinha et al suggested that a FIX binding exosite is located on the FXIa catalytic domain 
(Sinha et al., 2007), and proposed a model that required FIX to first engage this exosite 
before conversion to FIXα. Conversion of FIXα to FIXaβ follows in a reaction that 
requires the heavy chain exosite. The proposed mechanism is based primarily on the 
observation that the isolated factor XIa catalytic domain converts FIX to FIXaβ with a Km 
comparable to that of FXIa-WT, but a significantly reduced kcat. It was concluded that FIX, 
but not FIXα, bound to an exosite on the catalytic domain. Their data and interpretations 
are incompatible with our observation that removing the A3 domain increases Km for the 
overall reaction. Subsequently, the same group posited that catalytic domain amino acids 
Glu458 and Lys550 (Glu98 and Lys192 in chymotrypsin numbering) may be part of a FIX 
binding exosite (Su et al., 2011). However, substitutions for these residues resulted in 
~100-fold reductions in kcat for FIX conversion to FIXaβ, more consistent with a catalytic 
defect. Cumulatively, these findings are not consistent with our results showing that the A3 
domain contains the major binding site for proper activation of FIX and FIXα. To 
investigate this discrepancy further, we assessed cleavage of the Arg145-Ala146 and 
Arg180-Val181 bonds by FXIa isolated catalytic domain (FXIa-CD) (Figure 4-2B). Similar 
to results with FXIa/PKA3, we observed a ~90-fold decrease in catalytic efficiency for 
cleavage of FIX after Arg145, and an even greater defect for cleavage of FIX and FIXα 
after Arg180 by FXIa-CD. Kinetic analysis indicated the poor cleavage rate was due to an 
increased Km and to a lessert extent a decrease in kcat (Table 4-1 and 4-2). Cleavage after 
Arg180 by FXIa-CD was also similar to FXIa/PKA3. The low affinity of the FXIa catalytic 
domain for FIX or FIXα demonstrated that it is not likely to harbor a binding site that is 
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required for initial substrate recognition. The reason for the differences between our results 
and those of Sinha et al. are not clear; however, their study used a chromogenic assay to 
examine FIX activation, which would not facilitate examination of the initial cleavage 
converting FIX to FIXα with the detail we were able to achieve with our 
densitometry-based approach. 
The FXIa catalytic domain is attached to the heavy chain within a subunit by the 
Cys362–Cys482 disulfide bond (McMullen et al., 1991; Papagrigoriou et al., 2006). In 
FXIa-CD, the heavy chain is absent and Cys482 is replaced with serine. These changes 
could have altered FXIa-CD sufficiently to reduce its ability to bind FIX, even if a FIX 
binding site is present on the catalytic domain. The chimera FXIa-CD/PK-HC consists of 
the FXIa catalytic domain attached to the heavy chain of PK (Figure 4-2A). Like the FXI 
heavy chain, the PK heavy chain contains four apple domains, and it is connected to the 
catalytic domain through a single disulfide bond involving Cys482. Activation of FIX and 
FIXα by FXIa-CD/PK-HC (Tables 4-1 and 4-2) was similar to activation by FXIa/PKA3 
and FXIa-CD. Taken as a whole, these data indicate that a major exosite for binding of FIX 
and FIXα is located on the FXIa A3 domain. Loss of this exosite, either in chimeras 
(FXIa/PKA3 or FXIa-CD/PK-HC) or through absence of the heavy chain (FXIa-CD), 
results in loss of the high affinity site and a marked increase in Km for FIX activation. 
Although our data don't support the presence of a FIX binding exosite on the FXIa catalytic 
domain that is required for initial substrate recognition, they do not rule out the possibility 
that such a binding site is expressed as the result of initial binding of FIX to the A3 exosite 
(although such a process would not explain the differences between our results and 
published work). Previously, we noted that binding of FIX to FXIa results in a mixed-type 
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inhibition of cleavage of a tripeptide substrate by FXIa, consistent with FIX binding to A3 
causing changes in the protease domain, in addition to competing with the tripeptide 
substrate at active site (Ogawa et al., 2005). In the future, resolving the crystal structure of 
FIX in complex with full-length FXIa (with alanine substitution for serine 557) will 
enhance our understanding of this interaction. 
 
Binding of Factor XIa to Factor IX and Factor IXα 
As a complementary method to kinetic analysis, we studied binding of active 
site-blocked FXIa to immobilized FIX, FIXα, and FIXaβ using surface plasmon resonance 
(SPR). The active site of FXIa was inhibited by a chloromethyl ketone (CMK), preventing 
FIX activation after FXIa binding. Zymogen FXI-WT did not bind to any FIX species in 
the presence of Ca2+, nor did FXIa-WT in the presence of 10 mM EDTA (data not shown). 
In the presence of Ca2+, FXIa-WT bound to FIX, FIXα, and FIXaβ. Binding at equilibrium 
was plotted as a function of the FXIa-WT concentration (Figure 4-5 A-C). Kd for binding 
to FIX (130 ± 20 nM), FIXα (140 ± 20 nM), and FIXaβ (60 ± 10 nM) are comparable 
(Table 4-3), and are consistent with published results (Aktimur et al., 2003). Given the 
previous observation that FIXaβ is a competitive inhibitor of FIX activation by FXIa 
(Ogawa et al., 2005), our data indicate that FIX, FIXα and FIXaβ are likely binding to the 
same position, or positions that are near each other, on FXIa.  
Using SPR, we were not able to demonstrate binding of FXIa-CD, FXIa/PKA3, or 
FXIa-CD/PK-HC (Figure 4-5 D-G and Table 4-3) to FIX, FIXα, or FIXaβ at analyte 
concentrations up to 5 μM. In contrast, isolated FXIa heavy chain (FXIa-HC), and 
FXIa/PKA2 bound to FIX species with Kd values similar to those for FXIa-WT (Figure 4-5 
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H and I, Table 4-3). These results are consistent with our kinetic analysis, and indicate that 
high affinity binding between FIX or FIXα and FXIa is largely, if not completely, due to a 
Ca2+-dependent binding to the A3 domain.  
Recently, Marcinkiewicz et al. reported that cross-talk between the FXIa catalytic 
domain and heavy chain is required for expression of the FIX binding site on the heavy 
chain, based on observing that isolated FXIa heavy chain (FXIa-HC) does not bind to FIX 
(Marcinkiewicz et al., 2012). This is not compatible with our SPR study showing that 
FXIa-HC and FXIa-WT bound to FIX and FIXα with similar affinity. To confirm that the 
FXIa heavy chain does not need the catalytic domain to bind to FIX, we tested the capacity 
of FXIa-HC to inhibit FIX conversion to FIXaβ by FXIa-WT, as shown in the western 
blots in Figure 4-5J. FXIa-HC slowed the activation rate of FIX by FXIa-WT, consistent 
with the heavy chain engaging FIX in the absence of the catalytic domain. Furthermore, 
accumulation of FIXα in the presence of FXIa-HC supports the premise that FIXα is 
released from FXIa and can bind to the isolated heavy chain.  
Table 4-3. Affinity of FXIa binding to FIX, FIXα and FIXaβ.  
Surface plasmon resonance studies were preformed as described in “methods”. Data were 
corrected for non-specific binding by subtracting signals obtained with analytes infused through a 
flow cell without coupled protein. Binding was analyzed using a bivalent binding model for all 
species except FXIa-CD/PK-HC and FXIa-CD, which were evaluated with a 1:1 binding model. 
Kd values were calculated from the quotient of the derived dissociation (kd) and association (ka) 
rate constants, and were consistent with results calculated by steady state equilibrium analysis (not 
shown).  
Kd (nM) for binding of analyte to ligand Analyte 
factor IX factor IXα factor IXaβ 
FXIa-WT  130 ± 20 140 ± 30 60 ± 10 
FXIa-HC  90 ± 20 70 ± 10 10 ± 10 
FXIa-CD  > 5000 > 5000 > 5000 
FXIa/PKA3  > 3000 > 3000 > 3000 
FXIa-CD/PK-HC  > 5000 > 5000 > 5000 
FXIa/PKA2-Ser140  40 ± 10 40 ± 10 Not done 
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Figure 4-5. FXIa binding to FIX, FIXα, and FIXaβ. Surface Plasmon Resonance was used 
to assess binding of FXIa perfused over immobilized FIX, FIXα or FIXaβ in the presence of 
Ca2+ ions at 10 μl/min for 6 min. Dissociation was monitored for 10 min. Panels A to C – 
FXIa-WT binding. FXIa-WT concentrations tested were: 1, 5, 10 , 25, 37.5 , 75, 150, 300, 
and 500 nM. Affinity and kinetic parameters were determined after subtraction of 
non-specific binding from the control surface. Non-linear regression fitting of the steady state 
equilibrium binding of FXIa-WT to (A) FIX, (B) FIXα and (C) FIXaβ using a bivalent 
model. Panels D, H and I– SPR data for Ca2+ -dependent binding of (D) FXIa-WT, (H) 
FXIa-HC, and (I) FXIa/PKA2-Ser140 binding to FIX. Panels E-G –Binding curves for (E) 
FXIa-CD, (F) FXIa/PKA3, and (G) FXIa-CD/PK-HC at a single concentration (5000 nM). 
(J) FIX activation by FXIa-WT in the presence of FXIa-HC. Shown are western blots of time 
courses of FIX (100 nM) activated by FXIa-WT (1 nM) in the presence of vehicle control 
(left panel) or 1 μM FXIa-HC (right panel). Samples collected at various times (shown at 
bottom) into non-reducing SDS-sample buffer were size fractionated by SDS-PAGE. 
Detection was with a polyclonal anti-human FIX antibody and chemiluminescence. Positions 
of standards for FIX, FIXα, and FIXaβ are shown between the images. 
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Taken as a whole, the results reported above support an exosite-mediated 
release-rebind mechanism for FIX activation by FXIa (summarized in Figure 4-6), in 
which the efficiency of the second cleavage is enhanced by conformational changes 
resulting from the first cleavage. We propose that binding of FIX to the FXIa A3 domain is 
followed by docking with the active site and cleavage after Arg145 to form FIXα. FIXα is 
released from FXIa and then must rebind to FXI A3 prior to a second docking step with the 
active site, and cleavage after Arg180. The ratio of the catalytic efficiencies of the two 
cleavages determines whether FIXα accumulates. If the A3 domain exosite is available, 
Figure 4-6. Model for FIX activation by FXIa. In the schematic diagram of FXIa, 
apple domains are shown as four clustered gray circles with the exosite on A3 
indicated in black (E). The FXIa catalytic domain is a white ellipse with the active 
site indicated by a black circle (A). The FIX catalytic domain (dark gray ellipse) and 
light chain (light gray ellipse) are connected by a line representing a disulfide bond. 
The activation peptide is the white oval. Bi-directional arrows represent reversible 
binding, and uni-directional arrows represent proteolytic cleavage. FIX is activated 
by a FXIa subunit by sequential cleavage after Arg145 and Arg180, with the 
intermediate FIXα released and then rebound to the FXIa A3 domain. Details of the 
model are described in the text. 
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catalytic efficiency for cleavage after Arg180 is 7-fold greater than for cleavage after 
Arg145, and FIXα does not accumulate. In the absence of a functional exosite, the rates of 
both bond cleavages are markedly decreased, but the predominance of the catalytic 
efficiency of the second cleavage is lost, leading to FIXα accumulation. 
 
Summary 
In this chapter we describe a new mechanism for FIX activation by FXIa during blood 
coagulation. After cleavage of FIX at the Arg145-Ala146 bond, the intermediate FIXα is 
released from FXIa, and must rebind for cleavage at Arg180-Val181 to generate the 
protease FIXaβ. The catalytic efficiency of cleavage after Arg180 is 7-fold greater than for 
cleavage after Arg145, limiting FIXα accumulation. Initial binding of FIX and FIXα 
requires the exosite on the FXIa A3 domain, but not the A2 or catalytic domain. 
 
Methods 
Recombinant FXIa. HEK293 fibroblasts (ATCC-CRL1573) were transfected with 40 μg 
of pJVCMV containing a FXI cDNA and 2 μg of pRSVneo encoding a neomycin 
resistance marker using an Electrocell Manipulator 600, (BTX, San Diego, CA) (Ogawa et 
al., 2005). Cells were initially grown in Dulbecco’s modified Eagle medium (DMEM) with 
5% fetal bovine serum and 500 μg/mL G418, then switched to serum-free medium (Cellgro 
Complete, Mediatech, Herndon, VA). FXI was purified from conditioned media by affinity 
chromatography using anti-human FXI-IgG 1G5.12 (Ogawa et al., 2005). Protein 
concentrations were determined by colorimetric assay (Bio-Rad,), and confirmed by 
densitometry on SDS-PAGE by comparison to standard plasma FXI or FIX preparations. 
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FXI chimeras in which apple domains are replaced with PK apple domains have been 
described (Sun et al., 1996). We used FXI with the PK A2 or A3 domain (FXI/PKA2 or 
FXI/PKA3), and FXI in which the entire heavy chain is replaced with the PK heavy chain 
(FXI-CD/PK-HC) (Kravtsov et al., 2009). In FXI/PKA2, Lys140 was changed to Ser to 
prevent auto-proteolysis (Hooley et al., 2007). 
FXI was converted to FXIa by incubation with FXIIa (100:1 substrate:enzyme) at 37 
˚C for 24 hrs in 50 mM Tris-HCl pH 7.4, 100 mM NaCl (TBS). Conversion of the 80-kDa 
zymogen FXI subunits to the 45-kDa heavy chain and 35-kDa catalytic domain of FXIa 
was confirmed by SDS-PAGE. In studies of FIX activation by FXIa and FXIa variants, 
removal of FXIIa, or inhibition of FXIIa, had no effect on FIX or FIXα cleavage.   
To prepare isolated FXIa heavy chain (FXIa-HC) and isolated FXIa catalytic domain 
(FXIa-CD) (Fujikawa et al., 1986), FXI with Cys362 and Cys482 changed to Ser 
(FXI-Ser362/Ser482) was activated and passed through a soybean-trypsin inhibitor (SBTI) 
agarose column. FXIa-CD binds to the column and is eluted with TBS containing 200 mM 
benzamidine, while FXIa-HC flows through the column.   
Preparation of FIXα. FIX (14.3 µM) was incubated with 50 nM FXIa in TBS pH 7.4, 20 
mM EDTA for 12 min at 37 oC to generate FIXα. Contaminating FIXaβ was inhibited by 
incubating 90 min at 37 oC with biotinylated EGR-chloromethylketones (CK) (10-fold 
molar excess over FIX). After dialysis against PBS, strepavidin immobilized on agarose 
was added, and incubated for 1 hour at room temperature (RT) with mixing. Agarose was 
removed by centrifugation, and the supernatant containing FIXα was dialyzed against 50 
mM HEPES pH 7.4, 125 mM NaCl, 1 mg/mL polyethylene glycol 8000. 
Hydrolysis of S-2366 by FXIa. FXIa (6 nM) was incubated with S-2366 (50-2000 μM) in 
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TBS at RT (reaction volume 40 μl). Generation of free p-nitroaniline (pNA) was followed 
by continuous monitoring of absorbance at 405 nm on a SpectraMax 340 plate reader 
(Molecular Devices, Sunnyvale, CA). Rates of pNA generation (nM/s) were determined 
using an extinction coefficient of 9920 M-1 cm-1 (405 nm). Km and kcat for S-2366 
cleavage were determined by non-linear least squares fitting performed with Scientist 
Software (MicroMath Scientific Software).  
Activation of FIX and FIXα by FXIa. FIX or FIXα (25 nM to 5 μM) in Assay Buffer (50 
mM HEPES, pH 7.4, 125 mM NaCl, 5 mM CaCl2, 1 mg/mL polyethylene glycol [PEG] 
8000) was incubated at RT with FXIa species (1 to 240 nM active sites, depending on the 
protease and substrate tested) in tubes coated with PEG 20,000. At various times (0 to 640 
min), aliquots were removed into non-reducing SDS-sample buffer, size fractionated on 
17% polyacrylamide-SDS gels, and stained with GelCode Blue (Pierce). Gels were imaged 
under infrared wavelengths (excitation λ 685 nm, emission λ 720 nm) on an Odyssey 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). The instrument converts 
infrared data into grayscale images. Conversion of FIX to FIXα and FIXaβ, and FIXα to 
FIXaβ was assessed by densitometry. To determine the amount of protein per band, 
standards were run on a separate gel, with one standard also run on the gel with the time 
course samples. Full progress curves were constructed from data for the disappearance of 
FIX, and the appearance of FIXα and FIXaβ. In some reactions, monoclonal antibodies to 
FXIa or FIX were included. 
Kinetic Analyses. Steady-state kinetic parameters for FIX or FIXα cleavage were obtained 
by numerical integration fitting and least squares fitting of full progress curves of substrate 
depletion, and intermediate and product formation at substrate concentrations from 25 to 
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5000 nM; and by analysis of the initial rate dependence of substrate depletion as a function 
of substrate concentration. Rates of cleavage of the Arg145–Ala146 and Arg180–Val181 
bonds were analyzed simultaneously with KinTek Explorer Version 2.5 software (Johnson 
et al., 2009) using the reaction mechanism shown below. IXα* indicates the intermediate 
bound to FXIa in the correct orientation for cleavage after Arg180. 
 
 
We reported that the final product FIXaβ binds to FXIa and is a competitive inhibitor of 
FIX activation by FXIa (Ogawa et al., 2005). A similar assumption was made for product 
inhibition by FIXα. Kd and Ki values were initially constrained to those obtained from 
surface plasmon resonance studies (below) and full progress curve analysis of FIXaβ 
formation, and no rapid equilibrium assumptions were imposed on association and 
dissociation rates. By fitting full progress curves for FIX disappearance, and FIXα and 
FIXaβ appearance, Km, kcat, Kd, Ki, and catalytic efficiency (kcat/Km) were determined for 
both cleavages in FIX. The same method was used with FIXα as substrate. As FIXα 
preparations have ~20% FIX contamination, analyses of conversion of FIXα to FIXaβ 
included the cleavage of the FIX.  
Results of numerical analysis were compared with those obtained by conventional 
Michaelis-Menten analysis of both cleavages. With FIX as substrate, initial velocities (v0) 
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of cleavage after Arg145 were determined from the initial slopes of progress curves for 
disappearance of FIX, normalized to 1 nM FXIa active sites. Values for v0 were analyzed 
with the Michaelis-Menten equation, and values for Km and kcat were obtained from direct 
nonlinear least squares analysis using Scientist Software. With FIXα as substrate, Km and 
kcat for cleavage after Arg180 were determined in a similar manner. Competitive binding of 
FXIa to FIX in the FIXα preparation was calculated by a cubic equation, and was taken into 
account for determining the FXIa concentration available for the reaction with FIXα. 
Surface Plasmon Resonance (SPR). Binding studies were performed on a Biacore T100 
flow biosensor (Biacore, Uppsala, Sweden) at 25 °C. FIX, FIXα or FIXaβ were 
immobilized on carboxy-methyl dextran flow cells (CM5 sensor chips, GE Healthcare) 
using amine-coupling chemistry. To prevent cleavage of bound FIX or FIXα, FXIa active 
sites were blocked with FPR-CK. FIXaβ active sites were blocked with EGR-CK. Flow 
cell surfaces were activated with a mixture of 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide and N-hydroxysulfosuccinimide for 5 min (flow rate 10 μL/min), after which 
protein (30 μg/mL in sodium acetate, pH 4.0) was injected onto the surface. Unreacted sites 
were blocked for 5 min with 1 M ethanolamine. Analytes (FXIa species, 1 to 5000 nM) 
were perfused through flow cells in HBS-P Buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 
2 mM CaCl2, 1 mM benzamidine, 0.005% v/v P20) at 10 μL/min for 6 min. After changing 
to HBS-P Buffer without FXIa, analyte dissociation was monitored for 10 min. Flow cells 
were regenerated with HBS-P containing 30 mM EDTA. FXIa binding to FIX species was 
also tested in the absence of Ca2+ (10 mM EDTA). Data were corrected for non-specific 
binding by subtracting signals obtained with analytes infused through a flow cell without 
coupled protein.  
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Binding was analyzed with BIAevaluation software (Biacore) using a bivalent binding 
model for dimers (FXIa-WT, FXIa/PKA2, FXIa/PKA3) and a 1:1 binding model for 
monomers (FXIa-CD, FXIa-CD/PK-HC). Kd values were calculated from the quotient of 
the derived dissociation (kd) and association (ka) rate constants. In addition, a steady state 
affinity model was used in which Kd was derived from non-linear regression fitting of the 
response at equilibrium to FXIa concentration.  
FIX Activation in the Presence of FXIa-HC. FIX (100 nM) was incubated with FXIa-WT 
(1 nM) with or without FXIa-HC (1 μM) in assay buffer at RT. At various times, aliquots 
were removed into nonreducing SDS sample buffer, size fractionated on 12% 
polyacrylamide-SDS gels, and transferred to a nitrocellulose membrane. Western blots 
were performed using an HRP-conjugated goat polyclonal anti-human FIX IgG and 
chemiluminescence for detection. 
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CHAPTER V 
 
ANALYSIS OF NATURALLY OCCURING FACTOR XIa MUTATIONS AND 
IMPLICATIONS FOR THE MECHANISM OF  
FACTOR IX ACTIVATION 
 
Inherited deficiency of vitamin K-dependent coagulation proteases is often associated 
with circulating dysfunctional protein, and the mutations involved can provide information 
on structure-function relationships for these proteins. In contrast, FXI deficient patients 
typically have parallel reductions in FXI activity and antigen level (Saito et al., 1985). This 
may be due to the compact structure of FXI, and particularly the apple domain disk, which 
may render it more susceptible to mutation-induced misfolding. Of the ~150 missense 
mutations identified in the FXI genes of FXI deficient patients, only twelve are, or may be, 
associated with circulating dysfunctional protein (Cross Reactive Material positive or 
CRM+ deficiency). Eight of the CRM+ mutations are associated with point mutation in the 
catalytic domain, and only four involve the heavy chain (www.factorxi.org).  
In the following sections, data from two FXI CRM+ mutations will be discussed. Both 
mutations result in defective activation of FIX. One missense mutation results in a Gly 
substitution for Arg184 at the N-terminus of the FXI A3 domain, an area implicated in the 
exosite interaction with FIX (Sun et al., 1999). The second missense mutation causes a Met 
to Thr substitution at residue 575 in the catalytic domain near the active site. Both mutant 
proteases were purified and tested for their capacity to activate FIX. Studies of these 
naturally occurring FXI variants provide additional information on the mechanism of FIX 
activation by FXIa. 
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Functional Analysis of FXIa-Gly184 
Guella et al. described a 24 year old woman with 10% of normal plasma FXI activity 
but ~50% of the normal antigen level (Guella et al., 2008). This rare CRM+ patient is a 
compound heterozygote for point mutations in the FXI gene. One allele contained a 
mutation that disrupted an mRNA splice site, preventing FXI synthesis. The other 
contained a missence mutation resulting in a Gly substitution for Arg184, a residue in the 
region of A3 implicated in FIX activation. To evaluate the functional activity of the 
Arg184Gly mutation, the recombinant protein was expressed in HEK293 cells. The 
 
 
 Figure 5-1. Cleavage of S-2366 by FXIa-WT and FXIa-Gly184. (A, B) The rates of 
cleavage of the tripeptide substrate S-2366 by (A) 6 nM FXIa-WT or (B) FXI-Gly184. 
(C, D) Cleavage of S-2366 (500 nM) by (C) 6 nM FXIa-WT or (D) FXI-Gly184 in the 
presence of varying concentrations of FIXaβ. For all panels, data points represent 
averages of duplicate runs. 
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expression level was comparable to FXI-WT. FXI-Gly184 and FXI-WT migrate at similar 
position on SDS-PAGE (Data not shown). The tripeptide S-2366 was cleaved similarly by 
FXIa-WT (Figure 5-1A, Km 185 ± 40 μM, kcat 41 ± 2 sec-1) and FXIa-Gly184 (Figure 5-1B, 
Km 200 ± 40 μM, kcat 45 ± 2 sec-1) indicating, as expected, that the Gly184 substitution 
does not alter the catalytic active site.  
FXIa-WT and FXIa-Gly184 were tested in two types of plasma clotting assays. In the 
first, FXI was added to FXI-deficient plasma at various concentrations, and the clotting 
time of the supplemented plasma was measured in a standard activated partial 
thromboplastin time (aPTT) assay. Here, FXI must be activated by FXIIa, and FXIa then 
must activate FIX. FXI-Gly184 had ~25% of the activity of FXI-WT, consistent with 
results reported by Guella et al. In the second assay, FXIa was added directly to plasma, 
bypassing the requirement for activation of FXI by FXIIa. FXIa-Gly184 again 
demonstrated ~25% of the activity of FXIa-WT, indicating the reduced activity of 
FXI-Gly184 in the aPTT assay is due to a defect in FIX activation by FXIa. 
The results from plasma clotting assays are supported by previous studies with 
site-directed mutagenesis, which showed that the region on A3 domain that contains 
Arg184 is required for binding to FIX (Sun et al., 1999). Based on this, we assessed the 
affinity of FXIa-Gly184 for FIX. As discussed above, the interaction of FXIa with FIX 
involves both the A3 exosite and the active site. FIXaβ inhibits FXIa cleavage of the small 
peptide substrate S-2366 through a mixed mechanism, consistent with FIXaβ interacting 
with FXIa at the A3 domain and the active site (Ogawa et al., 2005). Ki for these reactions 
is indicative of the affinity of FIXaβ for FXIa (see “Methods” for kinetic analysis). For 
FXIa-Gly184, Ki for cleavage of S-2366 in the presence of FIXaβ (190 ± 30 nM, Figure 
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5-1D) was ~2-fold higher than FXIa-WT (90 ± 20 nM, Figure 5-1C), indicating binding of 
FIXaβ to FXIa-Gly184 is modestly weaker than to FXIa-WT. 
Next, we compared the kinetic parameters of FIX activation by FXIa-Gly184 with 
FXIa-WT, using the densitometry based approach described previously. FXIa-Gly184 
cleaves FIX more slowly than FXIa-WT, but significantly faster than FXIa/PKA3 (Figure 
5-2 and Table 4-1). Kms for cleavage of FIX after Arg145 and Arg180 by FXIa-Gly184 are 
3- and 2-fold higher, respectively, than for cleavage by FXIa-WT (Table 4-1), while kcats 
are comparable. The result is a 3-fold and 2-fold reduced catalytic efficiency for the two 
FIX cleavages, respectively. Similar to FXIa-WT, and unlike FXIa/PKA3, relatively little 
FIXα accumulates during FIX activation by FXIa-Gly184 (Figure 5-2A), indicating a 
higher catalytic efficiency for the second cleavage at the Arg180-Val181 bond. 
Michaelis-Menten analysis of conversion of FIX to FIXα was in agreement with the 
numerical integration analysis for cleavage after Arg145 (Table 4-2). These data indicate 
that the reduced capacity of FXIa-Gly184 to activate FIX is related to a modest decrease in 
affinity for both FIX and FIXα, resulting in a ~3-4 fold lower activity during blood 
coagulation due to a lower rate of FIXaβ generation. 
The data suggest that Arg184 is part of a binding site for FIX and FIXα on the A3 
domain. In the FXI zymogen crystal structure Arg184 is located on a loop connecting the 
A2 and A3 domains that is partially buried under the protease domain, and would not in the 
full-length zymogen. These data support the interpretation that Arg184 functions as a type 
of latch that keeps the catalytic domain in place over the A3 domain exosite in the be 
accessible to macromolecules such as FIX in aqueous phase (Papagrigoriou et al., 2006) 
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Figure 5-2. FIX cleavage by FXIa-Gly184. (A) Non-reducing 17% 
polyacrylamide–SDS gels of 100 nM FIX in assay buffer with Ca2+ incubated at 
room temperature with 3 nM active sites of FXIa-WT (top), FXIa/PKA3 (middle), or 
FXIa-Gly184 (bottom). The positions of standards for FIX, FIXα and FIXaβ are 
indicated at the right of each panel. (B, C) Progress curves of FIX disappearance (●), 
and FIXα (○) and FIXaβ (Δ) generation, for (B) FXIa-WT or (C) FXIa-Gly184 from 
(A). Lines represent least-squares fits to the data. (D) Initial rates of FIX 
disappearance for FXIa-WT (●), FXIa-Gly184 (○), and FXIa/PKA3 (), determined 
over the first 10 min of activation form (A). (E) Initial rates of FIXaβ formation for 
FXIaWT (●), FXIa-Gly184 (○), and FXIa/PKA3 (Δ), determined over the first 10 min 
of activation from (A). 
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This is consistent with the observations that FIX and FIXα do not bind to zymogen FXI, 
and with the premise that conformational changes occur upon conversion of FXI to FXIa 
that exposes the substrate binding exosite. In the zymogen, Arg184 forms salt bridges with 
Asp488 and Asn566 in the catalytic domain (Figure 5-3), and it is likely that these bonds 
must be disrupted upon FXI activation. Crystal structures of isolated FXIa protease domain 
show that Asp488 and Arg566 form intra-catalytic domain interactions that are not present 
zymogen, and that must be released after cleavage of the FXI Arg369-Ile370 bond to expose 
the exosite. The defect in FXIa-Gly184 in FIX activation is modest compared to the more 
severe defect seen with the chimeric protease FXIa/PKA3. This clearly indicates that the 
mutation does not completely disrupt the substrate binding exosite on A3, and that residues 
  
 
Figure 5-3. Position of Arg184 in FXI zymogen. Shown is a topology diagram of the 
zymogen FXI monomer with the A3 domain as a charged surface representation, and the 
A4 (gray) and catalytic domains (orange) as ribbon drawings. Note that Arg184 is covered 
by the catalytic domain. The inset shows specific interactions between side chains of the 
protease domain and the A3 domain. Arg184 forms salt bridges with Asp488 and Asn566
from the catalytic domain. (Image courtesy of Dr. Jonas Emsley.)  
72 
 
other than Arg184 are very likely involved in interaction with FIX. Data from studies 
investigating this possibility are presented in Chapter VI.  
 
Functional Analysis of FXI-Met575 
The naturally occurring CRM+ FXI catalytic domain mutation Thr575Met was first 
reported in 2004 (Quélin et al., 2004). The propositus was heterozygous for this mutation, 
with a point mutation that results in a severly truncated FXI polypeptide on the other allele. 
Subsequently, homozygosity for Thr575Met was reported in a 55 year-old Lebanese 
woman (Germanos-Haddad et al., 2005). The substitution occurs in a highly conserved 
region of the catalytic domain, in proximity to the active site. Recombinant FXI-Met575 
was expressed in HEK293 cells at levels comparable to FXI-WT, indicating that the 
mutation did not significantly disrupt protein folding. Conversion of FXI-WT and 
FXI-Met575 to FXIa-WT and FXIa-Met575, respectively, by FXIIa proceeded at similar 
rates (data not shown).  
Threonine is conserved at position 575 in FXI across species, indicating that the 
residue has functional importance. In the FXIa catalytic domain crystal structure, Thr575 
(chymotrypsin number 213) is in close proximity to the active site serine residue (Ser557, 
chymotrypsin Ser195), and forms the back wall of the S1-specificity pocket of the active 
protease (Jin et al., 2005) (Figure 5-4). This indicates that residue Thr575 either directly 
participates in substrate cleavage, or contributes to the correct conformation of the active 
site. The Thr575Met substitution very likely causes significant perturbation in the active 
site conformation, because of the long side chain of methionine.  
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First, we tested the capacity of FXIa-Met575 to cleave the tripeptide substrate S-2366 
(Glu-Pro-Arg-p-nitroaniline), which binds to FXIa through the S1 through S3 substrate 
binding sites. FXIa-Met575 cleaved S-2366 with ~30 fold reduced catalytic efficiency 
compared to FXIa-WT. Substrate saturation was not reached with S-2366 concentrations 
as high as 2000 μM, indicating a high Km for FXIa-Met575 (compared to 970 ± 40 μM for 
FXIa-WT) (Figure 5-5 A and B). Because we could not reach saturation, kcat could not be 
accurately determined. The decreased affinity for S-2366 suggests that the conformation of 
the S1-S3 sites in FXIa-Met575 are altered relative to FXIa-WT, consisted with predictions 
based on the crystal structure. The mutation may have altered the orientation of the 
catalytic triad of the active site, but this cannot be determined from the available data. 
Studies with a second tripeptide substrate, S-2288 (Ile-Pro-Arg-p-nitroaniline), gave 
A                          B 
   
Figure 5-4. Surface representations of FXIa catalytic domain. Components of the 
catalytic triad within the active site of FXIa are labeled in green(His413), magenta (D462) 
and yellow (S557). S1-S3 substrate binding sites are labeled as orange (Asp551), purple 
(Ser576) and Cyan (Gly578). Thr575 (red) is in proximity to the catalytic triad and S1 site. 
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similar results (Figure 5-5 C and D). We measured cleavage of S-2366 by FXIa-WT and 
FXIa-Met575 in the presence of a reversible inhibitor, aprotinin, which binds to the FXIa 
active site. As shown in Figure 5-5E, aprotinin competitively inhibited cleavage of S-2366 
by FXIa-WT, indicating that aprotinin and S-2366 bind to the active site in a mutually 
exclusive manner. In contrast, aprotinin inhibition of S-2366 cleavage by FXIa-Met575 
was significantly weaker, supporting the premise that the active site is altered in this 
protease. Based on the model in Figure 4-6, residues near the FXIa active site would likely 
be important for the docking interaction between the substrate FIX and the active site, but 
would not be as important for FIX affinity and specificity as they are for the small  
 
Figure 5-5. Cleavage of S-2366 by 
FXIa-Met575. A and B. Cleavage of 
S-2366 (0-2000 μM) by (A) 3 nM 
FXIa-WT and (B) 3 nM 
FXIa-Met575. C and D. Cleavage of 
S-2288 (0-2000 μM) by (C) 3 nM 
FXIa-WT  and  (D) FXIa-Met575.  
(E). Cleavage of 500 μM S-2366 by 3 nM FXIa-WT (○) and FXIa-Met575 (●) 
in the presence of various concentrations of aprotinin. 
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tripeptide substrates. This is because, as we have seen, FIX affinity and specificity are 
governed primarily by the exosite on the A3 domain of the FXIa heavy chain. We would 
anticipate, therefore, that the Thr575Met would decrease kcat for FIX activation by 
FXIa-Met575, but have little effect on Km. Consistent with the prolonged activated partial 
thromboplastin time (aPTT) noted in the patient homozygous for FXI-Met575 
A           
 
B 
 
C 
       
Figure 5-6. FIX activation by FXIa-Met575. Reducing western blots of time courses of 
100 nM FIX incubated at room temperature with (A) 2 nM FXIa-WT, (B) 5 nM 
FXIa/PKA3 or (C) 2 nM FXIa-Met575.  
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(Germanos-Haddad et al., 2005), the mutant protease activates FIX relatively slowly, with 
significant intermediate accumulation (Figure 5-6A) compared to FXIa-WT. The Kinetic 
parameters for FIX activation were determined, and are summarized in Table 4-1 and 4-2. 
As predicted the values for Km for FIX activation by FXIa-WT and FXIa-Met575 are 
similar, indicating affinity of the mutant protease for FIX is normal. FXIa-Met575 cleaved 
FIX with a marked decrease in kcat compared to FXIa-WT, most consistent with a catalytic 
defect. This supports the preliminary work from our group showing that FXIa with 
substitutions for another residue involved in active site conformation, Lys550 (Lys192 in 
chymotrypsin numbering), activates FIX with normal Km and reduced kcat (Schmidt et al., 
2008). 
Interestingly, during activation of FIX by FXIa-Met575 we noted accumulation of an 
intermediate that appears to be FIXaα (FIX with a single cleavage after Arg180) in addition 
to the previously described intermediate FIXα (Figure 5-6C). To date, we have not 
observed FIXaα accumulation during FIX activation by any protease with the exception of 
the protease from Russell Viper Venom. FIXaα is not seen in time course experiments of 
FIX activation by FXIa-WT or FXIa/PKA3 (Figure 5-6 A-C). The FIXaα generated with 
FXIa-Met575 appears to be a minor species. It is clearly seen on the western blot, but was 
not detectable on Coomassie Blue-stained gels (data not shown), and, therefore, cannot be 
included in kinetic analyses. However, this novel observation suggests that the ordered 
bond cleavage during normal FIX activation is determined by features of the FXIa active 
site, and this is perturbed in FXIa-Met575. 
Similar to FIX activation by FXIa, prothrombin activation by factor Xa, in the presence  
of factor Va, Ca2+ and phosphatidylserine-rich vesicles is a reaction that requires the 
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substrate to engage an exosite on the enzyme complex, followed by sequential cleavage 
after Arg320 and Arg271 to form the protease α-thrombin (Orcutt et al., 2004). However, 
during the ordered bond cleavage of prothrombin, substrate interaction with the exosite 
appears to dictate access to the Arg320 bond preferentially to the Arg271 bond 
(Krishnaswamy, 2005). Our data with FXIa-Met575 raises the possibility that the order of 
bond cleavage during FIX activation by FXIa may be dictated, at least partially, by 
residues around the active site. This is supported by the observation that only FIXα is 
observed in reactions where FIX is activation by the isolated FXIa catalytic domain.  
 
Summary 
Our understanding of the mechanism of FIX activation by FXIa is enhanced by 
functional studies of two naturally occurring CRM+ mutations in FXI deficient patients. 
We found a ~3 fold higher Km for FIX activation by FXIa-Gly184, suggesting Arg184 is 
part of the exosite. In contrast, FXIa-Met575 activates FIX with a comparable Km to 
FXIa-WT, but ~10-fold reduced kcat, indicating alteration of the structure within the active 
site in the catalytic domain. These results are consistent with the A3 exosite of FXIa being 
the major determinant of substrate affinity, while the active site is responsible for substrate 
catalysis after initial engagement at the exosite. 
 
Methods 
Recombinant Proteins. Recombinant FXIa was expressed as described in Chapter IV. In 
addition to FXI-WT, several variants were prepared. In FXI-Gly184, Arg184 is replaced  
with Gly, while in FXI-Met575, Thr575 is replaced with Met.  
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Plasma Clotting Assay. FXI activities were determined in a partial thromboplastin time 
(aPTT) assay. FXI deficient plasma (30 μL George King) was mixed with 30 μL FXI (0.3 
to 30 nM) in TBS with 0.1% BSA (TBSA) and 30 μL PTT-A reagent (Diagnostica Stago). 
After incubation at 37˚C for 5 min, 30 μL 25 mM CaCl2 was added, and time to clot 
formation was determined on an ST4 fibrometer (Diagnostica Stago). In a separate 
experiment, 30 μL of FXIa diluted in TBSA (0.3 to 30 nM) was mixed with 30 μL 
FXI-deficient plasma and 30 μL rabbit brain cephalin (Sigma). After incubation at 37 °C 
for 30 sec, 30 μL 25 mM CaCl2 was added, and time to clot formation determined. Results 
were compared to standard curves prepared with FXI-WT or FXIa-WT starting at 30 nM. 
Activities are percent of wild-type protein activity.  
Hydrolysis of chromogenic substrate by FXIa. FXIa (6 nM) was incubated with 50-2000 
μM S-2366 or S-2288 in TBS at RT. In separate experiments, FXIa (6 nM) was incubated 
with 500 μM S-2366 and varying concentrations of FIXaβ (FIXaβ does not cleave S-2366) 
in TBS with 5 mM CaCl2 at RT. Generation of free p-nitroaniline (pNA) was followed by 
monitoring absorbance at 405 nm. Rates of pNA generation (nM/s) were determined using 
an extinction coefficient of 9920 M-1 cm-1 (405 nm). Km, kcat and Ki for S-2366 cleavage 
were determined by non-linear least squares fitting performed with MicroMath Scientific 
Software. 
Factor IX activation followed by western blotting. Plasma FIX (100 nM) was incubated 
in assay buffer at room temperature with various factor XIa species. At various times, 7 
μL samples were mixed with 3 μL of reducing sample buffer, fractionated on 12% 
SDS-polyacrylamide gels, and then transferred to nitrocellulose. The primary antibody 
was goat anti-human FIX polyclonal IgG, and the secondary antibody was horseradish 
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peroxidase-conjugated anti-goat IgG. Detection was by chemiluminescence.  
The methods for FIX activation by FXIa and kinetic analysis were performed as 
described in Chapter IV.  
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CHAPTER VI 
 
STRUCTURAL BASIS FOR THE INTERACTION BETWEEN  
FACTOR IX AND FACTOR XIa 
 
Structure of the Factor XI A3 Domain  
The A3 domain of FXIa has been implicated in binding to heparin (Zhao et al., 1998), 
platelet glycoprotein 1b (Baglia et al., 2004), and FIX (Sun et al., 1999). In Chapter IV, we 
presented evidence that A3 contains an exosite that binds FIX and the activation 
intermediate FIXα that is central to the mechanism of FIX activation by FXIa. Furthermore, 
in Chapter V we characterized a naturally occurring mutation within the A3 domain of 
FXIa, Arg184Gly, with decreased affinity towards FIX that suggested a location for the 
FIX-binding exosite. To gain further insight into the structural basis of the FIX-FXIa 
interaction, we examined the topology of the FXIa A3 domain utilizing the crystal 
structure for zymogen FIX (Papagrigoriou et al., 2006). Based on the kinetic analysis, a 
FIX binding site should be a surface epitope on the A3 domain that is not present on PK A3, 
and should probably not be accessible to the aqueous phase in the zymogen FXI structure, 
given that FIX does not bind to the zymogen.  
The structural analysis software Metapocket (Zhang et al., 2011), which utilizes eight 
predictors to identify potential surface binding sites, identified three hydrophobic pockets 
on the surface of FXI A3 (Figure 6-1B). Pocket 1 is formed by the alkyl groups of the side 
chains of Arg184 and Arg210 with additional contributions from the side chains of Ile186, 
Leu262, and Phe221, and Phe206 from the α-helix (Figure 6-1 A and B). Charged surface 
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representations (Figure 6-1B) illustrate that Arg184 and Arg210 contribute to positively 
charged patches on either side of pocket 1. Arg184 and Asp185 run along one side of pocket 
1, with the other side formed primarily by the α-helix. Leu262 is in proximity to residues 
184 and 185 by virtue of the Cys182-Cys265 bond, and contributes to the wall of pocket 1 
(Figure 6-1A). These residues are highly conserved across mammalian species (Fujikawa 
 
Figure 6-1. The FXI A3 domain. (A) Topological diagram showing the A3 domain of 
human FXI, with the β-sheet indicated in yellow and the α-helix in gray. Side chains of 
residues in the locality of Arg184 are shown as sticks. (B) Surface representations of the 
FXI A3 domain are shown with partial transparency to highlight side chains of specific 
residues that are colored by atom type. Two rotations are shown related by 180°. The 
software program METAPOCKET identified three pockets on the surface of A3 (shown as 
red balls). (C) Topological diagram of the human prekallikrein (PK) A3 domain, with side 
chains of non-conserved residues in the area of the pocket in FXI shown as sticks. Note that 
the side chain of Arg209 in PK occupies the site of the hydrophobic pocket in FXI. (D) 
Charged surface representations of the FXI (left) and the PK (right) A3 domains. Blue 
indicates positive charge, and red indicates negative charge. Note the absence of pocket 1 
in the PK A3 domain model, owing to the Arg209 side chain. 
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et al., 1986; Ponczek et al., 2008), consistent with this area of the domain contributing to a 
FXIa specific function. The Arg184 side chain projects upward on one face of the β-sheet 
(yellow) adjacent to the Cys182-Cys265 disulfide bond. The Gly184 substitution would 
likely lead to loss of a positive charge that could contribute to electrostatic interactions 
with FIX, to the loss of hydrophobic interactions with the alkyl group of the Arg184 side 
chain, and would introduce flexibility into the main chain that could affect local loop 
conformation. Modeling of the PK structure was carried out previously utilizing the FXI 
crystal structure as a template (Hooley et al., 2007). The model suggests that hydrophobic 
pocket 1 in the FXI A3 domain is not present in PK (Figure 6-1 C and D). In FXI, residue 
209 on the α-helix is Gly (Figure 6-1A); while in PK it is Arg (Figure 6-1C). The PK 
Arg209 side chain is predicted to interfere with formation of the hydrophobic pocket in this 
location (Figure 6-1 C and D).  
As discussed in Chapter IV, hydrophobic pocket 1 and the adjacent Arg184 are buried 
beneath the catalytic domain in zymogen FXI, with Arg184 forming salt bridges with 
Asp488 and Asn566 on the catalytic domain (Figure 5-3). This is consistent with the 
observation that FIX binds to FXIa but not zymogen FXI, and is consistent with the 
hypothesis that Arg184 and pocket 1 may be part of a FIX binding site that is exposed 
during FXI conversion to FXIa through repositioning of the catalytic domain relative to the 
A3 domain (Samuel et al., 2007, Emsley et al., 2010).  
Hydrophobic pocket 2 is located on the opposite side of Phe206 from pocket 1 (Figure 
6-1B left panel), with Asn189, Phe223, Ser225, Gln226, and Glu227 contributing to its 
formation. It would seem that this pocket is less likely to be a component of a FIX-binding 
site specific to FXIa, as a similar pocket (with some substitutions) is predicted to be present 
84 
 
on the PK A3 domain. Furthermore, pocket 2 is exposed to the aqueous phase in the 
zymogen structure. Hydrophobic pocket 3, which is on the opposite side of A3 from pocket 
1 (Figure 6-1B right panel), is formed by Asp185, Phe187, Phe192, Leu246, Arg250 and 
Phe260. While not predicted to be present in PK, this pocket is also unobstructed in 
zymogen FXI. 
 
Investigations of Additional Residues on the Factor XI A3 Domain Involved in 
Factor IX activation 
The structural analysis suggests that hydrophobic pocket 1 and/or the charged residues 
around the pocket may be an area on the FXIa A3 domain that interacts with FIX. This is 
consistent with our observation that Arg184 contributes to binding of FIX and FIXα to 
FXIa. However, the functional defect caused by the Gly184 substitution is modest 
compared to the defect observed with FXIa/PKA3, showing that residues in addition to 
Arg184 contribute to FIX binding. Residues in proximity to Arg184 were analyzed for their 
importance to FIX activation. A comparison of the amino acid sequence of the human FXI 
and PK A3 domains assisted us in focusing on FXIa specific sequences. A FXI variant in 
which residues Ile183, Arg184 and Asp185 are each replaced with Ala (FXIa-Ala183-185) 
demonstrated a profound defect in plasma clotting activity (< 1% clotting activity of 
plasma FXIa in aPTT assay). Cleavage patterns and kinetic parameters for FIX activation 
by FXIa-Ala183-185 are shown in Figure 6-2A, Tables 6-1 and 6-2 (The kinetic parameters 
for FIX activation by FXIa-WT and FXIa/PKA3 are also listed for comparison). 
FXIa-Ala183-185 exhibits a defect in FIX activation that is comparable to that of 
FXIa/PKA3. Thus, replacement of Ile183, Arg184 and Asp185 completely disrupts the 
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specific interaction between the A3 domain and FIX and FIXα, and suggests that these 
residues in combination are a major component of the FIX-binding site. 
A concern with the alanine-substitution strategy is that the replacements may alter the 
general conformation of A3 domain and its exosite, without actually being part of the 
exosite. This is a limitation of most loss-of-function strategies. As a complementary 
approach, FXI/PKA3 was used as a scaffold to reintroduce FXI sequence to restore activity 
 
Figure 6-2. Progress curves of FIX activation by FXIa-Ala183-185 and FXIa/PKA3 
gain-of-function variants. Shown are progress curves of FIX disappearance (●), and 
FIXα (○) and FIXaβ (Δ) generation, for reactions containing 100 nM FIX and (A) 30 nM 
FXIa-Ala183-185, (B) 3 nM FXIa/PKA3-A, and (C) 3 nM FXIa/PKA3-B. Note the 
different FXIa concentrations used in the three reactions. FXIa concentrations represent 
the concentrations of active subunits. (D) Initial velocities of cleavage of FIX after 
Arg145 (conversion of FIX to FIXa) by FXIa-Ala183-185 (Δ), FXIa/PKA3-A (●), and 
FXIa/PKA3-B (○), as a function of FIX concentration.  
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Table 6-1. Kinetic parameters for cleavage of FIX by FXIa. 
Simulation of full-progress experimental traces was performed with KINTEK software 
(KINTEK EXPLORER Version 2.5), using the equation shown in methods in Chapter IV. 
Km and kcat for activation were calculated from individual rate constants for each step. 
Values are mean standard deviations for each experiment. Ki was fixed for reactions with 
FXIa-WT and FXIa/PKA3 on the basis of surface plasmon resonance results (Chapter IV). 
 
Cleavage of FIX after Arg145 
Protease  Substrate  kcat 1 (min-1) Kd 1 (μM) Km 1 (μM) 
Catalytic 
Efficiency 1 
(μM-1 min-1) 
Ki 1 (μM) 
FXIa-WT  FIX  12 ± 1  0.10 ± 0.01 0.20 ± 0.01 60 ± 6  0.14  
FXIa-WT no Ca2+  FIX  6.5 ± 0.4  4.9 ± 0.4  4.9 ± 0.4 1.3 ± 0.3  5  
FXIa/PKA3  FIX  4.9 ± 0.1  4.9 ± 0.2  4.9 ± 0.2 1.0 ± 0.1  3  
FXIa-Ala183-185 FIX  9 ± 1  8 ± 1  10 ± 2  0.9 ± 0.2  6 ± 1  
FXIa/PKA3-A  FIX  6.4 ± 0.2  1.3 ± 0.1  1.4 ± 0.1 4.6 ± 0.4  1.9 ± 0.1 
FXIa/PKA3-B  FIX  19 ± 2  0.06 ± 0.01 0.09 ± 0.02 200 ± 30  0.5 ± 0.1 
 
Cleavage of FIX after Arg180 
Protease  Substrate  kcat 2 (min-1) Kd 2 (μM)  Km 2 (μM) 
Catalytic 
Efficiency 2 
(μM-1 min-1) 
Ki 2 (μM) 
FXIa-WT  FIX  35 ± 6  0.06 ± 0.01 0.08 ± 0.01 400 ± 100  0.06  
FXIa-WT no Ca2+  FIX  3.6 ± 0.2  15 ± 1  15 ± 1  0.24 ± 0.04  5  
FXIa/PKA3  FIX  0.6 ± 0.1  7 ± 1  7 ± 1  0.09 ± 0.02  3  
FXIa-Ala183-185  FIX  0.4 ± 0.1  3 ± 1  3 ± 1  0.13 ± 0.01  0.29 ± 0.01 
FXIa/PKA3-A  FIX  1.7 ± 0.1  1.3 ± 0.1  1.3 ± 0.1 1.3 ± 0.1  0.28 ± 0.02 
FXIa/PKA3-B  FIX  39 ± 4  0.04 ± 0.01 0.07 ± 0.01 600 ± 100  0.30 ± 0.03 
 
toward FIX. The wild type PK sequence His183, Met184 and Asn185 in FXIa/PKA3 was 
replaced with Ile183, Arg184 and Asp185 from the FXIa sequence to create FXIa/PKA3-A. 
FXIa/PKA3-A has ~5% of FXIa-WT coagulant activity, with catalytic efficiencies for the 
cleavage after Arg145 and after Arg180 that are 4- and 10- fold greater, respectively, than 
for FXIa/PKA3 (Table 6-1). However, these values remain considerably lower than those 
for FXIa-WT, and accumulation of FIXα confirms that the exosite and the activation 
mechanism are not completely restored (Figure 6-2B). 
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Table 6-2. Kinetic parameters for cleavage of FIX by FXIa determined from initial 
velocities. 
 
Protease  Substrate Bond cleaved kcat 1 (min-1) Km 1  (μM)  
Catalytic 
Efficiency 1 (μM-1
min-1)  
FXIa-WT  FIX  Arg145  10 ± 1  0.27 ± 0.07  40 ± 10  
FXIa/PKA3  FIX  Arg145  6 ± 1  3.9 ± 0.9  1.6 ± 0.4  
FXIa-Ala183-185  FIX  Arg145  ND*  > 8  0.70 ± 0.10  
FXIa/PKA3-A  FIX  Arg145  5 ± 1  1.3 ± 0.4  4 ± 1  
FXIa/PKA3-B  FIX  Arg145  12 ± 1  0.08 ± 0.01  140 ± 20  
 
* ND, not determined. The initial velocity (v0) of cleavage of FIX after Arg145 was plotted 
against the initial substrate concentration, and analyzed with the Michaelis–Menten 
equation. Km and kcat were obtained from direct non-linear least squares analysis with 
Scientist Software. Owing to the low affinity between the enzyme and substrate in 
reactions with FXIa variants, we were not able to reach saturation in reactions with 
FXIa-Ala183–185 or FXIa/PKA3. Thus, values for Km are approximate, and the value for 
kcat for FXIa-Ala183–185 was not determined. 
 
As discussed above, the C-terminus (residues 260-264) of the FXI A3 domain is in 
proximity to the N-terminus where residues 183-185 reside, due to the Cys182-Cys265 
disulfide bond that connects the N- and C-termini of the A3 domain (Figure 6-1A) 
(McMullen et al., 1991; Papagrigoriou et al., 2006). To determine if the C-terminus of the 
A3 domain is required for proper formation of the FIX binding site, we replaced the PK 
sequence Tyr260-Ser261-Leu262-Leu263-Thr264 in FXIa/PKA3-A with 
Phe260-Ser261-Leu262-Gln263-Ser264 from FXI, creating FXIa/PKA3-B. Superimposing 
these changes on the N-terminal replacements for residues 183-185 restored normal FIX 
activation (Figure 6-2 C and D) to FXIa/PKA3. Indeed, FXIa/PKA3-B is a modestly more 
efficient activator of FIX than FXIa-WT (Tables 6-1 and 6-2), with catalytic efficiencies 
for the first and second cleavages that are 3.3- and 1.5-fold greater, respectively, than for 
FXIa-WT. As with FXIa-WT, cleavage of FIX by FXIa/PKA3-B was associated with little 
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FIXα accumulation. Thus, replacing six amino acids in the PKA3 domain (residues 183, 
184, 185, 260, 263 and 264) with the corresponding FXI residues is sufficient to restore 
exosite activity and the mechanism for FIX activation in FXIa/PKA3.    
While our data strongly suggest the residues near hydrophobic pocket 1 are required for 
formation of the FIX binding exosite on FXIa, we cannot rule out a contribution from 
pocket 3. In the crystal structure of the A3 domain, Arg184 and adjacent residues form a 
ridge between the hydrophobic pockets 1 and 3 that is not predicted to be present in PK 
(Figure 6-1 B and D). The substitutions in FXIa-Ala183-185 could disrupt the adjacent 
hydrophobic pockets, one or both of which could be involved in FIX binding. Residues 260 
to 265 actually run underneath the chain containing 183-185 (Figure 6-1A), with Leu262 
and Phe260 (Figure 6-1B) contributing to hydrophobic pockets 1 and 3, respectively. The 
C-terminal sequence from FXI A3 in FXIa/PKA3-B could, therefore, restore FIX binding 
by supplying missing components of the binding site, or by properly orienting structures 
such as residues 183 to 185 that are directly involved in binding. 
 
Localization of the Factor XIa Binding Site on the Factor IX Gla Domain.  
As discussed in Chapter III, the Gla domains of VKD coagulation proteases bind to 
phosphatidylserine-rich phospholipid membranes. These interactions are essential for 
formation of coagulation enzyme-substrate complexes involving these proteases. 
Published work from our laboratory indicates that the Gla domain of FIX may serve as a 
recognition site for FXIa (Aktimur et al., 2003). The importance of Ca2+ ions to the proper 
conformation of the Gla domain might be the reason that FIX activation by FXIa is calcium 
dependent, as most of the other reactions catalyzed by FXIa do not require calcium. In the  
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absence of Ca2+, the rates of FIX bond cleavage by FXIa are significantly slower than in 
the presence of Ca2+, with pronounced accumulation of FIXα (Figure 6-3 A and B). Km 
values for FIX activation in the absence of Ca2+ are similar to those generated with 
FXIa/PKA3 in the presence of Ca2+ (Table 6-1). Indeed, absence of Ca2+ has little effect 
on the overall rate of FIX cleavage by FXIa/PKA3 (Figure 6-3 C and D) or FXIa-CD 
(Figure 6-3 E and F). The data are consistent with the premise that a Ca2+-dependent 
interaction between the FXIa A3 domain and FIX is required for normal FIX activation. 
That this interaction involves the FIX Gla domain is suggested by the observation that 
replacing the Gla domain with the corresponding domain from FVII (Aktimur et al., 
 
Figure 6-3. FIX cleavage by FXIa – The 
importance of Ca2+ ions and the Gla domain. 
Shown are progress curves of FIX disappearance (●), 
and FIXα (○) and FIXaβ (▲) generation. FIX (1000 
nM) in Assay Buffer with Ca2+ was activated by by 
(A) FXIa-WT (5 nM active sites), (C) FXIa/PKA3 
(40 nM active sites), or  (E) FXIa-CD (40 nM active 
sites). FIX (1000 nM) in Assay Buffer with 25 mM  
EDTA activated at room temperature by (B) FXIa-WT (40 nM active sites), (D) 
FXIa/PKA3 (40 nM active sites), or  (F) FXIa-CD (40 nM active sites). (G) FIX (100 
nM) was activated by 3 nM FXIa-WT (active sites) in the presence of 1000 nM IgG SB 
249417. 
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2003) or protein C (Ndonwi et al., 2007) results in loss of FIX binding to FXIa, and that a 
monoclonal antibody to FIX (IgG SB 249417) that binds to FIX Gla domain inhibits FIX 
activation and causes significant FIXα accumulation (Figure 6-3G) (Aktimur et al., 2003). 
These observations suggest that a structural element specific to the FIX Gla-domain 
mediates binding to FXIa. The primary sequences of the human FIX and FVII 
 
Figure 6-4. FIX with FVII sequence in the Gla-domain. (A) Primary sequences of the 
human FIX and FVII Gla-domains. The numbering system shown is for FIX. The symbol 
γ indicates the position of Gla residues. Underlined sequences were changed from the FIX 
sequence to the FVII sequence to generate chimeras C1, C2, C3, and C4. The residues 
changed in each chimera are highlighted by the gray boxes. (B) Stained 
SDS–polyacrylamide gel of purified plasma FIX (pIX), recombinant wild-type FIX (WT), 
FIX/FVII chimeras (C1, C2, C3, and C4), and FIX in which Gla-domain residues 1–46 are 
changed to the FVII sequence (FIX/FVII-Gla [VIIGla]). The weaker band running 
underneath FIX C3 is contaminating bovine serum albumin from conditioned media. (C, 
D) FXIa (2 nM) was incubated with 250 nM FIX-WT (○), C1 (●), C2 (□), C3 (■), C4 (Δ) 
and FIX/VII-Gla (▲) (250 nM) in Assay Buffer with Ca2+, as described in methods. 
Shown are concentrations of (C) FIXaβ and (D) FIXα at various times as determined by 
densitometry of SDS–polyacrylamide gels. 
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Gla-domains are compared in Figure 6-4A. Based on the comparison, FIX/VII chimeras 
(designated C1 to C4) were prepared in which three to five residues of sequence within the 
FIX Gla-domain were replaced with FVII sequence (Figure 6-4 A and B). As reported, 
FXIa activated FIX with a FVII Gla domain significantly more slowly than FIX-WT 
(Figure 6-4C), with substantial accumulation of FIXα (Figure 6-4D) (Aktimur et al., 
2003). FIX-WT and chimeras C2, C3, and C4 were converted to FIXaβ at roughly 
comparable rates (Figure 6-4 C and D), with little FIXα accumulation. However, chimera 
C1 demonstrated a pronounced defect in activation by FXIa with significant FIXα 
accumulation, similar to what is observed during FIX activation by FXIa-Ala183-185.  In 
binding studies using surface plasmon resonance, C1 demonstrated a major defect in 
binding to immobilized FXIa (Kd >2000 nM), compared to FIX-WT (Kd 350 nM) and 
chimeras C2 (Kd 400 nM) and C4 (Kd 350 nM). There was insufficient chimera C3 to 
conduct an SPR study.  
The substitutions in chimera C1 are in the Ω-loop of the Gla-domain (Vadivel et al., 
2012), as shown in the topology image of the human factor IX Gla-domain in Figure 6-5. 
This structure, reported by Huang et al., is for the Gla-domain in complex with the 
conformation-specific anti-FIX IgG 10C12 (Huang et al., 2004). This region was 
previously reported to facilitate FIX binding to phosphatidylserine (PS)-rich surfaces in a 
Ca2+-dependent manner through a combination of charged and hydrophobic interactions 
(Vadivel et al., 2012). Similarly, the topography of the A3 domain in the vicinity of Arg184 
suggests that FIX binding may involve charged and hydrophobic interactions as well. This 
would be consistent with the hypothesis that the phospholipid-binding Ω-loop within the 
FIX Gla-domain is the region required for FIX binding to FXIa. The interaction between 
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the Gla domain of FIX and phospholipid surfaces enhances FIX activation by the 
FVIIa/tissue factor complex, and FX activation by FIXaβ, by reducing Km for the reactions 
(Brummel-Ziedins et al., 2012). Ca2+-dependent binding of FIX to the FXIa A3 domain 
also determines Km for FIX activation, suggesting the interaction serves a similar purpose 
to FIX binding to phospholipids during activation by FVIIa. Taken as a whole, the data 
presented in this chapter are consistent with a model in which residues in the Ω-loop of FIX 
and FIXα mediate Ca2+-dependent binding to the FXIa A3 domain through interactions 
involving residues adjacent to a hydrophobic pocket formed by the N- and C- termini of 
A3. 
 
Figure 6-5. Topological diagram of the FIX Gla-domain. Shown is the Gla domain 
with residues in the Ω-loop (4–11) that differ from the corresponding region of the 
human FVII Gla-domain highlighted in magenta. The positions of certain Gla residues 
are indicated by the symbol ‘γ’. Calcium ions in the vicinity of the Ω-loop are 
represented by green spheres. (Image courtesy of Dr .Jonas Emsley.) 
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Summary 
Inspection of the FXI crystal structure suggests that FXI Arg184 and adjacent residues 
contribute to charged areas and hydrophobic pockets that are not present on the A3 domain 
of the homolog PK. Mutagenesis studies indicate that residues 183-185 at the N-terminus 
of A3 and residues 260-264 at the C-terminus are critical for formation of a binding site for 
FIX and its activation intermediate FIXα that are required for normal conversion of FIX to 
FIXaβ by FXIa. Replacement of FIX residues forming the Ω-loop of the Gla-domain 
(amino acids 4 to 11) with FVII sequence produced a defect in activation by FXIa-WT 
similar to the one observed with loss of the A3 domain exosite. This suggests that the FIX 
Ω-loop may mediate the interaction with the exosite on the FXIa A3 domain for proper 
activation of FIX by FXIa. 
 
Methods 
Recombinant Proteins. Recombinant FXIa was expressed as described in Chapter IV. In 
FXI-Ala183-185 Ile183, Arg184, and Asp185 are replaced with alanine. In FXI/PKA3 the 
entire A3 domain (residues 182 to 265) is replaced with the PK A3 domain. Two modified 
forms of FXI/PKA3 were prepared. In FXI/PKA3-A, FXI sequence is restored at amino 
acids 183 to 185. In FXI/PKA3-B FXI sequence is restored at amino acids 183 to 185 and 
260 to 264.  
Recombinant FIX was expressed in HEK293 cells grown in media containing 10 
μg/mL vitamin K1 (for proper γ-carboxylation of Gla domain). FIX was purified from 
conditioned media by antibody affinity chromatography (Aktimur et al., 2003; Smith et al., 
2008). In addition to wild type FIX (FIX-WT), four FIX chimeric proteins were prepared 
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in which Gla-domain residues are replaced with corresponding residues from human FVII 
(C1 – residues 4, 5, 9, 10 and 11; C2 – 13, 19 and 22; C3 – 30, 32, 33, and 34; and C4 – 41, 
43, 44, and 46). 
The methods for FIX activation by FXIa and surface plasmon resonance were 
performed as described in Chapter IV.  
 
References 
Aktimur, A., Gabriel, M. A., Gailani, D., and Toomey, J. R. (2003) The factor IX 
γ-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and 
factor XIa. J Biol Chem 278, 7981–7987. 
 
Baglia, F.A., Gailani, D., López, J.A., Walsh, P.N. (2004) Identification of a binding site 
for glycoprotein Ib-α in the Apple 3 domain of factor XI. J Biol Chem 279, 45470-6. 
 
Brummel-Ziedins, K., and Mann, K.G. (2012) Molecular basis of blood coagulation, In: 
Hematology: basic principles and practice, 6th Ed., Churchill Livingstone-Elsevier, 
Philadelphia, pp 1821-41 
 
Emsley, J., McEwan, P.A., Gailani, D. (2010) Structure and function of factor XI. Blood 
115, 2569-2577. 
 
Fujikawa, K., Chung, D.W., Hendrickson, L.E., Davie, E.W. (1986) Amino acid sequence 
of human factor XI, a blood coagulation factor with four tandem repeats that are highly 
homologous with plasma prekallikrein. Biochemistry 25, 2417-24. 
 
Hooley, E., McEwan, P.A., and Emsley, J. (2007) Molecular modeling of the prekallikrein 
structure provides insights into high-molecular-weight kininogen binding and zymogen 
activation. J Thromb Haemost 5, 2461-2466. 
 
Huang, M., Furie, B.C., Furie, B. (2004) Crystal structure of the calcium-stabilized human 
factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol 
Chem 279, 14338-46. 
 
McMullen, B.A., Fujikawa, K., Davie, E.W. (1991) Location of the disulfide bonds in 
human coagulation factor XI: the presence of tandem apple domains. Biochemistry 30, 
2056-2060. 
 
Ndonwi, M., Broze, G.J., Agah, S., Schmidt, A.E., Bajaj, S.P. (2007) Substitution of the 
Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue 
95 
 
factor: lack of comparable effect by similar substitution in factor IX. J Biol Chem 282, 
15632-44. 
 
Papagrigoriou, E., McEwan, P.A., Walsh, P.N., and Emsley, J. (2006) Crystal structure of 
the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 13, 
557-558. 
 
Ponczek, M.B., Gailani, D., Doolittle, R.F. (2008) Evolution of the contact phase of 
vertebrate blood coagulation. J Thromb Haemost 6, 1876-1883. 
 
Samuel, D., Cheng, H., Riley, P.W., Canutescu, A.A., Nagaswami, C., Weisel, J.W., Bu, 
Z., Walsh, P.N., and Roder, H. (2007) Solution structure of the A4 domain of factor XI 
sheds light on the mechanism of zymogen activation. Proc Natl Acad Sci USA 104, 
15693-15698. 
 
Sun, M.F., Zhao, M., Gailani, D. (1999) Identification of amino acids in the factor XI apple 
3 domain required for activation of factor IX. J Biol Chem 274, 36373-8. 
 
Vadivel, K., Schmidt, A.E., Marder, V.J., Krishnaswamy, S., Bajaj, S.P. (2012) Structure 
and function of vitamin K-dependent coagulation and anticoagulation proteins, In: 
Hemostasis and Thrombosis: basic principles and clinical practice, 6th Ed., Lippincott, 
Williams & Wilkins, Philadelphia, pp 208-32 
 
Zhang, Z., Li, Y., Lin, B., Schroeder, M., Huang, B. (2011) Identification of cavities on 
protein surface using multiple computational approaches for drug binding site prediction. 
Bioinformatics 27, 2083-8. 
 
Zhao, M., Abdel-Razek, T., Sun, M.F., Gailani, D. (1998) Characterization of a heparin 
binding site on the heavy chain of factor XI. J Biol Chem 273, 31153–9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
CHAPTER VII 
 
THE DIMERIC STRUCTURE OF FACTOR XI  
AND ZYMOGEN ACTIVATION 
 
FXI is a dimer in all mammals in which it has been studied (Ponczek et al., 2008). This 
is an atypical structure for a trypsin-like enzyme, and unique among clotting proteases. 
That the dimeric structure is so highly conserved, and that its parent homolog (PK) is a 
monomer, implies that dimerization is critical for one or more specific aspects of FXI 
function. The FXIa substrate FIX must be cleaved at two sites to form the protease FIXaβ, 
raising the possibility that the two protease domains of a FXIa dimer facilitate FIX 
activation. However, work with 1/2-FXIa and monomeric FXIa showed that a single FXIa 
subunit is sufficient for FIX activation. 
Like FXIa, granzyme A, a cell-death inducing protein secreted by cytotoxic T 
lymphocyte, is a homodimeric serine protease. In granzyme A, the dimeric interface forms 
a recognition site for macromolecular substrates (an exosite) that is not present in the 
protease monomer (Bell et al., 2003). While this is not the case for FXIa activation of FIX, 
it is possible that the dimeric interface harbors, or helps to form, a binding site for FXI 
activating proteases or FXIa inhibitors. Supporting this hypothesis is an observation that 
FXI monomers are converted to FXIa significantly more slowly than FXI dimers (Wu et 
al., 2008). This suggests that dimerization facilitates normal activation of FXI. Based on 
their observation, a trans-activation mechanism was proposed in which the activating 
protease (FXIIa, thrombin or FXIa) binds to one FXI subunit within a dimer while 
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activating the opposite subunit (Samuel et al., 2007; Wu et al., 2008). We questioned this 
hypothesis, as PK, the homolog of FXI, is a monomer and is effectively activated by FXIIa. 
We investigated the importance of the FXI dimer to protease activation, using forms of 
plasma FXI with one or two activated subunits, and recombinant dimeric and monomeric 
FXI.  
 
 
 
 
Figure 7-1. Schematic diagrams of species generated during FXI activation. The 
gray ellipses represent the 4 apple domains (A1–A4) and the black circles represent 
the catalytic domains (CD) of zymogen FXI. The 2 subunits of the FXI dimer are 
connected by a hydrophobic interface involving the A4 domains and a disulfide bond 
involving Cys321. Activation of 1 FXI subunit by cleavage of the Arg369-Ile370 bond 
results in a species with 1 active site, referred to as 1/2-FXIa. The white three-quarter 
circle represents the activated protease domain. Subsequent cleavage of the 
Arg369-Ile370 bond on the second subunit results in generation of FXIa. FXI, 
1/2-FXIa, and FXIa migrate slightly differently on SDS-PAGE (inset), facilitating 
their identification and purification. The preparation of 1/2-FXIa shown in the inset 
has approximately 10% contamination with FXIa (upper of the 2 bands). Inhibition of 
the active protease domain (8) of 1/2-FXIa yields a species called 1/2-FXIai. 
Activation of the second subunit of 1/2-FXIai results in a species with 2 activated 
subunits, 1 of which is inhibited called FXIa-1/2i.
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 Activation of Factor XI subunits 
As described in Chapter II, activation of a FXI subunit involves cleavage of the 
Arg369-Ile370 bond; a process that can be mediated by several proteases including FXIIa, 
various forms of thrombin, or trypsin. Previously, we showed that conversion of zymogen 
FXI (no activated subunits) to FXIa (two activated subunits) by FXIIa or α-thrombin 
proceeds through a form with only one activated subunit (1/2-FXIa) (Figure 7-1) (Smith et 
al., 2008). 1/2-FXIa has identical activity on an active site basis to FXIa in terms of its 
ability to activate FIX and to induce clot formation in plasma. Because activated FXIa only 
requires one activated subunit to activate FIX, it is possible that a FXI subunit in each 
 
Figure 7-2. Activation of plasma FXI. (A and B) Plasma FXI (600nM) was incubated 
at 37 °C with (A) 60 nM FXIIa or (B) 600nM α-thrombin. Samples of each reaction 
were quenched in non-reducing sample buffer at the indicated times and size 
fractionated on 6% polyacrylamide-SDS gels. Positions for markers, and protein 
standards for factor XI (FXI), factor XIa (FXIa) and 1/2-FXIa are indicated. (C and D) 
Activation of 100 nM FXI ({) or 200 nM 1/2-FXIai (z) by (C) FXIIa (10 nM) or (D) 
α-thrombin (50 nM). At various times samples were tested for enzymatic activity by 
measuring cleavage of the chromogenic substrate S-2366 (500 μM) as described under 
Methods. Error bars represent one SD. The concentration of 1/2-FXIai was 200 nM in 
the activation assay to generate sufficient signal to detect in the chromogenic substrate 
assay. Reactions performed with 100 nM 1/2-FXIai would have slopes half as large as 
those for the progress curves shown. 
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dimer may have a function unrelated to catalysis, and that it may not need to be in an active 
conformation to perform that function.  
There is little information available regarding generation of 1/2-FXIa or its conversion 
to FXIa. It is difficult to distinguish the singly activated species from FXIa during 
activation time course experiments because of their comparable molecular masses. FXI 
activation is thought to be accompanied by a significant conformational change in the 
activated subunit (Samuel et al., 2007). Consistent with this, we noted that, 1/2-FXIa 
migrates slightly differently than FXI and FXIa (Figure 7-1 and 7-2) on non-reducing 6% 
SDS-PAGE, running in between the zymogen and fully activated species. FXI activation 
by FXIIa (Figure 7-2A) or α-thrombin (Figure 7-2B) is a slow process in the absence of a 
polyanion. With both proteases, 1/2-FXIa was noted to form prior to FXIa, and it appeared 
that conversion of FXI to 1/2-FXIa was a more rapid process than conversion of 1/2-FXIa 
to FXIa (Figure 7-2 A and B). Indeed, complete conversion of FXI to FXIa with 
α-thrombin is difficult to achieve, even with extended incubation.  
The relative rates of activation of the two subunits of dimeric FXI were compared. 
Conversion of plasma FXI to 1/2-FXIa was studied by measuring reaction rates at early 
time points prior to the appearance of fully active FXIa (compare open circles in Figure 7-2 
C and D). Activation of the first FXI subunit was 60-fold faster with FXIIa (15000 M-1 
sec-1) than with α-thrombin (250 M-1 sec-1). Activation of the second FXI subunit 
(conversion of 1/2-FXIa to FXIa) was assessed using a preparation of purified 1/2-FXIa as 
substrate (Figure 7-1). 1/2-FXIa was produced by limited digestion of FXI with 
α-thrombin (Smith et al., 2008). The reaction mixture, which contained a mixture of FXI 
and 1/2-FXIa, with a trace of FXIa, was applied to a benzamidine-Sepharose column. 
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1/2-FXIa bound to the column, while FXI passed through the column and appeared in the 
flow through. 1/2-FXIa was eluted from the resin with benzamidine. After purification, the 
active site of the activated subunit of 1/2-FXIa was irreversibly blocked by treatment with 
DIP (1/2-FXIai –Figure 7-1). This prevents this subunit from contributing to chromogenic 
substrate cleavage.  
Cleavage of the unactivated subunit of 1/2-FXIai was 40-fold faster with FXIIa than 
with α-thrombin (1200M-1 sec-1 and 30 M-1 sec-1, respectively). Cleavage of the first 
subunit was 12-fold faster than cleavage of the second subunit with FXIIa and 8- fold faster 
with α-thrombin (Compare closed circles to open circles in Figure 7-2 C and D), indicating 
that conformational changes accompanying activation of a subunit affect activation of the 
second subunit within a dimer.  
 
Activation of monomeric FXI 
The interface between FXI subunits has been discussed in detail in Chapter II. While 
Cys321 forms a disulfide bond connecting the A4 domains, FXI is a dimer even in the 
absence of this bond (Cheng et al., 2003). Leu284, Ile290, and Tyr329 form the hydrophobic 
core of the dimer interface (Papagrigoriou et al., 2006). We expressed FXI with Cys321 
replaced by serine, with or without alanine replacement for Leu284 or Ile290, as described 
by Wu et al. (Wu et al., 2008). On nonreducing denatured SDS-PAGE, FXI-WT, as 
expected, is a 160-kDa dimer (Figure 7-3A), while FXI-Ser321, FXI-Ser321,Ala284, and 
FXI-Ser321,Ala290 migrate as 80-kDa monomers because they lack the Cys321-Cys321 
disulfide bond that connects the two subunits in FXI-WT. On size exclusion 
chromatography, the peak retention volumes for FXI-WT (11.7 mL) and FXI-Ser321   
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(12.1 mL) are similar, indicating FXI-Ser321 is a non-covalently associated dimer despite 
lacking Cys321 (Figure 7-3B). In contrast, retention volumes for FXI-Ser321,Ala284 (13.5 
mL) and FXI-Ser321,Ala290 (13.7 mL) are similar to PK (13.3 mL), the monomeric 
homolog of FXI (Figure 7-3C), consistent with these molecules existing largely in a 
monomeric state.  
 
 
Figure 7-3. Recombinant FXI. (A) Recombinant FXI-Ser321 (321), 
FXI-Ser321,Ala284 (321/284) and FXI-Ser321,Ala290 (321/290) appear as 80 kDa 
monomers on 7.5% non-reducing SDS-PAGE because they lack the Cys321-Cys321 
inter-chain disulfide bond that connects the two subunits of the dimer in FXI-WT (160 
kDa band at right). Positions of molecular mass standards (kDa) are indicated at the 
left of the panel. Size-exclusion chromatography of (B) plasma FXI (pXI) and 
FXI-Ser321 (321) or (C) FXI-Ser321,Ala284 (321/284) and FXI-Ser321,Ala290 
(321/290) and plasma prekallikrein (PK). Shown are continuous readouts of optical 
density (280 nm) of solutions exiting a Superose-12 size exclusion column (flow rate 
1.0 ml/min). Protein retention volumes in mls are indicated below the curves. 
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Activation of monomeric FXI in the absence of polyanions 
Wu et al. showed that the monomeric FXI-Ser321,Ala284 and FXI-Ser321,Ala290 are 
activated more slowly than FXI-WT or FXI-Ser321 at low enzyme-to-substrate (E:S) ratios 
(Wu et al., 2008). Consistent with this, we observed slower monomer activation by FXIIa 
at an E:S ratio of 1:20 (Figure 7-4A). However, this discrepancy became smaller as the E:S 
ratio increased, and disappeared at a E:S ratio of 1:1 (Figure 7-4 B-D). Rates of FXI-WT 
activation by FXIIa exhibited a linear dependence on FXIIa concentration up to 30 nM, 
consistent with a second-order rate constant of 14000 M-1 sec-1 for the FXI-WT dimer, 
which is in agreement with the value determined for conversion of plasma FXI to 1/2-FXIa. 
However, the rate with 100 nM FXIIa was approximately 2-fold higher than expected from 
the linear dependence, suggesting facilitated activation when FXIIa occupies both subunits. 
FXI monomers were poorer substrates at low FXIIa concentrations, but similar rates for 
monomer and dimer activation were observed with FXIIa >30 nM. 
Modeling of FXI activation over a range of FXIIa concentrations suggests that FXI 
subunits harbor two productive binding sites with different affinities for FXIIa. The 
lower-affinity site would be contained within a subunit, while a higher-affinity site may 
extend onto the neighboring subunit. This is supported by the higher FXI activation rates at 
100 nM FXIIa than expected from the second-order rate constant calculated for activation 
by FXIIa at 5 to 30 nM. The behavior of the monomer at low FXIIa concentrations can be 
explained by absence of the higher-affinity site. As FXIIa concentration increases, the 
low-affinity sites common to monomers and dimers are saturated, resulting in comparable 
activation rates.  
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Figure 7-4. Activation of FXI. A-D. FXI-WT ({), FXI-Ser321 (z), 
FXI-Ser321,Ala284 (), or FXI-Ser321,Ala290 (U), 200 nM subunits for each protein, 
were incubated with FXIIa at (A) 5 nM, (B) 10nM, (C) 30 nM, or (D) 100 nM 
concentration. (E) FXI species in panels A-D (200 nM subunits) activated by 50 nM 
α-thrombin. F-G. Activation of FXI-WT ({), FXI-Ser321,Ala284 () or 
FXI-Ser321,Ala290 (U), 120 nM subunits each incubated with (F) 3 nM FXIIa or (G) 3 
nM α-thrombin in the presence of 50 nM poly-P. For panels A through G, samples of 
reactions were tested at various times for FXIa activity by measuring cleavage of S-2366 
(500 μM). Panel H. Michaelis-Menten nonlinear least squares analysis of the substrate 
concentration dependence of FXI-WT subunit activation by 3 nM α-thrombin in the 
presence of 50 nM poly-P. For all panels, error bars show one standard deviation (SD).  
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In contrast to FXI activation by FXIIa, similar activation rates were observed for FXI 
dimers and monomers in reactions with α-thrombin (Figure 7-4E), indicating that catalytic 
efficiencies for activation of monomer and a subunit within a dimer are comparable. 
However, a relatively high E:S ratio (1:4) was required, as slow activation rates precluded 
studying the process at lower ratios.  
 Activation of monomeric FXI in the presence of polyanions 
FXI activation can be accelerated by polyanions such as dextran sulfate (DS) (Gailani 
and Broze, 1991). Recently, Choi et al. showed that polyP released from platelet dense 
granules is a potent enhancer of FXI activation by thrombin and autoactivation, and is a 
strong candidate for a physiologic cofactor for FXI activation (Choi et al., 2011). We 
examined FXI activation by FXIIa or α-thrombin in the presence of polyP with a size 
distribution comparable to platelet polyP. PolyP increased the initial rate of FXI activation 
by FXIIa approximately 30-fold (500,000 M-1 sec-1, Figure 7-4F) and by α-thrombin 
approximately 3000-fold (700,000 M-1 sec-1, Figure 7-4G) compared with reactions 
without polyP (Figure 7-4 A-E). Michaelis–Menten analysis of FXI-WT activation by 
thrombin with polyP gave a rate of ~700,000 M-1 sec-1 with kcat 0.05 ± 0.01 s-1 and Km 70 
± 10 nM FXI dimer (Figure 7-4H). During the reactions, a mixture of 1/2-FXIa and FXIa is 
formed, and it is likely that modest FXI activation by these proteases (autoactivation) is 
responsible for the curvature of some time courses (Figure 7-4 G and H).  
We noted that the defect in FXIIa-mediated activation of FXI monomers in the absence 
of a polyanion remained evident in the presence of polyP (Figure 7-4F). The results with 
polyP are also consistent with the premise that FXI does not need to be a dimer to be 
activated by thrombin. The latter observation seems to be incompatible with a 
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trans-activation mechanism based on an analysis of the crystal structure of zymogen FXI 
(Papagrigoriou et al., 2006). It was proposed that the protease domain of FXI is interposed 
between a putative α-thrombin binding site on the A1 domain (Baglia et al., 1996) and the 
activation cleavage site. It was predicted that this would interfere with a thrombin molecule 
that bound to a FXI subunit activating that same subunit. However, our results clearly show 
that any binding site for α-thrombin likely lies within the FXI subunit undergoing 
activation (cis-activation). The reason for the discrepancy between our data and the 
previously published work is not clear. One possibility is that a significant conformational 
change occurs in a FXI subunit upon initial binding of thrombin, rendering the activation 
cleavage site accessible to the protease. Alternatively, the proposed thrombin binding site 
on A1 may not be correct. Additional work with site-directed mutants may help clarify this 
situation. 
 
Autoactivation of FXI 
Polyanions, including DS and polyP, induce FXI activation in the absence of an 
activating protease. The process is probably initiated by traces of FXIa in FXI preparations 
and probably requires FXI and an activated FXI species to bind in proximity on the 
polyanion (a template mechanism). The process has been referred to as FXI autoactivation. 
The effect of DS on plasma FXI is shown in Figure 7-5A (open circles). After a lag phase 
in which 1/2-FXIa formation predominates, there is rapid conversion to FXIa (Figure 
7-5B). Bands representing degradation products are observed on SDS-PAGE at later time 
points. It has been proposed that FXI autoactivation may involve an activated subunit in a 
dimer activating the other subunit within the same dimer (Wu et al., 2010). We tested this  
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Figure 7-5. FXI autoactivation. (A) Plasma FXI (120 nM subunits) was incubated with 
1 μg/ml DS (z) or 50 nM poly-P ({). At various times FXIa generation was determined 
by chromogenic substrate assay. (B) Plasma FXI (120 nM subunits) was incubated with 
1 μg/ml DS. Samples were collected into non-reducing sample buffer at the indicated 
time points and size fractionated on 6% polyacrylamide gels, then stained with GelCode 
blue (C) 120 nM subunits of plasma FXI ({) or 1/2-FXIai (z) were incubated with 1 
μg/ml dextran sulfate. At various times FXIa generation was determined chromogenic 
substrate assay. The FXI preparations in this panel were treated with DIP to inactivate 
contaminating FXIa, accounting for the longer lag phase compared to progress curves in 
panel A. (D) FXI-WT ({), FXI-Ser321 (z), FXI-Ser321,Ala284 () or 
FXI-Ser321,Ala290 (U), all 120 nM subunits, were incubated with 1 μg/ml dextran 
sulfate. At various times FXIa generation was determined by chromogenic substrate 
assay. (E) FXI-Ser321,Ala284 (321/284), FXI-Ser321,Ala290 (321/290) or FXIC321S 
(321) 120 nM subunits was incubated with 1 μg/ml dextran sulfate. Samples were 
collected into non-reducing sample buffer at the indicated time points and size 
fractionated on 7.5% polyacrylamide gels, then stained with GelCode blue. (F) FXI-WT 
({),FXI-Ser321,Ala284 () or FXI-Ser321,Ala290 (U), each at a concentration of 120 
nM subunits, was incubated with 50 nM poly-P. At various times FXIa generation was 
determined. For all panels error bars represent one S.D. 
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hypothesis by comparing the effects of DS on activation of FXI and 1/2-FXIai. 
Intra-subunit activation shouldn’t occur in 1/2-FXIai because its single activated subunit is 
irreversibly inhibited. In this study, FXI and 1/2-FXIai were treated with DIP to neutralize 
active subunits on contaminating FXIa. This likely accounts for the longer lag phases than 
those in Figure 7-5A. DS promoted autoactivation of the unactivated subunit of 1/2-FXIai 
in a similar manner to conversion of FXI to FXIa (Figure 7-5C). The amount of FXIa 
activity produced from 1/2-FXIai was half that generated from FXI, consistent with the 
difference in the maximum number of possible activated subunits. These data do not 
support the hypothesis that one activated FXI subunit in a dimer is required to activate the 
other subunit. Also, in contrast to published data suggesting that FXI monomers do not 
undergo autoactivation (Wu et al., 2008), we observed comparable activation rates for FXI 
dimers (FXI-WT and FXI-Ser321) and monomers (FXI-Ser321,Ala284 and 
FXI-Ser321,Ala290) in the presence of DS (Figure 7-5D). The SDS-PAGE gel in Figure 
7-5E shows changes in migration that occurred as zymogen monomer is activated. Note 
that there is no band representing an intermediate because the proteins are monomers. 
While the polyanion DS is not a candidate for a physiologic cofactor for FXI activation, 
polyP is. In the presence of polyP, sigmoidal progress curves for FXIa generation were 
observed that are similar to those with dextran sulfate (Figure 7-5A, black circles). This is 
consistent with a template mechanism in which polyP enhances FXI activation by bringing 
an activating protease and the substrate into proximity, and perhaps by inducing 
conformational changes in the protease and/or substrate. The activation profiles for 
FXI-WT, FXI-Ser321,Ala284 and FXI-Ser321,Ala290 with polyP were comparable (Figure 
7-5F). Furthermore, direct binding studies using SPR confirmed that FXI-Ser321,Ala284 
108 
 
and FXI-Ser321,Ala290 bind to polyP with Kd of 25 to 50 nM (FXI-WT Kd 5–25 nM). 
These results support the conclusion that the capacity to undergo polyanion-induced 
autoactivation is intrinsic to a FXI subunit, and does not require the dimeric conformation.  
Results of our in vitro analysis with polyP support the trans-activation hypothesis for 
FXI activation by FXIIa, but not for activation by thrombin or FXIa. The discrepancy 
between our data and the published work of Wu et al. showing defective monomer 
activation regardless of the activating protease may partly reflect functionally important 
differences between polyP (a linear molecule), and DS (a complex branched polymer of 
sulfated sugar residues). However, this does not completely explain the disparate results. In 
our study, FXI need not be a dimer to undergo autoactivation with DS or polyP. Our data 
indicate that FXI must be a dimer for normal activation by FXIIa in the presence or absence 
of a polyanion, but need not be a dimer for activation by thrombin. This points to different 
activation mechanisms for the two proteases.  
 
Monomeric FXI in Blood Coagulation  
Our in vitro data indicate that the dimeric structure of FXI is important for proper 
activation by FXIIa. We tested this hypothesis in a plasma-based system and in animal 
models. Obviously, as the complexity of the experimental system increases, our ability to 
account for all reactions and interactions involving the molecules of interest decreases (e.g. 
polyP has multiple effects on various coagulation factors and the fibrinolytic system). 
Therefore, we cannot attach direct causality from what is concluded in the purified system 
to the in vivo study. However, a consistency between in vitro and in vivo studies would 
support our predictions for mechanisms of FXI activation. 
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FXI monomers in FXI-dependent plasma coagulation 
The aPTT assay, which uses a non-physiologic trigger such as silica to initiate FXII 
activation, is widely used in clinical practice to test the integrity of the intrinsic pathway of 
coagulation. As Wu et al. observed, the monomeric FXI species FXI-Ser321,Ala284 and 
FXI-Ser321,Ala290 have similar capacity (116% and 117% of the FXI-WT, respectively) to 
reconstitute clot formation when used to supplement FXI-deficient plasma in the aPTT  
(Figure 7-6A). Note that in the aPTT FXI is activated by FXIIa. As discussed above, we 
demonstrated that FXI monomers are activated slowly by FXIIa at low enzyme to substrate 
ratios. The normal activities of the monomers in the aPTT can be attributed to the high 
FXIIa concentration generated in aPTT assay, which would mask the monomer activation 
defect, as indicated by results in Figure 7-4D. If we dilute the silica activator to reduce 
FXIIa generation, we seen longer clotting times in plasma reconstituted with monomers 
compared to dimers (Figure 7-6B). We see similar results if we use polyP to initiate 
clotting in plasma. In addition to enhancing FXI activation, polyP, like silica, promotes 
FXII activation (Müller et al., 2009). PolyP of 70 to 85 phosphate units is a relatively weak 
inducer of FXII activation. Similar to results with diluted PTT reagent, polyP-induced clot 
formation was slower in plasma containing FXI monomers than dimers (Figure 7-6C). 
The effect of polyP on thrombin-mediated FXI activation was tested in plasma 
containing the FXIIa inhibitor corn trypsin inhibitor (CTI). Clotting was induced with 
β-thrombin (Matafonov et al., 2011), a form of thrombin that converts fibrinogen to fibrin 
poorly due to disruption of anion-binding exosite I (Soslau et al., 2004). As this exosite is 
not involved in FXI activation, β-thrombin and α-thrombin activate FXI similarly 
(Matafonov et al., 2011). In the reactions shown in Figure 7-6D, β-thrombin activates FXI 
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bound to polyP, leading to α-thrombin generation from plasma prothrombin and clot 
formation. β-thrombin induced clot formation more rapidly in the presence of FXI-WT 
(~100 seconds) than in its absence (~750 seconds), confirming the system’s FXI 
dependence (Figure 7-6D). FXI monomers and dimers support β-thrombin–initiated 
Figure 7-6. Plasma clotting assays. (A) FXI-WT (WT), FXI-Ser321 (321), 
FXI-Ser321,Ala284 (321/284), or FXI-Ser321,Ala290 (321/290) was added to 
FXI-deficient human plasma anticoagulated with 0.32% sodium citrate to a final 
concentration of 30 nM. –XI indicates vehicle treated control plasma. Plasma containing 
FXI (30 μL) was mixed with an equal volume of PTT reagent, followed by incubation 
for 5 minutes at 37°C. Thirty microliters of 25 mM CaCl2 was added and time to fibrin 
clot formation was determined. Proteins were tested in triplicate. (B-C) FXI-deficient 
plasma-containing vehicle or 30 nM FXI-WT, FXI-Ser321,Ala284, or 
FXI-Ser321,Ala290 supplemented with 60 μM PC–PS vesicles was incubated with (B) 
30 μL 1:256 dilution of PTT-reagent or (C) 30 μL poly-P (final concentration 50 nM). 
Mixtures were incubated for 1 minute at 37°C before addition of CaCl2 and measuring 
time to clot formation, as above. (D) FXI-deficient plasma containing 8 μM corn trypsin 
inhibitor (to inhibit FXIIa), 60 μM PC–PS vesicles, and 200 nM poly-P (final 
concentration 50 nM) was mixed with an equal volume of 30 nM FXI-WT, 
FXI-Ser321,Ala284, or FXI-Ser321,Ala290. β-thrombin was added to a final 
concentration of 1.5 nM, followed by incubation for 1 minute at 37°C. CaCl2 was added 
and the time to clot formation was measured. For all panels, error bars represent 1 SD. 
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clotting similarly (Figure 7-6D), consistent with data in Figure 7-4G and in support of the 
hypothesis that FXI need not be a dimer for activation by thrombin in plasma in the 
presence of polyP.   
FXI Monomers in a Model of Arterial Thrombosis 
FXI deficient (FXI-/-) mice are relatively resistant to injury-induced arterial 
thrombosis (Cheng et al., 2010; Wang et al., 2005), and infusion of human plasma-derived 
FXI into these animals restores the wild type phenotype in thrombosis models (Wang et al., 
2005). Several lines of evidence suggest that FXI is activated by FXIIa during these 
experimentally-induced thromboses in mice (Wang et al., 2005; Cheng et al., 2010). 
Physiologic counterparts to the non-biologic polyanions used in vitro have been proposed 
to be involved in the thrombotic process. In particular, polyP released from platelets 
appears to play a role (Müller et al., 2009), possibly by activating FXII, and enhancing FXI 
activation. As the in vitro studies described above indicate that the dimeric structure of FXI 
is involved in activation by FXIIa, we postulated that FXI monomers would not 
reconstitute FXI-/- mice as well as dimeric FXI in a model of carotid artery thrombosis 
induced by application of concentrated ferric chloride to the exterior of the vessel (Wang 
et al., 2005; Cheng et al., 2010).  
Recombinant FXI-WT expressed in HEK293 cells has a very short plasma half-life 
(<20 minutes) compared to human plasma FXI (> 3 hours) after infusion into mice, likely 
as a consequence of differences in glycosylation or other post-translational modifications. 
This makes it difficult to establish a stable plasma concentration of protein during the 
45-minute time frame of the carotid artery thrombosis model. Instead, we transiently 
expressed human FXI-WT, FXI-Ser321,Ala284, and FXI-Ser321,Ala290 in FXI-/- 
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Figure 7-7. FeCl3-induced carotid artery occlusion in FXI-deficient mice 
expressing human FXI. (A) FXI-/- mice underwent HTI with human FXI-WT cDNA 
in expression vector pJVCMV. Shown are concentrations of human FXI in mouse 
plasma at various times post-HTI. (B) Concentrations of FXI levels in plasma from 
FXI-/- mice 24 hours post-HTI with constructs for human FXI-WT (WT), 
FXI-Ser321,Ala284 (321/284), or FXI-Ser321,Ala290 (321/290). Normal human 
plasma is shown for comparison. For panels A and B, error bars represent 1 standard 
deviation. (C) Western blot of mouse plasmas 24 hours post-HTI with constructs for 
human FXI-WT, FXI-Ser321,Ala284, or empty vector control (pJV). A sample of pure 
human FXI (XI) and a sample of FXI-deficient mouse plasma (XIdp) are shown for 
comparison. Positions of molecular mass standard (kDa) are shown at the left of the blot. 
Positions for FXI dimer (D) and monomer (M) are indicated on the right. (D) Groups of 
10 FXI-/- mice underwent HTI with constructs for FXI-WT, FXI-Ser321,Ala284, 
FXI-Ser321,Ala290, or empty vector control (pJV). Twenty-four hours later, the 
animals were tested in a carotid artery thrombosis model in which thrombus formation is 
induced by exposing the vessel to 3.5% FeCl3. Each bar indicates the percent of mice in 
each group with occluded arteries 30 minutes after applying FeCl3. Plasma FXI levels of 
the mice in this study are shown in panel B. 
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mice using the technique of hydrodynamic tail-vein injection (HTI) (Liu et al., 1999; 
Zhang et al., 1999; Sebesty´en et al., 2006). Here, the cDNA constructs used to express 
protein in HEK293 cells are rapidly infused into the tail vein of the mouse in a large 
volume of fluid (2 mL of lactated Ringer solution). The process results in swelling of the 
liver, and a transient transfection of hepatocytes (among other tissues) with the construct. 
Infusion of 15 μg FXI-WT construct into FXI-/- mice reproducibly results in expression of 
human FXI-WT reaching a peak 12-24 hours post DNA infusion (Figure 7-7A), with 
plasma concentrations comparable to the FXI level in normal human plasma (15-45 nM, 
avg. 30 nM; Figure 7-7B). Larger amounts of DNA did not result in a further increase in 
plasma levels, indicating a maximum expression level was reached with 15 μg of 
construct. Using this technique, peak plasma concentrations of FXI-Ser321,Ala284 and 
FXI-Ser321,Ala290 were achieved that were similar to those for FXI-WT (Figure 7-7B), 
consistent with the conclusion that the dimeric structure is not required for protein 
secretion (Wu et al., 2008). Western blots of mouse plasma 24 hours post-infusion 
confirmed the presence of human FXI species of appropriate size (Figure 7-7C). The 
aPTTs of plasmas from mice expressing FXI-WT, FXI-Ser321,Ala284, and 
FXI-Ser321,Ala290 (25–33 seconds) were similar to those of plasma from wild-type mice, 
and shorter than plasma from untreated FXI-/- mouse (>45 seconds). 
Wild type C57Bl/6 mice consistently develop occlusive platelet-rich thrombi in the 
carotid arteries after the vessel is exposed to a 3.5% solution of FeCl3, while FXI-/- mice do 
not form occlusive thrombi at this concentration. All FXI-/- mice expressing FXI-WT 
developed occlusion within 15 minutes of FeCl3 exposure, consistent with experiments 
using infusions of human plasma FXI (Wang et al., 2005). Mice treated with pJVCMV 
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control (no FXI cDNA) remained resistant to thrombus formation (Figure 7-7D). 
Interestingly, arteries of 70% of FXI-/- mice expressing FXI-Ser321,Ala284 and 100% 
expressing FXI-Ser321,Ala290 remained patent (Figure 7-7D). These results demonstrate 
that FXI monomers can be synthesized and circulate in vivo. However, dimeric FXI, but 
not monomeric FXI, reconstitutes the wild-type phenotype in FXI-/- mice in a 
FXIIa-dependent thrombosis model, suggesting that the dimeric structure of FXI plays a 
role in FXIIa-dependent thrombosis.  
The reason for the different capacities of FXI-Ser321,Ala284 and FXI-Ser321,Ala290 to 
support arterial thrombus formation after vessel injury with FeCl3 (Figure 7-7D) may 
reflect subtle differences between the 2 proteins that are not obvious in in vitro assays. It is 
not surprising that a monomer would exhibit some activity in the thrombosis model, as the 
defect in FXIIa-mediated activation observed in vitro, while significant, is not total. 
Interestingly, FXI-/- mice expressed FXI dimers and monomers comparably. In the past, it 
was suspected that intracellular processing and secretion of FXI required dimerization. 
Meijers et al. noted that the FXI A4 domain mutation Phe283Leu found in patients with 
FXI deficiency causes a partial defect in dimerization, with monomers retained within the 
transfected cells (Meijers et al., 1992). Similar results were reported for the A4 mutation 
Glu350Gly (FXI Nagoya III), which causes a severe dimerization defect (Kravtsov et al., 
2004). However, most missense mutations causing FXI deficiency result in poor protein 
secretion, regardless of the effect on dimer formation. Subsequent work with mutations 
targeting the FXI dimer interface, and the data presented here show that dimerization is not 
a prerequisite for protein secretion.  
This study suggests that the dimeric structure of FXI is important for protease activity 
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in vivo, at least under the conditions of the model. Based on this, it is tempting to postulate 
that FXI dimerization is an adaptation to enhance zymogen activation. However, there are 
reasonable objections to this proposal. In vitro, FXI monomers were defective only when 
FXIIa was the activating protease. Given the absence of hemostatic abnormalities 
associated with FXII deficiency, there is no compelling evidence indicating FXI activation 
by FXIIa is required for hemostasis. Thrombin may be the more important FXI activator 
during hemostasis (Furie and Furie, 2009; Spronk et al., 2009), while FXIIa may contribute 
to pathologic coagulation through FXI activation. PK is a monomer with a domain 
structure identical to that of FXI, and PK is efficiently activated by FXIIa in vitro (Gailani 
et al., 2010). Reducing FXII expression in mice with antisense oligonucleotides results in 
decreased PK activation, indicating FXIIa activates PK in vivo (Revenko et al., 2011). 
Cumulatively, these observations raise the possibility that aspects of protease function 
unrelated to zymogen activation drove the evolution of the FXI dimer. There is evidence 
that FXI needs to be dimeric to function properly in the presence of platelets. FXI may bind 
to a platelet through one subunit, while binding to its substrate factor IX through the other 
(Gailani et al., 2001). In this scenario, the dimer may be an adaptation to facilitate proper 
protease localization and function in flowing blood.  
 
Summary 
During activation, FXI is initially converted to a species with one active subunit 
(1/2-FXIa). For both FXIIa and thrombin, the rate of conversion of FXI to 1/2-FXIa is 3-4 
fold faster than conversion of 1/2-FXIa to XIa, indicating that 1/2-FXIa accumulates 
during coagulation and may be an important species. PolyP released from platelets can 
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enhance FXI activation. FXI monomers were activated more slowly than dimers by FXIIa 
in the presence of polyP. However, this defect was not observed when thrombin was the 
activating protease, nor during FXI autoactivation, suggesting that FXIIa and thrombin 
activate FXI by different mechanisms. Consistent with this, monomeric FXIs were 
defective in reconstituting FXII-initiated clot formation, while functioned normally in 
thrombin-initiated clot formation. Transient expression of human FXI in FXI-/- mice 
restores the wild type phenotype in a ferric chloride-induced carotid artery thrombosis 
model, but monomeric variants are defective in this model. These results indicate that the 
dimeric structure of FXI is required for proper activation by FXIIa, but not by thrombin or 
FXIa. This may contribute to a protective effect for thrombus formation in vivo. 
 
Methods 
Recombinant FXI. Recombinant FXI-WT, FXI with serine replacing Cys321 (FXI-Ser321), 
or FXI-Ser321 with alanine replacing Leu284 or Ile290 (FXI-Ser321,Ala284, 
FXI-Ser321,Ala290) were expressed in HEK293 cells as described (Wu et al., 2008). FXI 
was treated with 500 μM diisopropylfluorophosphate (DIP) to inhibit traces of FXIa, then 
dialysis into TBS. FXI (20 μg) was passed over a Superose-12 column equilibrated with 50 
mM sodium phosphate, pH 7.4, 150mM NaCl (Cheng et al., 2003). Retention volumes 
were compared with protein standards and with plasma FXI and PK. FXI binding to 
immobilized polyP was determined by SPR, as described in the published paper (Choi et 
al., 2011). 
Polyphosphate. Sodium phosphate glass from Sigma-Aldrich. PolyP (75 to 100 phosphate 
units) was prepared by gel electrophoresis, as described (Smith et al., 2010), except that a 
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model 491 Prep cell (Biorad) was used for continuous elution electrophoresis. PolyP 
concentrations are given based on an average polymer of 80 phosphate units.  
Plasma FXI and FXIa Species with one Active Site. FXI purified from human plasma (HP; 
600 nM) was incubated with thrombin (900 nM) for 6 hours at 37°C. Reactions were 
terminated with 20 μM hirudin, applied onto a SBTI-agarose column, and eluted with TBS 
containing 200 mM benzamidine, 1 mM EDTA. Eluate contained 1/2-FXIa (Smith et al., 
2008). 1/2-FXIa (500 nM) in TBS was incubated with 500 μM DIP, irreversibly inhibiting 
the active site(s) of 1/2-FXIa and contaminating FXIa (confirmed by chromogenic 
substrate assay). The inhibited preparation is referred to as 1/2-FXIai. 
FXI Activation. FXI (200 nM subunits [100 nM dimer]) was incubated with FXIIa (5 to 
100 nM) or α-thrombin (50 nM) in 30 mM HEPES pH 7.4, and 50 mM NaCl with 0.1% 
BSA (HBSA) at 37°C. For FXI (120 nM subunits) activation in the presence of polyP (50 
nM), 3 nM FXIIa, or α-thrombin was used. At various times, 1.5 μM corn trypsin inhibitor 
(FXIIa) or hirudin (α-thrombin) was added to aliquots to terminate activation, mixed with 
an equal volume of 1 mΜ S-2366. pNA generation was monitored at 405 nm, and 
activation rates were determined by linear regression of time dependences of FXIa active 
site generation. Second order rate constants kcat/Km (M-1s-1) were obtained by dividing 
initial rates (v0) by protease and substrate concentrations and by measuring initial slopes of 
FXIIa or FXI concentration dependences of v0. FXI-WT activation by FXIIa (5 to 100 nM) 
was modeled by numerical integration using KinTek Explorer version 2.5 software 
(Johnson et al., 2009). For FXI-WT activation by thrombin in the presence of polyP, a FXI 
concentration dependence (30–480 nM subunits) was established to define the extent of 
saturation. 
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FXI autoactivation was induced by incubating FXI (120 nM subunits) with DS (1 
μg/mL, 500,000 Da) or polyP (50 nM) in HBSA at 37°C. At various times, 18 μL samples 
were mixed with an equal volume of 1 mM S-2366, 4 μg/mL polybrene. Conversion of FXI 
to FXIa was followed by monitoring at a wavelength of 405 nm. FXI activation was also 
analyzed by SDS-PAGE. FXI (120 nM subunits) in HBS containing 1 mg/mL PEG 8000 
was incubated at 37°C with 1 μg/mL DS. At various times, aliquots were removed and 
placed into nonreducing sample buffer, size-fractionated on 7.5% polyacrylamide-SDS 
gels, and stained with GelCode Blue (Pierce). Gels were imaged with an Odyssey infrared 
imaging system. 
FXI Activity in Plasma. FXI-deficient plasma (30 μL, George King) was mixed with 30 
μL FXI (0.3–30 nM) in TBSA. Contact activation was initiated with 30 μL PTT-A reagent 
(Diagnostica Stago, undiluted, or diluted 1:256 in TBSA with 60 μM 
phosphatidylcholine–phosphatidylserine [PC–PS] vesicles) or 200 nM polyP (with 60 μM 
PC–PS). After incubation at 37°C (5 min for PTT reagent, 1 min for 1:256 PTT reagent or 
polyP), 30 μL of 25 mM calcium chloride (CaCl2) was added, and time to clot formation 
was determined on an ST4 fibrometer (Diagnostica Stago). In separate experiments, 30 μL 
FXI (5 μg/mL) in TBSA was mixed with equal volumes of FXI-deficient plasma 
containing 8 μM corn trypsin inhibitor, 60 μM PC–PS, and 200 nM polyP. β-thrombin (1.5 
nM) was added and incubated for 1 min at 37°C. Clotting was initiated with 30 μL of 25 
mM CaCl2.  
Expression of FXI in Mice by Hydrodynamic Tail-Vein Injection. The C57Bl/6 
FXI–deficient (FXI-/-) mice (24–27 g) were anesthetized with 50 mg/kg intraperitoneal 
pentobarbital. pJVCMV/FXI constructs (15 μg) in 2 mL lactated Ringer’s solution were 
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infused over 20 sec into the tail vein. Plasma was prepared from 25 μL blood samples 
collected at various times post hydrodynamic tail-vein injection (HTI), and FXI 
concentration was determined by enzyme-linked immunosorbent assay (ELISA). Western 
blots of plasma FXI (1 μL per lane) were prepared using anti-FXI IgG 14E11 (Cheng et al., 
2010).  
Carotid Artery Thrombosis Model. The FXI-/- mice underwent HTI with pJVCMV/FXI 
constructs. Twenty four hours post-HTI, mice were anesthetized, and the right common 
carotid artery was fitted with a Doppler flow probe (model 0.5 VB; Transonic System). 
Thrombus formation was induced by applying 3.5% ferric chloride (FeCl3) to the artery, as 
described (Wang et al., 2005; Cheng et al., 2010) Flow was monitored for 30 minutes. 
After the experiment, blood was collected and plasma FXI concentration was determined 
by ELISA. 
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CHAPTER VIII 
 
EXPRESSION OF FACTOR XI HETERODIMERS: A NOVEL APPROACH TO 
INVESTIGATING THE DIMERIC STRUCTURE 
 
The preliminary work presented in this chapter will serve as the basis for future 
investigation into the functional significance of FXI’s unique dimeric structure in flowing 
blood. FXI(a) is thought to bind to platelet receptors through the A2 and A3 domains. This 
interaction may be essential for keeping FXI localized to an injury site in flowing blood. 
Interestingly, binding sites for FIX and the platelet receptor GP Ibα are in proximity to each 
other on the A3 domain of FXI (Sun et al., 1999; Baglia et al., 1995), suggesting that a 
FXIa subunit could not bind to its substrate and the platelet surface simultaneously. We 
postulate that the dimeric structure may offer a solution to this conundrum. FXI could bind 
to the platelet through one subunit, while interacting with the substrate FIX through the 
other (Figure 8-1).  
As discussed in the previous chapter, monomeric FXI is activated poorly by low 
concentrations of FXIIa, which may make interpretations of results in complex systems 
difficult. It has been observed that patients with a single allele coding for a non-secretable 
FXI variant can have a bleeding disorder inherited in a dominant manner because the 
product of this allele can form a heterodimer with normal FXI subunits, trapping them 
within cells (Kravtsov et al., 2004). This inspired us to develop a new strategy to produce 
recombinant FXI carrying different mutations on each subunit (FXI heterodimers). 
Recombinant FXI heterodimers will be used in the future to test the hypothesis that one 
FXIa subunit binds to a surface while the other binds to FIX in flowing blood. 
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Generation of a Factor XI Heterodimer with an Unactivatable Subunit 
Purification of FXI heterodimers with different mutations on each subunit requires 
labeling one or each subunit with protein tags that enables the selection of heterodimeric 
FXI by sequential chromatography steps. As described in Chapter II, FXI has a relatively 
compact structure, and placing tags in FXI has a high chance of affecting apple domain 
folding, leading to abnormal structure and poor secretion. We chose a polyhistidine 
(polyHis) tag because of its relatively small size and charge. The polyHis tag can bind to 
metal ions such as Co2+ or Ni2+ immobilized on a matrix. The efficiency of this 
purification system is dependent on the length of the tag as well as the availability of the 
Figure 8-1 Postulated model of factor XI activity on the platelet surface. The FXI 
dimer binds to platelet GPIb and ApoER2 complex through A3 and A2, and becomes 
activated on the platelet surface. FXIa may then bind to FIX, possibly through the A3 
domain that is not involved in binding to platelets, and converts FIX to FIXaβ.  
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tag on the protein surface. Usually a minimum of six histidine residues is required for 
optimal purification. 
 
 
Figure 8-2. Preparation of FXI heterodimer. (A) Topology diagram showing FXI 
zymogen structure. Residues 367-372 that were changed to histidine are labeled in red 
(where the arrow points to). Note that this region is solvant-exposed and relatively 
flexible. (B) FXI-WT and FXI- FXI-His367-372 (both 300nM) were activated by FXIIa 
(30nM). Aliquots were taken from the reaction mix at indicated times into reducing 
sample buffer, fractionated on 12% polyacrylamide-SDS gels, and analyzed by western 
blotting. (C) Schematic of the strategy for expression of FXI heterodimers. 293-6E cells 
were transfected with FXI-WT (WT, black line) and FXI- FXI-His367-372 (grey line 
with star, star stands for the His-tag). Theoretically the cell will express FXI-WT, 
heterodimer, and homodimeric FXI-His367-372 in a 1:2:1 ratio. (D) Conditioned 
medium containing FXI-WT homodimers, FXI His 367-372 homodimers and the 
heterodimers (lane 1) were activated by FXIIa overnight, and visualized by western 
blotting (lane 2). As a control, recombinant FXIa-WT expressed in conditioned medium 
under same conditions was also activated and shown on the blot (lane 3 and 4). Positions 
for standards for FXI zymogen, FXIa and the half activated heterodimer are shown to 
the right of the blot.  
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In the FXI crystal structure, the activation loop connecting the heavy chain and 
catalytic domain appears to have a relatively loose structure that is separate from the tightly 
packed apple domains and the catalytic domain (Figure 8-2A). This flexible loop is solvent 
exposed, and forms fewer interactions with other parts of the protein. A tag placed in this 
loop could be used to remove the activation cleavage site (Arg369-Ile370) rendering the 
subunit not activatable. We replaced FXI residues 367-372 on FXI with histidine to create 
the protein FXI-His367-372. Since zymogen FXI will not bind to FIX, A FXI heterodimer 
with one subunit fixed in the zymogen state will be a useful tool to investigate the 
importance of dimeric structure in protease function.  
FXI-His367-372 homodimer (two unactivatable subunits in each FXI molecule) was 
expressed in HEK293 fibroblasts. The protein was expressed at a comparable level, and 
migrated at the same position on SDS-PAGE, as FXI-WT, indicating that the histine 
substitution did not disrupt overall protein conformation. As we predicted, reducing 
western blots of time courses of FXI-His367-372 activation by FXIIa revealed dramatically 
impaired activation compared to FXI-WT (Figure 8-2B).  
The FXI heterodimer with one wild type subunit and one subunit containing the His-tag 
at the activation loop was generated by co-expressing FXI-WT and FXI-His367-372 cDNA 
in HEK293 cells. Most of the recombinant proteins in our lab are produced by cells stably 
transfected with vectors containing FXI cDNA, using resistance to a drug as a selection 
strategy. However, attempts to stably co-transfect HEK293 cells with equal amounts of 
vectors encoding two selection markers, or to transfect the cell line already stably 
expressing FXI-WT with FXI-His367-372 cDNA, resulted in clones primarily expressing 
only one FXI variant. Based on the study by Kravtsov et al., we decided to cotransfect 
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293-6E cells (293 cells growing in suspension to ensure high throughput protein 
production) with equal amounts of vectors containing a cDNA for FXI-WT or 
FXI-His367-372 (Kravtsov et al., 2004). Hypothetically, wild type and mutant FXI 
polypeptides should be synthesized in equal amounts. Therefore, wild type homodimer 
(both subunits can be activated), heterodimer (only the wild type subunit can be activated) 
and mutant homodimer (both subunits cannot be activated) should be produced and 
secreted into medium in a 1:2:1 ratio (Figure 8-2C). When conditioned medium containing 
a mixture of heterodimers and homodimers is fully activated by FXIIa, FXI-WT 
homodimer will be converted to FXIa, the heterodimer will be converted to ½-FXIa, and 
mutant homodimer will remain in the zymogen form. This was confirmed by western 
blotting on non-reducing PAGE in Figure 8-2D.  
 
Labeling the C-terminus of Factor XI with a Polyhistidine-tag 
Purification of FXI heterodimers with different mutations on each subunit requires 
labeling one or each subunit with different protein tags, enabling the selection of 
heterodimers by sequential chromatography steps. Labeling the activation loop results in 
an unactivatable FXI subunit. A different strategy is required for tagging a FXI subunit 
without interfering with FXI function. In the FXI crystal structure the C-terminus of the 
protein is a relatively flexible region that is surface exposed.  
A FXI variant with six histidine residues added onto the C-terminus (FXI-HisCT) was 
expressed in 293-6E cells (HEK293 cells growing in suspension). FXI-HisCT was present 
in conditioned medium at a concentration of ~2 μg/mL. This is similar to the expression 
level of FXI-WT. On non-reducing SDS-PAGE, FXI-HisCT and FXI-WT migrate as 160 
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kDa proteins (Figure 8-3A).  After complete activation, both proteases appear as a pair of 
45 kDa and 35 kDa bands on reducing SDS-PAGE (Figure 8-3A). Attempts to put a 
His-tag at N-terminus of FXI resulted in low protein levels in the conditioned medium, and 
this strategy was not pursued further. 
The protein with a C-terminal His-tag was added to FXI-deficient plasma and tested in 
an aPTT assay. FXI-HisCT had comparable activity to FXI-WT (clotting time 33.4 ± 0.85s 
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Figure 8-3. Characterization of FXI-HisCT. (A) Left: non-reducing SDS-PAGE of 
recombinant FXI-WT (WT) and FXI-HisCT (His) stained with GelCode blue. Right 
panel: reducing SDS-PAGE of the zymogen (FXI) and protease (FXIa) forms of the 
proteins in the left panel. The positions of FXI zymogen (XI) and the heavy chain 
(XIa-HC) and catalytic domain (XIa-CD) of FXIa are shown to the right of the panel. 
The positions of molecular mass standards for both gels are indicated on the left in 
kilodaltons.(B) 300 nM FXI-WT ({) and FXI-HisCT (z) were activated by 30 nM 
FXIIa, FXIa activity was determined by cleavage of S-2366. (C and D) FIX (100 nM) 
was activated by FXIa-WT ({) and FXI-HisCT (z) (2 nM active site). FIX and 
FIXaβ in the reaction mix were measured by the infrared intensity of corresponding 
bands on SDS-PAGE. 
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for FXI-WT, 34 ± 0.3s for FXI-HisCT). FXI-HisCT and FXI-WT were activated by FXIIa 
similarly (Figure 8-3B), and the activated proteases had similar capacities to cleave the 
tripeptide chromogenic substrate S-2366 (data not shown). In addition, FXIa-CTHis and 
FXIa-WT activated FIX with similar reaction rates and cleavage patterns (Figure 8-3 C and 
D). These findings indicate that attaching a small tag to the C-terminus of FXI can be done 
without compromising protease function. We are testing other small peptide tags (like 
FLAG and c-myc) in the same position.  
The data discussed in this chapter provide a foundation for future development of a 
useful strategy for testing the dimeric structure of FXI. To test the hypothesis that FXI 
needs to be a dimer to simultaneously interact with the substrate FIX and platelets, FXI 
heterodimer with a wild type subunit and a subunit that lacks the capacity to bind to both 
FIX and a platelet will be expressed. We anticipate that such a heterodimer would fail to 
function in a FXI-dependent flow system if the dimer is required for simultaneous binding 
to platelets and FIX. The heterodimer should, however, function normally in a static 
plasma clotting assays such as the aPTT because the single wild type subunit would be 
sufficient to perform the required functions of the protein. A variety of FXI heterodimers 
with defects in various funcrtions can be created to facilitate investigation of the role of the 
FXI dimer in interactions with blood and blood vessel components.  
 
Summary 
While the results in Chapter VII indicate that the FXI dimeric structure is required for 
proper zymogen activation in some situations, the possibility that the dimer is an 
adaptation for binding to a surface and substrate simultaneously is an alternative 
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explanation that needs to be persued. We developed a strategy to express FXI heterodimers 
with different mutations on each subunit. Attaching a small tag to the C-terminus of FXI 
allows purification of heterodimers from homodimers. Utilizing this strategy, we will 
evaluate the importance of FXI’s dimeric structure to thrombus formation in flowing blood 
in the future. 
 
Methods 
His-tag Fused FXI cDNA. Mutations to introduce a His-tag consisting of six histidine 
substitutions for FXI residues 367-372 (FXI-His367-372) were introduced into the 
wild-type FXI in pJVCMV. In addition, six His residues were added to the C-terminus of 
FXI (FXI-HisCT).  
Expression of FXI in Suspension. 293-6E human embryonic kidney cells were 
transfected with 19 μg FXI-HisCT, FXI-WT or FXI-His367-372 in pJVCMV, together with 
1 μg pEGFP vector. In the co-transfection assay, 293-6E cells were transfected with 9.5 μg 
FXI-His367-372 and 9.5 μg FXI-WT, together with 1 μg pEGFP vector. Transfection 
complexes were generated by incubating vectors with 40 μg polyethyleneiminie (PEI) in 2 
mL F17 medium for 10 minutes at room temperature. Cells were directly dispensed in 125 
mL flasks at 1 × 106 cells/mL before transfection. Flasks were shaken constantly at 37°C 
in a 5% CO2 incubator. Twenty-four hours following transfection the cells received a 
peptone feed of 0.5% TN-1. Cells were sampled for growth rate, viability and GFP 
expression daily. 120 hours after transfection, conditioned media was collected by 
centrifugation at 1500 g for 5 minutes, and stored at -20°C pending purification. 
Purification of FXI-HisCT by Co2+-Charged Affinity Resin. The conditioned medium 
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was passed over a 1 mL Co2+-charged affinity resin column. After loading, the column 
was washed with 10 volumes of 50mM sodium phosphate (pH7.4), 100 mM NaCl, 5 mM 
Benzamidine (washing buffer), followed by elution with 150 mM Imidazole in washing 
buffer. Protein-containing fractions were pooled and concentrated in an ultra-filtration 
concentrator (Amicon, Inc, Beverly, MA), dialyzed against TBS, and stored at -80°C. 
Proteins were analyzed by SDS-polyacrylamide gel electrophoresis for purity, and protein 
concentration was measured by dye binding assay (Bio-rad). Activation of FXI by FXIIa, 
activation of plasma derived FIX by FXIa, and the coagulant activity of FXI in aPTT assay 
were performed as described in previous chapters. 
 
References 
Baglia, F., Jameson, B., Walsh, P. (1995) Identification and characterization of a binding 
site for platelets in the apple 3 domain of coagulation factor XI. J Biol Chem 270, 
6734-6740.  
 
Kravtsov, D.V., Wu, W., Meijers, J.C., Sun, M.F., Blinder, M.A., Dang, T.P., Wang, H., 
Gailani, D. (2004) Dominant factor XI deficiency caused by mutations in the factor XI 
catalytic domain. Blood 104, 128-134. 
 
Rapaport, S., Proctor, R., Patch, M., Yettra, M. (1961) The mode of inheritance of PTA 
deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. 
Blood 18, 149-165. 
 
Sun, M.F., Zhao, M., Gailani, D. (1999) Identification of amino acids in the factor XI apple 
3 domain required for activation of factor IX. J Biol Chem 274, 36373-8. 
 
 
 
 
 
131 
 
CHAPTER IX 
 
FACTOR XI ANION-BINDING SITES ARE REQUIRED FOR PRODUCTIVE 
INTERACTIONS WITH POLYPHOSPHATE 
 
The rates for FXI activation by FXIIa or thrombin are relatively low in solution, 
suggesting that a cofactor is required to enhance the rate of activation in vivo. Choi and 
coworkers demonstrated that polyP released from platelet dense granules enhance FXI 
activation by thrombin, and promote FXI activation by FXIa, through a mechanism 
requiring both activating protease and substrate to bind to polyP (Choi et al., 2011). This is 
consistent with an observation made 40 years ago that activated platelets support FXI 
activation (Walsh, 1972). We subsequently showed that polyP enhances FXI activation by 
α-thrombin and FXIIa by ~3000 and ~30-fold respectively (in Chapter VII), further 
supporting the hypothesis that polyP is a physiologic enhancer of FXI activation.   
PolyP in human platelets contain 60-100 phosphate groups, and have a number of 
procoagulant and pro-inflammatory properties (Müller et al., 2009). Previous work 
indicates that a minimum polyP chain length is required to support FXI activation, 
consistent with the notion that a single polyP chain must be long enough to allow FXI and 
an activating protease to bind to it (Choi et al., 2011). PolyP is highly negatively-charged, 
suggesting that it may interact with FXI through electrostatic interactions. Electrostatic 
interactations are also involved in FXI and FXIa binding to heparin (Zhao et al., 1998; 
Yang et al., 2009). Heparin enhances the inhibition of several coagulation proteases by the 
serpin antithrombin (AT) through allosteric and ternary (template) mechanisms (Tollefsen 
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and Zhang, 2013). The latter typically involve binding of the catalytic domain to heparin 
through electrostatic interactions involving a specific anion binding site (ABS) comprised 
of lysine and arginine residues (Vadivel et al., 2012).  The heparin binding site on 
α-thrombin is referred to as anion binding exosite II (ABE II), and is comprised of Arg89, 
Arg98, Arg245, Lys248 and Lys252 (chymotrypsin numbering) (Sheehan and Sadler, 1994). 
The same site is involved in α-thrombin binding to polyP (Mutch et al., 2010). In FXIa 
there is an ABS on the catalytic domain 170-loop containing residues Lys529, Arg530 and 
Arg532 (Figure 2-6) (Yang et al., 2009). In addition, FXIa has a novel ABS on its A3 
domain (Arg250, Lys252, Lys253 and Lys255) (Figure 2-6) (Zhao et al., 1998). Both ABSs 
bind heparin, and both are required for full expression of heparin cofactor activity during 
AT inhibition of FXIa. The FXI homolog PK contains basic residues in the catalytic 
domain 170-loop in the same locations as in FXI (McMullen et al., 1991), and heparin 
enhances AT inhibition of activated PK (α-kallikrein) (Venneröd and Laake, 1975). 
However, PK lacks the ABS on the A3 domain found in FXI, suggesting this feature 
supports specific FXI functions. In this chapter, experiments evaluating the importance of 
the FXI ABSs to the interaction with polyP are presented.  
 
Activation of Factor XI in the Presence of Polyanions 
We expressed and purified recombinant FXI-WT, FXI with alanine replacing Arg250, 
Lys252, Lys253 and Lys255 (FXI-ABS1), FXI with alanine replacing Lys529, Arg530 and 
Arg532 (FXI-ABS2), or FXI with both sets of substitutions (FXI-ABS1/2) HEK293 cells. 
The proteins all migrate at the appropriate 160 (unreduced) and 80 (reduced) kDa positions 
on SDS-PAGE (Figure 9-1). After conversion to FXIa, the proteases cleave the substrate 
S-2366 with similar Km and kcat (not shown). 
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Factor XI Autoactivation 
Dextran sulfate (DS), heparin and polyP induce FXI activation through a mechanism 
requiring FXI binding to the polyanion (Gailani and Broze, 1991; Choi et al., 2011). As 
discussed in Chapter VII, a sigmoidal progress curve is observed during FXI activation 
induced by these polyanions (Figure 9-2). We suspect activation is initiated by traces of 
FXIa in the FXI preparations. Treating the preparations with DFP to inhibit contaminating 
FXIa can prolong the lag phase in the activation curve, but does not prevent activation. 
 
 
 
Figure 9-1. Recombinant FXI ABS mutants. Purified FXI-WT, FXI-ABS1 (-1), 
FXI-ABS2 (-2) and FXI-ABS1/2 (-1/2) run under non-reducing (left) and reducing 
(right) conditions on a 10% polyacrylamide-SDS gel. Positions of molecular mass 
standards in kilodaltons are on the left. 
Figure 9-2. FXI activation in the presence of heparin or polyP. FXI-WT ({), 
FXI-ABS1 (U), FXI-ABS2 (z) or FXI-ABS1/2 (▲) incubated with (A) 400 nM 
heparin or (B) 50 nM polyP. FXIa generation was determined by chromogenic assay.  
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However, DFP-treated FXI preparations still cleave S-2366 at a low but detectable rate 
suggesting persistent FXIa contamination in the picomolar range for a solution of 100 nM 
FXI zymogen. In the presence of heparin, FXI-WT and FXI-ABS2 were activated 
similarly, while FXI-ABS1 and FXI-ABS1/2 demonstrated significant activation defects 
(Figure 9-2A). Comparable results were obtained with dextran sulfate (data not shown), 
indicating that the A3 domain ABS, but not the catalytic domain ABS, is required to 
support autoactivation induced by these polyanions. In reactions with polyP, in contrast, 
both FXI-ABS1 and FXI-ABS2 demonstrated longer lag phases than FXI-WT, while 
ABS-1/2 failed to activate (Figure 9-2B). This indicates that polyP must interact with both 
ABSs to promote optimal activation, and suggests that the autoactivation reactions differ in 
some way from those supported by heparin or DS. 
  
Figure 9-3. FXI activation by α-thrombin or FXIIa. (A and B) FXI-WT ({), 
FXI-ABS1 (U), FXI-ABS2 (z) or FXI-ABS1/2 (▲), 200 nM subunits, incubated with 
(A) 50 nM α-thrombin or (B) 5 nM FXIIa. (C and D) Activation of 120 nM subunit of 
FXI (symbols same as in panels A and B) by 3 nM (C) α-thrombin or (D) FXIIa in the 
presence of 50 nM polyP. FXIa generation was determined by chromogenic assay. 
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Factor XI Activation by Thrombin and FXIIa 
Work presented in Chapter VII shows that FXI activation by thrombin and FXIIa is 
enhanced by polyP. To test the importance of the FXI ABSs in this process, we compared 
activation rates for FXI-WT and the FXI ABS mutants by thrombin and FXIIa. In the 
absence of polyP, second order rate constants for FXI-WT activation by α-thrombin 
(Figure 9-3A, 240 M-1 sec-1) or FXIIa (Figure 9-3B, 16,600 M-1 sec-1) were roughly 
comparable to those for FXI ABS mutants (Table 9-1). PolyP enhanced FXI-WT activation 
by α-thrombin ~3000-fold (Figure 9-3C, 713,000 M-1 sec-1) and by FXIIa ~30-fold 
(Figure 9-3D, 543,000 M-1 sec-1). Rates were moderately reduced for FXI-ABS1 
activation by α-thrombin (34%)  and FXIIa (42%). There were greater reductions for 
FXI-ABS2 (5-fold for α-thrombin, 3-fold for FXIIa). With FXI-ABS1/2, rate constants 
were ~20- and ~7-fold lower, respectively, demonstrating the importance of both FXI 
ABSs to polyP enhancement of FXI activation by these proteases. 
 
Table 9-1. The effect of polyP on rates of FXI activation by thrombin and FXIIa.  
Shown are second order rate constants derived from curves in figure 9-3 for activation of 
FXI by α-thrombin or FXIIa in the absence or presence of 50 nM polyP. 
 
 
 α-Thrombin FXIIa 
Protein No PolyP With PolyP Fold-Increase No PolyP 
With 
PolyP Fold-Increase
FXI-WT 240 714,000 2975 16,600 543,000 33 
FXI-ABS1 230 450,000 1957 20,000 375,000 19 
FXI-ABS2 270 153,000 567 12,100 135,000 11 
FXI-ABS1/2 190 29,000 152 10,600 49,000 5 
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The activation rate of FXI was plotted against a range of polyP concentrations. 
PolyP-dependences of FXI activation by α-thrombin (Figure 9-4A) and FXIIa (Figure 
9-4B) have bell-shaped distributions, with an optimal concentration of polyP for the 
maximal rate of enhancement. This is consistent with a template mechanism requiring 
protease and substrate to bind to polyP. To confirm this, we looked at FXI activation by a 
recombinant α-thrombin with residue 89 changed from Arg to Glu (rIIaR89E). Residue 89 
is part of the ABE II on thrombin, and is essential for normal binding to heparin and polyP 
 
Figure 9-4. FXI activation by thrombin or FXIIa variants. (A and B) Concentration 
dependence of polyP-enhanced FXI-WT (120 nM subunits) activation by 3 nM (A) 
α-thrombin or (B) FXIIa. (C) FXI-WT (200 nM subunits) incubated with 50 nM ({) 
rIIaWT or (z) rIIaR89E. (D) FXI-WT (120 nM subunits) was activated by 3 nM ({) 
rIIaWT or (z) rIIaR89E in the presence of 50 nM polyP. (E) FXI-WT (200 nM 
subunits) was incubated with 10 nM ({) FXIIa or (z) β-FXIIa. (F) FXI-WT (120 nM 
subunits) incubated with 3 nM ({) FXIIa  or (z) β-FXIIa in the presence of 50 nM 
polyP. FXIa generation was determined by chromogenic assay. 
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(Olson, 1988; Sheehan and Sadler, 1994; Mutch, et al., 2010). In the absence of polyP, FXI 
is activated comparably by wild type α-thrombin (rIIaWT) and rIIaR89E (Figure 9-4C. 177 
and 124 M-1 sec-1, respectively); however, in the presence of polyP the rate constant for 
rIIaR89E (16,500 M-1 sec-1) was ~35-fold lower than for rIIaWT (573,000 M-1 sec-1) 
(Figure 9-4D). This demonstrates the importance of α-thrombin binding to polyP during 
FXI activation. β-FXIIa, a degradation product of FXIIa, lacks the anion-binding heavy 
chain.  β-FXIIa activates FXI at ~40% of the rate of FXIIa (7,300 and 17,100 M-1 sec-1, 
respectively) without polyP (Figure 9-4E), but showed a more profound defect with polyP 
(Figure 9-4F. 13,600 and 293,000, respectively; a >20-fold difference). Again, this is 
consistent with a template mechanism requiring FXIIa to bind to polyP during this 
reaction. 
The data demonstrate that polyP enhances FXI activation by α-thrombin, FXIIa or 
autoactivation through a template mechanism that requires FXI and the activating protease 
to bind to polyP. Both FXI ABSs are required to observe optimal enhancement. This 
contrasts with reactions in the presence of DS or heparin, where the A3 ABS alone is 
required to support activation, even though both ABSs are known to bind to these 
polyanions. An examination of the FXI structure suggests that ABSs are positioned on the 
FXI zymogen subunit in a manner that would allow a single polymer to span both sites 
(Figure 2-6). We postulate that the difference we observed between polyP and other 
polyanions may be related to specific structural features of the polyanions, or perhaps may 
reflect different affinities for FXI. While our studies strongly implicate a template 
mechanism is involved in FXI activation in the presence of polyP, we cannot rule out 
additional mechanisms, including allosteric changes in FXI or the protease upon polyP 
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binding that increase the catalytic efficiency of the reaction. 
 
Effects of PolyP on Factor XIa Activity and Inhibition 
Hydrolysis of S-2366 by FXIa in the presence of polyanions 
Previously, we noted that FXIa-mediated cleavage of the tripeptide S-2366 is partially 
inhibited by heparin. This appears to be due to an allosteric effect of the polyanion on the 
protease active site. We investigated the effect of heparin and polyP on the cleavage of 
S-2366 by FXIa-WT, FXIaABS-1, FXIaABS-2 and FXIaABS-1/2. We observed that both 
heparin and polyP inhibit the cleavage of S-2366 by FXIa-WT in a concentration 
dependent manner (Figure 9-5A). PolyP produces a less pronounced effect than heparin 
(Figure 9-5B). For both polyanions, the catalytic domain ABS is required to observe 
inhibition, as polyanions do not affect S-2366 cleavage by FXI-ABS2 or FXI-ABS1/2. 
Interestingly, the absence of the A3 domain ABS (FXI-ABS1) reduces inhibition 
somewhat, perhaps by changing the manner in which polyanions bind to the catalytic 
domain ABS. The results are consistent with the conclusion that heparin and polyP engage 
both ABSs on FXIa.  
Activation of FIX by FXIa in the presence of polyanions 
As discussed in Chapter IV, FXIa-WT activates FIX by cleaving the protein after 
Arg145 to produce FIXα (Figure 9-5C), and then after Arg180 to form FIXaβ (Figure 9-5D) 
(Vadivel, et al., 2012). As mentioned, the catalytic efficiency of the second cleavage is 
greater than the first, limiting FIXα accumulation. Central to this mechanism is the FIX 
binding exosite on the FXIa A3 domain. When FIX is activated by FXIa-WT in the 
presence of heparin or DS, there is significant FIXα accumulation (Figure 9-5C) and 
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Figure 9-5. Effects of polyanions on FXIa activity. (A and B) FXIa-WT 
({), FXIaABS-1 (U), FXIaABS-2 (z) or FXIaABS-1/2 (▲), 6 nM active 
sites, was supplemented with (A) heparin or (B) polyP, then tested for its 
ability to hydrolyze S2366. (C and D) FIX (100 nM) was incubated in Assay 
Buffer at RT with 3 nM (active sites) FXIa-WT with ({) vehicle, (z) 400 nM 
unfractionated heparin, (▲) 1 μg/ml dextran sulfate or (U) 50 nM polyP. 
Samples were removed into nonreducing SDS-sample buffer and 
size-fractionated on 17% polyacrylamide-SDS. Conversion of FIX to (C) 
FIXα and (D) FIXaβ was determined by densitometry of stained gels. (E and 
F) FXIa-WT (6 nM active sites) incubated in TBSA with antithrombin (130 
nM) and (z) unfractionated heparin or ({) polyP. kobs for each polyanion 
concentration was determined as described under methods. 
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reduced rates of FIXaβ formation (Figure 9-5D).  These data suggest that the polyanions 
sterically interfere with FIX binding to the A3 exosite. PolyP, in contrast, does not alter 
FIX activation. This is consistent with the premise that polyP interacts differently with 
FXIa than does dextran sulfate or heparin, despite using the same binding sites. It is 
possible that FIX can displace polyP from the A3 domain more easily than other 
polyanions. Alternatively, the geometry of binding may be different enough to prevent 
interference with the factor IX binding exosite.  
Effects of Polyanions on Antithrombin-Mediated Inhibition of FXIa 
In plasma, FXIa activity is regulated by several members of the serpin family of 
protease inhibitors, including AT. FXIa inhibition by AT is enhanced 40-fold by heparin at 
therapeutic concentrations (Zhao et al., 1998). The heparin-dependence of AT inhibition of 
FXIa (Figure 9-5E) is bell-shaped, indicating the FXIa and AT both bind to the heparin 
(Olson, 1988; Zhao et al., 1998).  PolyP has little effect on AT inhibition of FXIa (Figure 
9-5E). At polyP concentrations >1 μM a modest saturable inhibition is observed (Figure 
9-5F), consistent with an allosteric effect due to polyP binding to FXIa. AT up to 6 μM did 
not bind to polyP in surface plasmon resonance studies (S.A. Smith and J.H. Morrissey, 
Univ. of Illinois-Urbana, personal communication), consistent with results reported by 
Church and coworkers (Church et al., 1988). 
Both heparin and polyP appear to interact with the same general areas on FXI and 
thrombin. Although it has the capacity to enhance FXI activation specifically, and contact 
activation in general, heparin produces a net anticoagulant effect in plasma because it 
serves as a cofactor for AT-mediated protease inhibition. PolyP, on the other hand, is 
procoagulant in vivo. The interaction between heparin and AT involves a well-defined 
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pentasaccharide sequence within the heparin molecule, which is absent in polyP (van 
Boeckel et al., 1994). As a result, polyP does not bind AT, and predictably lacks the 
capacity to function as a cofactor for AT. Our results showing that polyP does not 
significantly accelerate FXIa inhibition by AT, and does not interfere with FIX activation 
by FXIa, support the hypothesis that polyP is, on balance, a promoter of coagulation.  
 
The Importance of Factor XI ABSs in Blood Coagulation 
Factor XI in Plasma Assays 
To understand the importance of the FXI interaction with polyanions in plasma 
coagulation, we performed aPTT assays using silica as a triggering agent in FXI-deficient 
plasma supplemented with recombinant FXI. FXI-WT and FXI-ABS1 restored clotting 
times of FXI-deficient plasma comparably, while FXI-ABS2 and FXI-ABS1/2 gave 
slightly longer clotting times (1.2 and 1.35 times of FXI-WT, respectively) (Figure 9-6A).  
 
 
Figure 9-6. Plasma clotting assays. (A) FXI-deficient plasma supplemented with 30 
nM FXI-WT, FXI-ABS1, FXI-ABS2, FXI-ABS1/2, or vehicle (C) and incubated aPTT 
reagent. After recalcification, time to clot formation was measured on a coagulometer. 
(B) Clotting times of FXI-deficient plasma supplemented with FXI as in panel A 
incubated for 3 min with 50 nM polyP and 10 μM PC/PS vesicles. (C) Clotting times of 
FXI-deficient plasma supplemented with FXI incubated for 3 min with 50 nM polyP, 10 
μM PC/PS vesicles, and 1.5 nM β-thrombin. CTI (4 μM) was used to block 
contributions from FXII/XIIa in experiments in panel C. For all panels, proteins were 
tested in triplicate. Error bars represent one standard deviation. 
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Replacing silica with polyP resulted in longer clotting times (Figure 9-6B), because polyP 
of ~80 phosphate units are relatively weak FXII activators (Smith et al., 2010). With 
polyP, differences in clotting times between plasma supplemented with different FXI 
variants are evident, and in line with the results in Figure 9-3D. In Figure 9-6C, FXII 
activation and FXIIa activity are blocked in plasma with CTI, and FXI is activated in the 
presence of polyP by adding β-thrombin. As discussed in Chapter II, β-thrombin is a 
cleavage product of α-thrombin that converts fibrinogen to fibrin poorly (Matafonov et al., 
2011). While β-thrombin and α-thrombin activate FXI similarly in solution, β-thrombin is 
a more potent FXI activator in plasma than is α-thrombin, because fibrinogen does not 
compete with FXI for the enzyme (Emsley et al., 2010). As with polyP-enhanced FXIIa 
activation of FXI (Figure 9-6B), polyP-dependent β-thrombin activation of FXI in plasma 
is compromised by loss of the FXI ABSs. These results indicate that the ability of polyP to 
enhance α-thrombin-mediated or FXIIa-mediated FXI activation in plasma also requires 
both ABSs. 
Thrombus Formation in vivo 
As discussed in Chapter VII, FXI-WT can be transiently expressed in FXI-/- mice by 
HTI. FXI ABS mutants were expressed in FXI-/- mice using this technique (Figure 9-7A). 
Twenty-four hours post-HTI, the plasma FXI concentrations of ABS mutants are 
comparable to the normal FXI level in human plasma (30 nM), while FXI-WT 
concentrations were modestly lower (Figure 9-7B). Carotid arteries of wild type mice 
occlude within 15 minutes of exposure to 3.5% FeCl3, while FXI-/- mice are resistant to 
occlusion (consistent with the results in Figure 7-7D). All FXI-/- mice expressing FXI-WT 
developed arterial occlusion after FeCl3 exposure (Figure 9-7C). However, despite plasma 
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FXI levels that were ~40% higher on average than FXI-WT expressing mice, only about 
half of the mice expressing FXI lacking one or both anion-binding sites developed arterial 
occlusion (Figure 9-7C). 
PolyP appears to contribute to thrombus formation in the mouse arterial thrombosis 
model used in this study. In this model, an antithrombotic effect can be produced by 
treating mice with alkaline phosphatase to destroy polyP (Müller et al., 2009), or by 
administering compounds that neutralize polyP (Smith et al., 2012; Jain et al., 2012). 
 
Figure 9-7. FeCl3-induced carotid artery occlusion. (A) FXI western blot of mouse 
plasmas 24 hours post-HTI with constructs for FXI-WT, FXI-ABS1 (-1), FXI-ABS2 
(-2), FXI-ABS1/2 (-1/2) or empty vector (JV). Normal human plasma (NP) is in the 
left lane and FXI-deficient mouse plasma (XIdP) in the right lane. Positions of 
molecular mass standard (kDa) are shown on the left, and FXI is indicated on the right. 
(B) Concentrations of FXI in mouse plasma 24 hours post-HTI. Error bars indicate 1 
SD (n=10 per construct). (C) FXI-/- mice underwent HTI with FXI constructs (n=10 
per construct). 24 hours post-HTI, mice were tested in a model in which thrombus 
formation in the carotid artery is induced with 3.5% FeCl3. Bars indicate percent of 
mice with occluded arteries 30 min post-FeCl3 application.  
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Based on the importance of the FXI anion-binding sites to interactions with polyP and 
heparin (and presumably heparin-like molecules), hypothetically, loss of one or both sites 
could result in (1) an enhanced sensitivity to FeCl3-induced thrombosis because of reduced 
AT-mediated inhibition, (2) a decrease in sensitivity to FeCl3-induced thrombosis due to 
decreased affinity for polyP, or (3) a combination of the effects leading to an intermediate 
result. The results presented here indicate, on balance, that loss of the FXI ABSs produces 
an antithrombotic effect, supporting the notion that targeting the FXI interaction with 
polyanions such as polyP may be a useful antithrombotic strategy. 
 
Summary 
PolyP is released from activated platelets and produces procoagulant effects in plasma. 
Several laboratories, including our own have reported that polyP accelerates FXI activation 
by thrombin, FXIIa and FXIa. Our results indicate that the two anion binding sites (ABSs) 
found on each subunit of FXI are required for productive interactions with polyP. This 
contrasts to some extent with the FXI interaction with polyanions such heparin and DS, 
which only require the ABS on the A3 domain for autoactivation. Interestingly, unlike 
heparin and DS, polyP does not interfere with FIX activation by FXIa, consistent with the 
impression that polyP is, on balance, a promoter of thrombin generation and coagulation. 
Studies with FXI ABS mutants in plasma and in a mouse thrombosis model support the 
hypothesis that the FXI ABSs are required for expression of the cofactor effect of polyP 
during FXI activation. Given this, therapeutic targeting of the interaction between the FXI 
ABSs and polyP may prevent FXI from contributing to thrombotic processes. 
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Methods 
Recombinant FXI. Recombinant wild type FXI (FXI-WT), FXI with alanine replacing 
Arg250, Lys252, Lys253 and Lys255 in the A3 domain (FXI-ABS1) (Zhao et al., 1998), FXI 
with alanine replacing Lys529, Arg530 and Arg532 in the catalytic domain (FXI-ABS2) 
(Yang et al., 2009), or both sets of substitutions (FXI-ABS1/2) were expressed and 
purified as described. FXI was incubated with 500 µM DIP on ice for 1 hr to inhibit traces 
FXIa, followed by dialysis into TBS. FXI was activated with FXIIa (20:1 FXI:FXIIa) at 37 
˚C for 24 hrs in TBS.  
Recombinant Thrombin. Wild type α-thrombin (rIIaWT) and α-thrombin with Arg89 
replaced by Glu (rIIaR89E) were prepared as described (Sheehan and Sadler, 1994). 
Prothrombin forms of both proteins were expressed in BHK cells, and purified from 
medium by barium sulfate precipitation and chromatography on DEAE-Sephacel. 
α-Thrombin was generated by incubating Prothrombin with Oxyuranus scutellatus venom, 
and purified by ion-exchange chromatography. Thrombin active sites were titrated with 
hirudin.  
Hydrolysis of S-2366 by FXIa. FXIa-WT (12 nM active sites) was incubated with 50-2000 
μM S-2366 in TBS with 0.1% BSA (TBSA) at RT. Rates of pNA generation were 
determined as in Chapter V. In a separate experiment, 12 nM FXIa-WT was incubated with 
S-2366 (500 μM) and varying concentrations of heparin or polyP.  
FXI Activation. FXI autoactivation was performed as described in Chapter VI. In the 
absence of polyP, FXI (200 nM subunits) was incubated with FXIIa (10 nM) or thrombin  
(50 nM) in HBSA at 37 ºC. Reactions in the presence of polyP (50 nM) contained FXI (120 
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nM subunits) and 3 nM FXIIa or thrombin.  
FIX Activation by FXIa. FIX (100 nM) in Assay Buffer was incubated at RT with FXIa (3 
nM active sites) with vehicle, 1 μg/mL dextran sulfate, 400 nM heparin, or 50 nM polyP. 
At various times, aliquots were removed into non-reducing SDS-sample buffer, size 
fractionated on 17% polyacrylamide gels, and stained with GelCode Blue (Pierce). Gels 
were imaged under infrared wavelengths, and conversion of FIX to FIXα and FIXaβ was 
assessed by densitometry as described in Chapter IV.  
Inhibition of FXIa by Antithrombin. FXIa (6 nM active sites) was incubated with AT 
(130 nM), and heparin (100 to 104 nM) or polyP (10-3 to 104 nM) in TBSA at 37°C. At 
various times, 50 μL was removed into 50 μL of TBSA containing 1 mM S-2366 and 4 
µg/mL polybrene. FXIa activity was determined by monitoring changes at a wavelength of 
405 nm. Initial linear rates of pNA formation were expressed as mOD/min for 100 µl 
reactions. Progress curves of residual FXIa activity (E/E0) were analyzed by direct 
nonlinear least squares fitting to a first-order decay equation, E/E0 = e-kobs.t in which kobs 
is the first-order inactivation rate constant (s-1) and t is time (s).  The semi-logarithmic 
dependence of kobs on [heparin] was analyzed with a model in which heparin forms a 
ternary complex with FXIa and AT (Olson, 1988). The data for polyP were analyzed by a 
quadratic equation kobs = kobs,unc + F(kobs,lim – kobs,unc), where   
 
kobs,unc is the rate constant for AT inactivation in the absence of polyP, and kobs,lim is 
the limiting rate constant at high polyP concentration.  [FXIa]o and [P]o are 
147 
 
concentrations of FXIa active sites and polyP, and KFXIa,P is the apparent dissociation 
constant for polyP binding to the FXIa subunit, assuming 1 binding site for the polyP chain 
on each FXIa subunit.  
The methods for testing FXI activity in plasma and FXI deficient mice were described 
in Chapter VII. 
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CHAPTER X  
 
IMPLICATIONS OF THE RESEARCH AND FUTURE DIRECTIONS 
 
Despite research over the course of six decades, the functions of the proteins that make 
up the plasma contact system (FXII, FXI, PK and HK) in normal health and in disease are 
not well understood. To some extent this is due to the long practice of studying these 
proteins in systems triggered with non-physiologic substances. This contributed to the 
impression that contact reactions are in vitro artifacts that do not reflect the physiologic 
roles of the proteins. Another contributing factor is, until recently, a general lack of 
enthusiasm for studying contact proteins, because of the unimpressive phenotypes 
associated with their deficiencies. While contact activation was originally thought to be a 
physiologically relevant trigger for coagulation in certain situations, it is now established 
that only FXI is required for normal hemostasis, and its role is relatively minor compared 
to the VKD coagulation proteases. The observation that FXI can be activated by thrombin 
further reinforced the impression that FXII, PK and HK were not likely to contribute to 
coagulation in a substantial way. 
There has a been resurgence in interest in a role for contact activation in coagulation, 
initially based on observations indicating that FXI contributes to thrombosis in humans and 
in animal models, and then by work revealing that mice lacking FXII (Renné et al., 2005; 
Kleinschnitz et al., 2006), HK (Merkulov et al., 2008), or PK (Revenko et al., 2011; Bird et 
al., 2012) are resistant to thrombosis. The data suggest that a process similar to classic 
contact activation contributes to pathologic clot formation and/or growth. A case is 
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building for a mechanism in which FXI is activated on or near the surface of aggregating 
platelets, possibly by FXIIa, leading to inappropriate thrombin generation, fibrin 
production and platelet activation within a blood vessel lumen. The ability of polyP, a 
polyanion released from platelet dense granules, to enhance FXI activation, and to some 
extent FXII activation, provides a convincing link between activated platelets and the 
contact system. Several polyP binders, including cationic proteins, polymers and small 
molecules have demonstrated anti-thrombotic properties in vitro and in vivo (Smith et al., 
2012), consistent with the importance of polyP in pathologic processes. 
With the realization that FXI contributes to thrombosis, there is active interest in 
targeting the protein for therapeutic purposes. A major underlying goal of the work 
presented in this thesis is to provide data that will inform rational design of therapeutic 
approaches targeting FXI. Specifically, we wanted to (1) establish the mechanism and 
structural basis of FIX activation by FXIa, (2) determine the mechanism by which FXI/XIa 
interacts with polyP, and (3) investigate the importance of FXI’s dimeric structure to 
zymogen activation. FXI’s unusual structure (for a coagulation protease) makes it difficult 
to predict structure-function relationships by extrapolating from the large literature for 
VKD proteins. During the course of the work, we came to appreciate the complexities of 
studying a protease that can have one or two active sites, interacting with a substrate that 
must be cleaved at more than one location. We hope that our results will provide a 
foundation for future work on the roles of FXI in vascular biology. 
 
Factor IX Activation by Factor XIa 
We demonstrated that FIX activation by FXIa involves an exosite-mediated 
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release-rebind mechanism (Geng et al., 2012). Similar processes have been reported for 
activation of prothrombin by FXa (Orcutt and Krishnaswamy, 2004), and FX activation by 
the FVIIa/TF complex (Baugh et al., 2000). During FIX activation by FXIa, the efficiency 
of the second cleavage after Arg180 is enhanced by conformational changes resulting from 
the first cleavage after Arg145. The 7-fold greater catalytic efficiency of the second 
cleavage explains the absence of significant accumulation of the intermediate FIXα. A 
similar mechanism appears to explain the limited accumulation of the intermediate 
meizothrombin during prothrombin activation by FXa (Orcutt and Krishnaswamy, 2004). 
As presented in Chapters IV, V and VI, our data disagree with previous proposals for the 
mechanism by which FXIa activates FIX on several key points, which are listed in 
Table10-1.  
 
Table 10-1. Features of models for FIX activation by FXIa. 
Feature Published Our Results 
General Mechanism “Processive” Release-Rebind 
Initial Exosite Interaction Catalytic Domain A3 domain 
Primary Heavy Chain FIX Binding Site  A2 Domain A3 Domain 
Catalytic Domain Exosite Evidence For No Evidence For 
Binding to Catalytic Domain Required 
before Binding to Heavy Chain Yes No 
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The features listed in Table 10-1 for published models come primarily from one 
laboratory. The reason that our results are so discrepant with results from this group is not 
entirely clear; however, our experiments incorporated several features that we feel are 
better suited to the analysis of this reaction. First, we used densitometry of full time course 
experiments on SDS-polyacrylamide gels to establish progress curves for formation of 
both the intermediate FIXα and the protease FIXaβ. The published data relied primarily on 
a chromogenic assay in which FIXaβ generated in the first stage of an assay was used to 
generate FXa in the second stage. It is difficult to achieve reproducibility with this 
two-stage approach, and the assay does not yield information about non-enzymatic (FIXα) 
intermediate accumulation. Second, we used chimeras and site-directed mutants of FXI 
and PK to identify exosites, using loss-of-function and gain-of-function strategies. In 
comparison, the older published work relied on peptide inhibition approaches, which can 
be difficult to interpret, as peptides may not accurately mimic epitopes on the whole 
protein.  
Mutagenesis analysis identified residues in the FXIa A3 domain that either constitute a 
FIX-binding exosite, or are required for proper conformation of the exosite. The inability 
of FIX to bind to zymogen FXI indicates the exosite is either not formed or unavailable. 
That the residues we identified as components of the exosite are buried in the zymogen 
structure are consistent with this hypothesis. Presumably a conformational change induced 
by subunit activation exposes this site, allowing binding to occur. Evidence for a 
significant conformational change in FXI upon activation to FXIa is indirect, coming from 
rotary shadowing electron microscopic images that appear to show a shape difference 
between FXI and FXIa. Strategies that resolve the three-dimensional structures of FXIa, 
such as crystallographic structures of the molecule alone or in complex with FIX are 
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needed to better define the structural elements involved in the FIX-FXIa interaction. FXIa 
is apparently a difficult molecule to crystalize, hampering efforts in this regard. 
Most protease-substrate interactions required for thrombin generation during 
hemostasis occur on phosphatidylserine-rich membranes of activated platelets or damaged 
tissues, and require a protein cofactor. The Kms for these reactions are heavily influenced 
by the protease and substrate binding to the phospholipid, while the presence of the 
cofactor enhances kcat. FXIa activation of FXI appears to be the exception to this model, as 
phospholipid does not enhance the reactions and no cofactor appears to be required. For 
this reaction, Km is largely determined by an interaction between the FIX Gla-domain with 
the FXIa A3 domain. The involvement of the Gla-domain suggests that FXIa should 
compete with phospholipid for FIX. Consistent with this, using surface plasmon resonance, 
we recently determined that FXIa, but not FXIa/PKA3, inhibits FIX binding to 
immobilized phosphatidylserine-rich surfaces (Gailani et al., 2013; 2014).  
While our data suggest that FXIa would activate FIX equally well in solution and on a 
surface, the environments in which the reaction occurs in vivo are not established. Despite 
the absence of a Gla-domain, FXI and FXIa do bind to platelet receptors such as 
glycoprotein 1bα (Baglia et al., 2004) and ApoER2 (White-Adams et al., 2009), 
suggesting FXIa-mediated FIX activation may occur on the platelet surface. FIXaβ would 
then be in a position to participate in FX activation on the platelet in the presence of the 
cofactor FVIIIa. While the FXI/XIa-platelet interaction does not appear to influence 
protease function in static clotting and thrombin generation assays, we predict that it may 
be necessary for maintaining the correct position of FXIa relative to a clot in flowing blood. 
We are developing flow systems in the laboratory to test FXI variants such as the 
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monomers described in Chapter VII and the heterodimer described in Chapter VIII, which 
function reasonably normally in static assays, but would be predicted to fail under flow if 
one subunit of the dimer was required solely for binding to a platelet.    
 
The Factor XIa A3 Domain as an Antithrombotic Target 
In humans, compelling epidemiologic data support a role for FXI in arterial and venous 
thrombotic disorders (Doggen et al., 2006; Meijers et al., 2000). These observations have 
spurred an interest in developing inhibitors of FXIa as antithrombotic drugs. Approaches 
that have been investigated include (1) inhibition of FXI activation or FXIa activity with 
monoclonal antibodies (Tucker et al., 2009; Cheng et al., 2010), (2) reduction of plasma 
FXI with anti-sense oligonucleotides (Crosby et al., 2013), and inhibition of FXIa with (3) 
synthetic protease active site inhibitors (Quan et al., 2014), (4) synthetic allosteric 
inhibitors (Karuturi et al., 2013), or (5) naturally occurring active site inhibitors (Ma et al., 
2013). While the traditional pharmacologic approach is to target the active site of the 
protease form of a target, data with antibodies directed against FXI provide a compelling 
argument for targeting the FXI A3 domain as an antithrombotic approach.  
As discussed, exosite interactions are largely responsible for affinity and specificity of 
enzyme-substrate interactions in coagulation. IgG O1A6 is an anti-human FXI/XIa 
antibody that binds to the A3 domain, blocking the interaction between FIX and the exosite 
on FXIa (Tucker et al., 2009). The antibody was tested in baboons using implantable 
collagen-coated grafts to induce thrombosis within arteriovenous shunts (Tucker et al., 
2009). O1A6 markedly reduced platelet and fibrin accumulation within the grafts, 
preventing occlusion and reducing thrombin-antithrombin (TAT) complex levels 
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downstream from the graft by >90%. This is consistent with a potent effect on thrombin 
generation. While, O1A6 was more effective than high dose aspirin in this model, unlike 
aspirin, it did not increase the bleeding time (Tucker et al., 2009). The impressive 
antithrombotic effect of O1A6 was superior to those of an anti-FXI antibody (14E11) that 
blocks FXI activation by FXIIa (but not FXIa activation of FIX), and an anti-FXII antibody 
that prevents FXII activation (15H8). Surprisingly, in plasma clotting assays and flow 
models, O1A6 was considerably more potent than antibodies that block the FXIa active 
site (data not shown). This counterintuitive observation has been confirmed by 
investigators at other institutions. While the reason for this is not certain, we speculate that 
the relative “weakness” of the antibodies that target the active site may stem from their 
inability to prevent FIX from engaging FXIa at the A3 domain exosite. There are data to 
suggest that engagement of the exosite by FIX changes the protease active site. Given this, 
an antibody that effectively blocks the active site of free FXIa, may not be a good inhibitor 
of the active site of the FXIa-FIX complex. 
Another advantage of targeting the A3 domain exosite is the specificity of the 
interaction. The catalytic domain of FXIa shares structural features in common with other 
members of the family of trypsin-related proteases. Inhibitors designed to target the active 
site of FXIa often cross-react, at least to some extent, with the plasma proteases 
α-kallikrein (a homolog of FXIa), activated protein C, FXa or thrombin, as well as the 
digestive enzyme trypsin.  Inhibition of an exosite offers a more specific strategy for 
anti-thrombotic therapy. By identifying the structural basis for exosite mediated FIX-FXIa 
interaction, our data could facilitate development of small peptide or other small molecule 
inhibitors that target the exosite of FXIa. 
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The Factor XIa Interaction with Polyphosphate 
FXI is activated slowly in solution by FXIIa and thrombin, implying that a cofactor is 
required to generate sufficient FXIa in vivo. The positive effects of polyanions such as 
dextran sulfate, silica and celite on FXI activation have been recognized for decades, and 
suggested that a cofactor for FXI activation may have polyanionic properties. PolyP would 
seem to qualify as such a cofactor. The ability of polyP to enhance FXII and FXI activation 
provides a link between activated platelets, FXI activation by contact activation, and FXI 
activation by thrombin.  
FXI/XIa has two anion binding sites per subunit that are required for normal cofactor 
activity of heparin during FXIa inhibition by antithrombin. This contrasts with other 
coagulation proteases, and FXIa’s homolog α-kallikrein, which have only one anion 
(heparin) binding site. The novel anion binding site on the FXI A3 domain is conserved 
across mammalian species suggesting functional importance. Our data suggest the 
possibility that the A3 and catalytic domain anion binding sites may function as a single 
larger binding site required for polyP-dependent interactions. We speculated above that 
FXI and FXIa may bind to platelet surface proteins, but it is also possible that the 
interaction with the platelet count be indirect, through polyP. While the polyanion binding 
mutants described in Chapter IX function reasonably normally in static plasma clotting 
assays, it will be interesting to test their ability to support fibrin formation and platelet 
activation in flow models. 
The role of orthophosphate polymers (polyP) in FXI activation may reflect a more 
general mechanism by which FXI interacts with other polyphosphates that contribute to 
thrombus formation. RNA and DNA are polymers with phosphate backbones that appear 
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to contribute to thrombosis in mouse models (Kannemeier et al., 2007; Brill et al., 2012). 
Recent work indicates that DNA in chromatin material extruded from activated neutrophils 
(neutrophil extracellular traps or NETs) may be prominent in human venous thrombi. The 
release of NETs during neutrophil activation is thought to contribute to the innate immune 
response to pathogens, with the sticky viscous chromatin material trapping invading 
organisms. This material appears to also be prothrombotic (Fuchs et al., 2010; Brill et al., 
2012). Interestingly, a significant amount of the fibrous material in venous clots thought to 
be fibrin may actually be DNA released from neutrophils. Our FXI polyanion binding 
variants provide us with the tools to determine if FXI interacts with nucleic acid polymers 
in a manner similar or different to standard polyP. 
Investigators at Virginia Commonwealth University are designing FXIa inhibitors that 
work through an allosteric mechanism. The drugs are meant to dock at the anion binding 
site on the catalytic domain through ionic interactions, followed by additional binding 
interactions (some hydrophobic) that cause allosteric changes to the protease active site. 
We have tested some of these compounds and verified that they inhibit FXIa cleavage of a 
chromogenic substrate in a non-competitive manner, and are inhibitors of FIX activation 
by FXIa. Our FXIa anion binding variants can be used to verify the importance of the anion 
binding sites to the mechanism of action of these drugs. 
 
Thoughts on the Factor XI/XIa Homodimer 
One of the most provocative features of FXI is its homodimeric structure. From an 
evolutionary perspective, a gene for a protease with four apple domains that probably 
represents PK first appears in amphibians. An analysis of the predicted sequence of the A4 
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domain in the gene from the frog Xenopus indicates the encoded protein is a monomer. The 
gene for FXI is the result of a duplication involving this PK gene. Originally, the 
duplication was thought to have occurred during mammalian evolution (Ponczek et al., 
2008), but recent analysis indicates that separate genes for PK and a dimeric FXI protein 
are present in a primitive mammal (the duck billed platypus, a monotreme), suggesting 
duplication may have occurred in a reptilian ancestor. The function of the dimer has 
remained elusive, although results from our mouse carotid artery thrombosis studies 
indicate it is required for protease function in vivo under at least some circumstances.   
A homodimeric structure is required for substrate recognition in the case of granzyme 
A (Hink-Schauer et al., 2003), and for catalysis in the case of cyclooxygenase-2 (Dong et 
al., 2011). For granzyme A, the substrate binds to an exosite on one subunit and is 
catalyzed by the other. In essence, the non-catalytic subunit serves as an exosite.  For 
cyclooxygenase-2, the homodimer functions as a conformational heterodimer, with the 
activity of a catalytic monomer regulated by the other (allosteric) monomer. The dimeric 
structure of FXIa does not appear to be required for substrate recognition or catalysis 
(Smith et al., 2008; Wu et al., 2008). The work presented in Chapter VII shows that 
monomeric FXI is activated poorly by FXIIa at high protease to substrate ratios. This may 
explain the poor performance of monomers in our in vivo thrombosis model, which 
requires FXI activation by FXIIa. The in vitro data suggest that there are high affinity 
FXIIa binding sites on the FXI dimer that mediate dimer-dependent activation, with lower 
affinity sites supporting dimer-independent activation. Presumably, for the high affinity 
sites, FXIIa binds to one subunit of a FXI dimer while activating the other. This suggests 
that dimerization is an adaptation for proper activation; however, the parent homolog of 
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FXI, PK, is a monomer that is activated efficiently by FXIIa. Furthermore, FXIIa 
activation is not thought to be important for hemostasis. Indeed, FXI monomers are 
activated normally by thrombin. 
As outlined in Chapter VIII, we are currently investigating the possibility that the 
dimeric conformation of FXIa is an adaptation that allows the protease to bind to a surface 
(perhaps a receptor on activated platelets) through one subunit, while engaging the 
substrate FIX through the other. The observation that binding sites for GP1b and factor IX 
are both located on the A3 domain suggests that for a single subunit platelet binding and 
FIX binding would be mutually exclusive events. Previously, members of our laboratory 
published a study using a monomeric FXI/PK chimera (FXI/PKA4) that lent credence to 
this hypothesis (Gailani et al., 2001), although not all subsequent work was in support of 
this notion (Sinha et al., 2005). Future studies with FXI monomers and heterodimers using 
flow systems in which thrombin generation is platelet-dependent should allow us to 
confirm or disprove this model. 
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